Appendix H. Excluded Studies with Rationale

Table H1. Excluded Studies with Rationale

Bibliography	Reason for Exclusion
Abel, S., Hasan, S., White, R., Schumacher, L., Finley, G., Colonias, A., Wegner, R. E.. **Stereotactic Ablative Radiotherapy (SABR) in Early Stage Non-Small Cell Lung Cancer: a National Cancer Database (NCDB) Propensity Matched Analysis Comparing Survival in Adenocarcinoma and Squamous Cell Carcinoma.** *International journal of radiation oncology biology physics.* 2019. 104:232- 10.1016/j.ijrobp.2019.01.018	Publication type
Achard, V., Jaccard, M., Vanhoutte, F., Siva, S., Heikkilä, R., Dirix, P., Liefhooghe, N., Otte, F. X., Gomez-Iturriaga, A., Berghen, C., et al.. **Oligorecurrent nodal prostate cancer: radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial.** *Radiotherapy and oncology.* 2022. 172:1-9 10.1016/j.radonc.2022.04.020	Intervention
Adachi, T., Nakamura, M., Shintani, T., Mitsuyoshi, T., Kakino, R., Ogata, T., Ono, T., Tanabe, H., Kokubo, M., Sakamoto, T., et al.. **Multi-institutional dose-segmented dosiomic analysis for predicting radiation pneumonitis after lung stereotactic body radiation therapy.** *Medical physics.* 2021. 48:1781-1791 10.1002/mp.14769	Aim
Aghdam, N,Royce, TJ,Burri, RJ,Obayomi-Davies, O,Mezeckis, M,Meier, R,Fuller, DB, Chen, RC,Lanciano, RM,Haas, JA. **5-year Biochemical Outcomes of Stereotactic Body Radiotherapy with Intraprostatic Dose Escalation for Unfavorable Prostate Cancer.** *International Journal of Radiation Oncology, Biology, Physics.* 2019. 105:E263-E264 #DOI#	Publication type
Ahmed, A., Usera, B. M., Feinstein, S., Kamal Aldin, M. A., Monjazeb, A. M., Daly, M. E.. **Recurrence Risk and Survival Following SBRT for Lung Cancer: impact of Prognostic Factors Used for Patient Selection in a Randomized Trial.** *International journal of radiation oncology biology physics.* 2022. 114:e366-e367 10.1016/j.ijrobp.2022.07.1495	Publication type
Ahmed, Kamran A,Barney, Brandon M,Macdonald, O Kenneth,Miller, Robert C,Garces, Yolanda I,Laack, Nadia N,Haddock, Michael G,Foote, Robert L,Olivier, Kenneth R. **Stereotactic body radiotherapy in the treatment of adrenal metastases.** *American journal of clinical oncology.* 2013. 36:509-513 #DOI#	Sample size
Alayed Y, Cheung P, Chu W, et al. Two StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): Results from a prospective clinical trial. *Radiotherapy and Oncology*. 2019;135:86-90. doi: https://doi.org/10.1016/j.radonc.2019.03.002.	Sample size
Alayed Y, Cheung P, Pang G, et al. Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials. *Radiother Oncol.* 2018;127(2):213-218. doi: 10.1016/j.radonc.2018.03.005.	Sample size
Alayed Y, Cheung P, Vesprini D, et al. SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal Irradiation. *International Journal of Radiation Oncology, Biology, Physics.* 2019;104(1):36-41. doi: https://dx.doi.org/10.1016/j.ijrobp.2018.11.011.	Sample size
Alayed Y, Quon H, Cheung P, et al. Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials. *Radiother Oncol.* 2019;140:105-109. doi: 10.1016/j.radonc.2019.06.018.	Comparator

Alayed Y, Quon H, Ong A, et al. Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT). *Radiother Oncol.* 2020;149:8-13. doi: 10.1016/j.radonc.2020.04.039.	Comparator
Alayed, Y., Cheung, P., Vesprini, D., Liu, S., Chu, W., Chung, H., Musunuru, H. B., Davidson, M., Ravi, A., Ho, L., Deabreu, A., D'Alimonte, L., Bhounr, Z., Zhang, L., Commisso, K., Loblaw, A.. **SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal Irradiation.** *International Journal of Radiation Oncology, Biology, Physics.* 2019. 104:36-41 https://dx.doi.org/10.1016/j.ijrobp.2018.11.011	Sample size
Alayed, Y., Quon, H., Cheung, P., Chu, W., Chung, H. T., Vesprini, D., Ong, A., Chowdhury, A., Panjwani, D., Helou, J., Pang, G., Korol, R., Davidson, M., Ravi, A., McCurdy, B., Zhang, L., Mamedov, A., Deabreu, A., Commisso, A., Commisso, K., Loblaw, A.. **Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials.** *Radiotherapy & Oncology.* 2019. 140:105-109 https://dx.doi.org/10.1016/j.radonc.2019.06.018	Comparator
Alayed, Y., Quon, H., Ong, A., Cheung, P., Chu, W., Chung, H., Vesprini, D., Chowdhury, A., Panjwani, D., Pang, G., et al.. **Accelerating prostate stereotactic ablative body radiotherapy: efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT).** *Radiotherapy and oncology.* 2020. 149:8-13 10.1016/j.radonc.2020.04.039	Aim
Alayed, Y.,Cheung, P.,Pang, G.,Mamedov, A.,D'Alimonte, L.,Deabreu, A.,Commisso, K., Commisso, A.,Zhang, L.,Quon, H. C.,Musunuru, H. B.,Helou, J.,Loblaw, D. A.. **Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials.** *Radiother Oncol.* 2018. 127:213-218 #DOI#	Sample size
Alongi, F.,Cozzi, L.,Arcangeli, S.,Iftode, C.,Comito, T.,Villa, E.,Lobefalo, F.,Navarria, P., Reggiori, G.,Mancosu, P.,Clerici, E.,Fogliata, A.,Tomatis, S.,Taverna, G.,Graziotti, P., Scorsetti, M.. **Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study.** *Radiat Oncol.* 2013. 8:171 #DOI#	Sample size
Aluwini, Shafak,van Rooij, Peter,Hoogeman, Misha,Bangma, Chris,Kirkels, Wim J, Incrocci, Luca,Kolkman-Deurloo, Inger-Karine. **CyberKnife stereotactic radiotherapy as monotherapy for low-to intermediate-stage prostate cancer: early experience, feasibility, and tolerance.** *Journal of endourology.* 2010. 24:865-869 #DOI#	Sample size
Al-Wassia, R.,Dal Pra, A.,Shun, K.,Shaban, A.,Corriveau, C.,Edelstein, C.,Deschenes, J., Ruo, R.,Patrocinio, H.,Cury, F. L.,DeBlois, F.,Shenouda, G.. **Stereotactic fractionated radiotherapy in the treatment of juxtapapillary choroidal melanoma: the McGill University experience.** *Int J Radiat Oncol Biol Phys.* 2011. 81:e455-62 #DOI#	Sample size
Alyamani N, Song J, van Katwyk S, et al. Cost–Utility Analysis of Radiation Treatment Modalities for Intermediate-Risk Prostate Cancer. *Current Oncology.* 2021;28(4):2385-2398. https://mdpi-res.com/d_attachment/curroncol/curroncol-28-00219/article_deploy/curroncol-28-00219-v3.pdf?version=1625708085.	Setting
Amin, N. P., Sher, D. J., Konski, A. A.. **Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013.** *Applied Health Economics & Health Policy.* 2014. 12:391-408 https://dx.doi.org/10.1007/s40258-014-0106-9	Publication Date

Amini, A., Verma, V., Simone, C., Chetty, I., Choi, J. I., Chun, S., Donington, J., Edelman, M., Higgins, K., Kestin, L., et al.. **American Radium Society® (ARS) Appropriate Use Criteria on Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer (NSCLC).** *International journal of radiation oncology biology physics.* 2020. 108:E48- 10.1016/j.ijrobp.2020.02.582	Publication type
Andolino DL, Forquer JA, Henderson MA, et al. Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver. *Int J Radiat Oncol Biol Phys.* 2011;80(3):692-697. doi: 10.1016/j.ijrobp.2010.03.020.	Population
Andolino, D. L.,Johnson, C. S.,Maluccio, M.,Kwo, P.,Tector, A. J.,Zook, J.,Johnstone, P. A.,Cardenes, H. R.. **Stereotactic body radiotherapy for primary hepatocellular carcinoma.** *Int J Radiat Oncol Biol Phys.* 2011. 81:e447-53 #DOI#	Sample size
Andratschke, N.,Zimmermann, F.,Boehm, E.,Schill, S.,Schoenknecht, C.,Thamm, R., Molls, M.,Nieder, C.,Geinitz, H.. **Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: patterns of failure.** *Radiotherapy & Oncology.* 2011. 101:245-9 #DOI#	Population
Anstadt, Emily J,Shumway, Richard,Colasanto, Joseph,Grew, David. **Single community-based institutional series of stereotactic body radiation therapy (SBRT) for treatment of liver metastases.** *Journal of Gastrointestinal Oncology.* 2019. 10:330 #DOI#	Sample size
Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M, 3rd, Gottschalk A. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. *Radiat Oncol.* 2014;9:42. doi: 10.1186/1748-717X-9-42.	Outcomes
Anwar, M.,Weinberg, V.,Chang, A. J.,Hsu, I. C.,Roach, M., 3rd,Gottschalk, A.. **Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.** *Radiat Oncol.* 2014. 9:42 #DOI#	Outcomes
Aoki, M., Akimoto, H., Sato, M., Hirose, K., Kawaguchi, H., Hatayama, Y., Seino, H., Kakehata, S., Tsushima, F., Fujita, H., Fujita, T., Fujioka, I., Tanaka, M., Miura, H., Ono, S., Takai, Y.. **Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.** *J Radiat Res.* 2016. 57:533-540 10.1093/jrr/rrw045	Sample size
Aoki, M., Hatayama, Y., Kawaguchi, H., Hirose, K., Sato, M., Akimoto, H., Fujioka, I., Ono, S., Tsushima, E., Takai, Y.. **Clinical outcome of stereotactic body radiotherapy for primary and oligometastatic lung tumors: a single institutional study with almost uniform dose with different five treatment schedules.** *Radiation oncology (London, England).* 2016. 11:#pages# 10.1186/s13014-016-0581-2	Population
Arcelli, A., Bertini, F., Morganti, A. G., Guido, A., Deodato, F., Cilla, S., Scotti, V., Rosetto, M. E., Djan, I., Parisi, S., et al.. **SBRT vs conventionally fractionated radiochemotherapy for pancreatic cancer: a case-control study.** *Radiotherapy and oncology.* 2020. 152:S554-S555 10.1016/S0167-8140(21)01059-8	Publication type
Ashram, S., Bahig, H., Barry, A., Blanchette, D., Celinksi, A., Chung, P., Darko, J., Donath, D., Doucet, R., Erickson, A., et al.. **Planning Trade-offs for Stereotactic Ablative Radiotherapy in Patients with 4-10 Metastases: a Sub-study of the SABR-COMET-10 randomized trial.** *International journal of radiation oncology, biology, physics.* 2022. #volume#:#pages# 10.1016/j.ijrobp.2022.05.035	Publication type

Augugliaro, M., Marvaso, G., Ciardo, D., Corrao, G., Gandini, S., Pepa, M., Fodor, C., Zerini, D., Rojas, D. P., Bonizzi, G., et al.. **Radiosa trial: radioablation +/- hormonotherapy for prostate cancer oligorecurrences (AIRC IG-22159).** *Anticancer research.* 2020. 40:4616-4617 10.21873/anticanres.14463	Publication type
Baba, F.,Shibamoto, Y.,Ogino, H.,Murata, R.,Sugie, C.,Iwata, H.,Otsuka, S.,Kosaki, K., Nagai, A.,Murai, T.,Miyakawa, A.. **Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size.** *Radiation Oncology*. 2010. 5:81 #DOI#	Population
Backlund, E., Yang, M., Grozman, V., Masucci, G., Falkenius, J., Eriksson, H., Jovanovic, B., Hammarlund, K., Isacsson, U., Radu, C., et al.. **Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial.** *Acta oncologica.* 2022. 61:869-873 10.1080/0284186X.2022.2079959	Sample size
Bahig, H., Tonneau, M., Blais, N., Wong, P., Filion, E., Campeau, M. P., Vu, T., Al-Saleh, A., Tehfe, M., Florescu, M., et al.. **Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: a registry-based phase II randomized trial (SUPPRESS-NSCLC).** *Clinical and translational radiation oncology*. 2022. 33:115-119 10.1016/j.ctro.2021.12.008	Publication type
Baine, M. J., Verma, V., Schonewolf, C. A., Lin, C., Simone, C. B., 2nd. **Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer.** *Lung Cancer.* 2018. 118:20-26 https://dx.doi.org/10.1016/j.lungcan.2018.01.021	Population
Ball D, Mai GT, Vinod S, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. *Lancet Oncol.* 2019;20(4):494-503. doi: 10.1016/S1470-2045(18)30896-9.	Population
Ball, D., Mai, G. T., Vinod, S., Babington, S., Ruben, J., Kron, T., Chesson, B., Herschtal, A., Vanevski, M., Rezo, A.. **Quality of life in the CHISEL randomized trial of stereotactic ablative radiotherapy (SABR) versus standard radiotherapy for stage I non-small cell lung cancer (Trans-Tasman Radiation Oncology Group 09.02).** *Annals of oncology*. 2018. 29:#pages# 10.1093/annonc/mdy445	Publication type
Ball, D.,Mai, G. T.,Vinod, S.,Babington, S.,Ruben, J.,Kron, T.,Chesson, B.,Herschtal, A., Vanevski, M.,Rezo, A.,Elder, C.,Skala, M.,Wirth, A.,Wheeler, G.,Lim, A.,Shaw, M., Schofield, P.,Irving, L.,Solomon, B.,Trog Chisel investigators. **Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.** *Lancet Oncol.* 2019. 20:494-503 #DOI#	Population
Barriger RB, Forquer JA, Brabham JG, et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. *Int J Radiat Oncol Biol Phys.* 2012;82(1):457-462. doi: 10.1016/j.ijrobp.2010.08.056.	Population
Barry, A., Atenafu, E., Kim, J., Brierley, J., Ringash, J., Brade, A., Dinniwell, R., Wong, R., Cho, C., Kim, T., et al.. **STEREOTACTIC BODY RADIOTHERAPY FOR HEPATOCELLULAR CARCINOMA WITH MACROVASCULAR INVASION.** *Radiotherapy and oncology*. 2019. 139:S97- 10.1016/S0167-8140(19)33297-9	Publication type
Basina, B. R.,Olson, C.,Roy, D. K.,Yen, C. P.,Schlesinger, D.,Nagayama, K.,Sheehan, J. P.. **Radiation dose and incidence of new metastasis in the anterior temporal lobe**	Population

structures of radiosurgically treated patients. *Journal of Neurosurgery.* 2010. 112:122-9 #DOI#	
Baumann, P.,Nyman, J.,Hoyer, M.,Gagliardi, G.,Lax, I.,Wennberg, B.,Drugge, N.,Ekberg, L.,Friesland, S.,Johansson, K. A.,Lund, J. S.,Morhed, E.,Nilsson, K.,Levin, N.,Paludan, M., Sederholm, C.,Traberg, A.,Wittgren, L.,Lewensohn, R.. **Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study.** *Radiotherapy & Oncology.* 2008. 88:359-67 #DOI#	Population
Baumann, P.,Nyman, J.,Hoyer, M.,Wennberg, B.,Gagliardi, G.,Lax, I.,Drugge, N.,Ekberg, L.,Friesland, S.,Johansson, K. A.,Lund, J. A.,Morhed, E.,Nilsson, K.,Levin, N.,Paludan, M., Sederholm, C.,Traberg, A.,Wittgren, L.,Lewensohn, R.. **Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy.** *J Clin Oncol.* 2009. 27:3290-6 #DOI#	Population
Baydoun, A., Traughber, B., Morris, N., Abi Zeid Daou, M., McGraw, M., Podder, T. K., Muzic, R. F., Jr., Lo, S. S., Ponsky, L. E., Machtay, M., Ellis, R.. **Outcomes and toxicities in patients treated with definitive focal therapy for primary prostate cancer: systematic review.** *Future Oncology.* 2017. 13:649-663 https://dx.doi.org/10.2217/fon-2016-0354	Intervention
Becker, G.,Jeremic, B.,Pitz, S.,Buchgeister, M.,Wilhelm, H.,Schiefer, U.,Paulsen, F., Zrenner, E.,Bamberg, M.. **Stereotactic fractionated radiotherapy in patients with optic nerve sheath meningioma.** *International Journal of Radiation Oncology, Biology, Physics.* 2002. 54:1422-9 #DOI#	Population
Bell, L., Roderick, S., Eade, T., Hruby, G., Kneebone, A.. **Randomised clinical trial investigating dose escalated prostate stereotactic body radiotherapy: seeing beyond the obstacles.** *Journal of medical radiation sciences.* 2021. 68:31- 10.1002/jmrs.481	Publication type
Belluomini, L., Dionisi, V., Palmerio, S., Vincenzi, S., Avancini, A., Casali, M., Riva, S. T., Menis, J., Mazzarotto, R., Pilotto, S., et al.. **Study Design and Rationale for Espera Trial: a Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Immunotherapy Induction.** *Clinical lung cancer.* 2022. 23:e269-e272 10.1016/j.cllc.2021.07.004	Publication type
Benedict, Stanley H,Yenice, Kamil M,Followill, David,Galvin, James M,Hinson, William, Kavanagh, Brian,Keall, Paul,Lovelock, Michael,Meeks, Sanford,Papiez, Lech. **Stereotactic body radiation therapy: the report of AAPM Task Group 101.** *Medical physics.* 2010. 37:4078-4101 #DOI#	Publication type
Bentsen, K. K., Hansen, O., Jeppesen, S. S.. **COMBINATION OF G8 SCREENING TOOL AND HAND-GRIP STRENGTH TO PREDICT OVERALL SURVIVAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED WITH STEREOTACTIC BODY RADIOTHERAPY.** *Journal of geriatric oncology.* 2019. 10:S15-S16 10.1016/S1879-4068(19)31145-2	Publication type
Bergman, D.,Modh, A.,Schultz, L.,Snyder, J.,Mikkelsen, T.,Shah, M.,Ryu, S.,Siddiqui, M. S.,Walbert, T.. **Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma.** *J Neurooncol.* 2020. 148:353-361 #DOI#	Population
Berwouts, D., De Wolf, K., De Neve, W., Olteanu, L. A. M., Lambert, B., Speleers, B., Goethals, I., Madani, I., Ost, P.. **Variations in target volume definition and dose to normal tissue using anatomic versus biological imaging (18F-FDG-PET) in the**	Sample size

treatment of bone metastases: results from a 3-arm randomized phase II trial. *Journal of medical imaging and radiation oncology. (no pagination), 2016. Date of publication: 2016.*. 2016. #volume#:#pages# 10.1111/1754-9485.12507	
Bestvina, C. M., Pointer, K. B., Karrison, T., Al-Hallaq, H., Hoffman, P. C., Jelinek, M. J., Juloori, A., Melotek, J. M., Murgu, S., Partouche, J., et al.. **A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study.** *Journal of thoracic oncology.* 2022. 17:130-140 10.1016/j.jtho.2021.08.019	Sample size
Bezjak, A., Paulus, R., Gaspar, L. E., Timmerman, R. D., Straube, W. L., Ryan, W. F., Garces, Y. I., Pu, A. T., Singh, A. K., Videtic, G. M., McGarry, R. C., Iyengar, P., Pantarotto, J. R., Urbanic, J. J., Sun, A. Y., Daly, M. E., Grills, I. S., Sperduto, P., Normolle, D. P., Bradley, J. D., Choy, H.. **Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.** *Journal of Clinical Oncology.* 2019. 37:1316-1325 https://dx.doi.org/10.1200/JCO.18.00622	Population
Bhattasali O, Chen LN, Woo J, et al. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer. *Radiat Oncol.* 2014;9(1):52. doi: 10.1186/1748-717X-9-52.	Outcomes
Bhattasali, O.,Chen, L. N.,Woo, J.,Park, J. W.,Kim, J. S.,Moures, R.,Yung, T.,Lei, S., Collins, B. T.,Kowalczyk, K.,Suy, S.,Dritschilo, A.,Lynch, J. H.,Collins, S. P.. **Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.** *Radiat Oncol.* 2014. 9:52 #DOI#	Outcomes
Bibault JE, Dussart S, Pommier P, et al. Clinical outcomes of several IMRT techniques for patients with head and neck cancer: a propensity score-weighted analysis. *Int J Radiat Oncol Biol Phys.* 2017;99(4):929-937. doi: 10.1016/j.ijrobp.2017.06.2456.	Intervention
Bibault, Jean-Emmanuel,Dewas, Sylvain,Vautravers-Dewas, Claire,Hollebecque, Antoine,Jarraya, Hajer,Lacornerie, Thomas,Lartigau, Eric,Mirabel, Xavier. **Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity.** *PloS one.* 2013. 8:e77472 #DOI#	Sample size
Bilal, H.,Mahmood, S.,Rajashanker, B.,Shah, R.. **Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?.** *Interact Cardiovasc Thorac Surg.* 2012. 15:258-65 #DOI#	Study design
Biswas, T.,Okunieff, P.,Schell, M. C.,Smudzin, T.,Pilcher, W. H.,Bakos, R. S.,Vates, G. E., Walter, K. A.,Wensel, A.,Korones, D. N.,Milano, M. T.. **Stereotactic radiosurgery for glioblastoma: retrospective analysis.** *Radiation Oncology.* 2009. 4:11 #DOI#	Population
Blanchard, P., Foulon, S., Louvel, G., Habibian, M., Fizazi, K.. **A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation: a GETUG-AFU trial.** *Cancer radiotherapie.* 2017. 21:491-494 10.1016/j.canrad.2017.06.007	Non-English
Bledsoe, J. M.,Link, M. J.,Stafford, S. L.,Park, P. J.,Pollock, B. E.. **Radiosurgery for large-volume (> 10 cm3) benign meningiomas.** *Journal of Neurosurgery.* 2010. 112:951-6 #DOI#	Population
Boike, Thomas P,Lotan, Yair,Cho, L Chinsoo,Brindle, Jeffrey,DeRose, Paul,Xie, Xian-Jin, Yan, Jingsheng,Foster, Ryan,Pistenmaa, David,Perkins, Alida. **Phase I dose-escalation**	Sample size

study of stereotactic body radiation therapy for low-and intermediate-risk prostate cancer. *Journal of clinical oncology.* 2011. 29:2020 #DOI#	
Bolzicco, G.,Favretto, M. S.,Scremin, E.,Tambone, C.,Tasca, A.,Guglielmi, R.. **Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results.** *Technol Cancer Res Treat.* 2010. 9:473-7 #DOI#	Sample size
Bonomo P, Cipressi S, Saieva C, et al. Clinical outcome of stereotactic body radiotherapy for abdominal lymph node metastases. *Tumori.* 2013;99(5):611-616. doi: 10.1177/030089161309900509.	Sample size
Bonomo, P., Cipressi, S., Saieva, C., Greto, D., Masi, L., Paiar, F., Di Cataldo, V., Meattini, I., Cecchini, S., Mangoni, M., Doro, R., Iermano, C., Bonucci, I., Livi, L., Biti, G.. **Clinical outcome of stereotactic body radiotherapy for abdominal lymph node metastases.** *Tumori.* 2013. 99:611-6 10.1177/030089161309900509	Sample size
Boyer, M. J.,Papagikos, M. A.,Kiteley, R.,Vujaskovic, Z.,Wu, J.,Lee, W. R.. **Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer.** *Radiat Oncol.* 2017. 12:14 #DOI#	Sample size
Bradley, J. D.,El Naqa, I.,Drzymala, R. E.,Trovo, M.,Jones, G.,Denning, M. D.. **Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant.** *International Journal of Radiation Oncology, Biology, Physics.* 2010. 77:1146-50 #DOI#	Sample size
Brand D, Tree A, Fernandez K, et al. PH-0602: Dosimetric impact of central OAR review on rectal and bladder constraint attainment in PACE-B trial. *Radiotherapy and Oncology.* 2020;152:S339-S340. doi: 10.1016/s0167-8140(21)00624-1. *	Publication type
Brand DH, Tree A, Ostler P, et al. Patient Reported Acute Toxicity in PACE-B, an International Phase III Randomised Controlled Trial Comparing Stereotactic Body Radiotherapy to Conventionally Fractionated or Moderately Hypofractionated Radiotherapy (CFMHRT) for Localised Prostate Cancer. *International journal of radiation oncology biology physics.* 2019;105(1):S55-S56. doi: 10.1016/j.ijrobp.2019.06.490.	Publication type
Brand, D. H., Tree, A., Ostler, P., van der Voet, H., Loblaw, D. A., Chu, W., Ford, D., Tolan, S., Jain, S., Martin, A., et al.. **Patient Reported Acute Toxicity in PACE-B, an International Phase III Randomised Controlled Trial Comparing Stereotactic Body Radiotherapy to Conventionally Fractionated or Moderately Hypofractionated Radiotherapy (CFMHRT) for Localised Prostate Cancer.** *International journal of radiation oncology biology physics.* 2019. 105:S55-S56 10.1016/j.ijrobp.2019.06.490	Publication type
Brand, D., Tree, A., Fernandez, K., Naismith, O., Brueningk, S., Hall, E., Gulliford, S., Van As, N.. **Dosimetric impact of central OAR review on rectal and bladder constraint attainment in PACE-B trial.** *Radiotherapy and oncology.* 2020. 152:S339-S340 10.1016/S0167-8140(21)00624-1	Publication type
Broomfield, JA, Hirte, H, Elit, L, Kong, I, Patel, M, Voruganti, S, Smith, C, Chow, T, Swaminath, A. **Stereotactic ablative radiation therapy for gynecological malignancies in the oligometastatic setting.** *International Journal of Radiation Oncology, Biology, Physics.* 2014. 90:S908 #DOI#	Publication type
Brower JV, Forman JD, Kupelian PA, et al. Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer. *Radiotherapy & Oncology.* 2016;118(1):99-104. doi: https://dx.doi.org/10.1016/j.radonc.2015.12.018.	Intervention

Brown, W. T.,Wu, X.,Fayad, F.,Fowler, J. F.,Amendola, B. E.,Garcia, S.,Han, H.,de la Zerda, A.,Bossart, E.,Huang, Z.,Schwade, J. G.. **CyberKnife radiosurgery for stage I lung cancer: results at 36 months.** *Clinical Lung Cancer*. 2007. 8:488-92 #DOI#	Sample size
Brown, W. T.,Wu, X.,Wen, B. C.,Fowler, J. F.,Fayad, F.,Amendola, B. E.,Garcia, S.,De La Zerda, A.,Huang, Z.,Schwade, J. G.. **Early results of CyberKnife image-guided robotic stereotactic radiosurgery for treatment of lung tumors.** *Computer Aided Surgery*. 2007. 12:253-61 #DOI#	Sample size
Bryant AK, Mundt RC, Sandhu AP, et al. Stereotactic Body Radiation Therapy Versus Surgery for Early Lung Cancer Among US Veterans. *Annals of Thoracic Surgery*. 2018;105(2):425-431. doi: https://dx.doi.org/10.1016/j.athoracsur.2017.07.048.	Population
Bucknell, N., Kron, T., Herschtal, A., Irving, L., Siva, S., Ball, D.. **P2.17-21 A Post-Hoc Analysis of TROG 09.02 (CHISEL) Phase III Trial Investigating Pulmonary Function Changes After SABR and Conformal Radiation Therapy.** *Journal of thoracic oncology*. 2019. 14:S892- 10.1016/j.jtho.2019.08.1932	Publication type
Buckstein, M., Kim, E., Facciuto, M., Sung, M., Taouli, B., Schwartz, M., Rosenzweig, K.. **Phase II Trial Using Combination of TACE and SBRT for Unresectable Single Large HCC: interim Report.** *International journal of radiation oncology biology physics*. 2019. 105:E214-E215 10.1016/j.ijrobp.2019.06.2059	Publication type
Buergy, D., Wurschmidt, F., Gkika, E., Horner-Rieber, J., Knippen, S., Gerum, S., Balermpas, P., Henkenberens, C., Voglhuber, T., Kornhuber, C., Barczyk, S., Roper, B., Rashid, A., Blanck, O., Wittig, A., Herold, H. U., Brunner, T. B., Klement, R. J., Kahl, K. H., Ciernik, I. F., Ottinger, A., Izaguirre, V., Putz, F., Konig, L., Hoffmann, M., Combs, S. E., Guckenberger, M., Boda-Heggemann, J.. **Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis.** *International Journal of Cancer*. 2021. 149:358-370 https://dx.doi.org/10.1002/ijc.33546	Intervention
Burkon, P., Selingerova, I., Slavik, M., Kazda, T., Vrzal, M., Slampa, P.. **External beam APBI in early breast cancer: randomised prospective single institution study.** *Radiotherapy and oncology*. 2021. 161:S920-S921 10.1016/S0167-8140(21)07557-5	Publication type
Burkon, P., Slavik, M., Kazda, T., Vrzal, M., Slampa, P.. **Breast Cancer: toxicity, QoL and Economy after External Beam APBI.** *International journal of radiation oncology biology physics*. 2020. 108:e52- 10.1016/j.ijrobp.2020.07.1101	Publication type
Buyyounouski, Mark K,Price, Robert A,Harris, Eleanor ER,Miller, Robert,Tomé, Wolfgang,Schefter, Tracey,Parsai, E Ishmael,Konski, Andre A,Wallner, Paul E. **Stereotactic body radiotherapy for primary management of early-stage, low-to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee.** *International journal of radiation oncology, biology, physics*. 2010. 76:1297-1304 #DOI#	Publication type
C, De La Pinta, Latorre, R. G., Fuentes, R.. **SBRT in Localized Renal Carcinoma: A Review of the Literature.** *Anticancer Research*. 2022. 42:667-674 https://dx.doi.org/10.21873/anticanres.15525	Publication type
Cai, Y.,Chang, Q.,Xiao, E.,Shang, Q. L.,Chen, Z.. **Transcatheter arterial chemoembolization (TACE) combined with gamma-knife compared to TACE or Gamma-knife alone for hepatocellular carcinoma.** *Medicine (Baltimore)*. 2018. 97:e10890 #DOI#	Setting

Cao Y, Chen H, Sahgal A, et al. An international pooled analysis of SBRT outcomes to oligometastatic spine and non-spine bone metastases. *Radiother Oncol.* 2021;164:98-103. doi: 10.1016/j.radonc.2021.08.011.	Population
Cao, C., D'Amico, T., Demmy, T., Dunning, J., Gossot, D., Hansen, H., He, J., Jheon, S., Petersen, R. H., Sihoe, A., et al.. **Surgery versus SABR for resectable non-small-cell lung cancer.** *Lancet oncology.* 2015. 16:e370-e371 10.1016/S1470-2045(15)00036-4	Publication type
Cao, M., Qiao-Guan, G., Zhouhuizi, S., Steinberg, M. L., Nickols, N. G., Kupelian, P. A., King, C. R., Kishan, A. U.. **Clinical Assessment of the Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer.** *International journal of radiation oncology biology physics.* 2019. 105:E758-E759 10.1016/j.ijrobp.2019.06.788	Publication type
Cao, Y., Chen, H., Sahgal, A., Erler, D., Badellino, S., Biswas, T., Dagan, R., Foote, M. C., Louie, A. V., Poon, I., Ricardi, U., Redmond, K. J.. **Volumetric burden of metastatic lesions drives outcomes in patients with extracranial oligometastatic disease.** *Cancer Medicine.* 2021. 10:8091-8099 https://dx.doi.org/10.1002/cam4.4332	Outcomes
Cao, Y., Chen, H., Sahgal, A., Erler, D., Badellino, S., Biswas, T., Dagan, R., Foote, M. C., Louie, A. V., Poon, I., Ricardi, U., Redmond, K. J.. **An international pooled analysis of SBRT outcomes to oligometastatic spine and non-spine bone metastases.** *Radiotherapy & Oncology.* 2021. 164:98-103 https://dx.doi.org/10.1016/j.radonc.2021.08.011	Population
Casamassima, F.,Livi, L.,Masciullo, S.,Menichelli, C.,Masi, L.,Meattini, I.,Bonucci, I., Agresti, B.,Simontacchi, G.,Doro, R.. **Stereotactic radiotherapy for adrenal gland metastases: university of Florence experience.** *Int J Radiat Oncol Biol Phys.* 2012. 82:919-23 #DOI#	Sample size
Casamassima, F.,Masi, L.,Bonucci, I.,Polli, C.,Menichelli, C.,Gulisano, M.,Pacini, S., Aterini, S.,Cavedon, C.. **Relevance of biologically equivalent dose values in outcome evaluation of stereotactic radiotherapy for lung nodules.** *International Journal of Radiation Oncology, Biology, Physics.* 2008. 71:145-51 #DOI#	Sample size
Castelluccia, A., Mincarone, P., Tumolo, M. R., Sabina, S., Colella, R., Bodini, A., Tramacere, F., Portaluri, M., Leo, C. G.. **Economic Evaluations of Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A Systematic Review.** *International Journal of Environmental Research & Public Health [Electronic Resource].* 2022. 19:30 https://dx.doi.org/10.3390/ijerph191710800	Outcomes
Ceylan, C., Hamaci, A., Ayata, H., Berberoglu, K., Kilic, A., Guden, M., Engin, K.. **Re-Irradiation of Locoregional NSCLC Recurrence Using Robotic Stereotactic Body Radiotherapy.** *Oncol Res Treat.* 2017. 40:207-214 10.1159/000457129	Sample size
Cha, H., Park, H. C., Yu, J. I., Kim, T. H., Nam, T. K., Yoon, S. M., Yoon, W. S., Kim, J. W., Kim, M. S., Jang, H. S., Choi, Y., Kim, J. H., Kay, C. S., Jung, I., Seong, J.. **Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07).** *Cancer Research & Treatment.* 2017. 49:61-69 https://dx.doi.org/10.4143/crt.2016.097	Study design
Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. *Lancet Oncol.* 2015;16(6):630-637. doi: 10.1016/S1470-2045(15)70168-3.	Study design
Chang, Brian K,Timmerman, Robert D. **Stereotactic body radiation therapy: a comprehensive review.** *American journal of clinical oncology.* 2007. 30:637-644 #DOI#	Publication type

Chang, D. T.,Schellenberg, D.,Shen, J.,Kim, J.,Goodman, K. A.,Fisher, G. A.,Ford, J. M., Desser, T.,Quon, A.,Koong, A. C.. **Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas.** *Cancer.* 2009. 115:665-72 #DOI#	Sample size
Chang, D. T.,Swaminath, A.,Kozak, M.,Weintraub, J.,Koong, A. C.,Kim, J.,Dinniwell, R., Brierley, J.,Kavanagh, B. D.,Dawson, L. A.,Schefter, T. E.. **Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis.** *Cancer.* 2011. 117:4060-9 #DOI#	Sample size
Chang, J. H.,Chang, J. W.,Choi, J. Y.,Park, Y. G.,Chung, S. S.. **Complications after gamma knife radiosurgery for benign meningiomas.** *Journal of Neurology, Neurosurgery & Psychiatry.* 2003. 74:226-30 #DOI#	Population
Chang, J. Y., Feng, L., Lin, S. H., Welsh, J. W., Antonoff, M., Gomez, D. R., Heymach, J.. **Phase II randomized clinical trial comparing immunotherapy plus stereotactic ablative radiotherapy (I-SABR) versus SABR alone for stage I, selected stage IIa or isolated lung parenchymal recurrent non-small cell lung cancer: I-SABR.** *Journal of clinical oncology.* 2018. 36:#pages# 10.1200/JCO.2018.36.15-suppl.TPS8580	Publication type
Chang, J. Y., Lin, S. H., Yao, L., Gandhi, S., Liao, Z. X., Chun, S. G., Jeter, M., Welsh, J. W., Lee, P., Antonoff, M., et al.. **I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: interim analysis adverse effects.** *Journal of clinical oncology.* 2020. 38:#pages# 10.1200/JCO.2020.38.15-suppl.9035	Publication type
Chang, J. Y.,Balter, P. A.,Dong, L.,Yang, Q.,Liao, Z.,Jeter, M.,Bucci, M. K.,McAleer, M. F., Mehran, R. J.,Roth, J. A.,Komaki, R.. **Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer.** *Int J Radiat Oncol Biol Phys.* 2008. 72:967-71 #DOI#	Sample size
Chang, J., Feng, L., Lin, S. H., Welsh, J. W., Antonoff, M. B., Gomez, D., Heymach, J.. **Randomized Clinical Trial Comparing Immunotherapy Plus SABR (I-SABR) Versus SABR Alone for Early Stage NSCLC.** *Journal of thoracic oncology.* 2018. 13:S740-10.1016/j.jtho.2018.08.1249	Publication type
Chang, S. D.,Gibbs, I. C.,Sakamoto, G. T.,Lee, E.,Oyelese, A.,Adler, J. R., Jr.. **Staged stereotactic irradiation for acoustic neuroma.** *Neurosurgery.* 2005. 56:1254-61; discussion 1261-3 #DOI#	Population
Chao, S. T.,Thakkar, V. V.,Barnett, G. H.,Vogelbaum, M. A.,Angelov, L.,Weil, R. J., Rasmussen, P.,Reuther, A. M.,Jamison, B.,Neyman, G.,Suh, J. H.. **Prospective study of the short-term adverse effects of gamma knife radiosurgery.** *Technology in Cancer Research & Treatment.* 2012. 11:117-22 #DOI#	Sample size
Chapet, O., De Laroche, G., Dorel, S. B., Latorzeff, I., Supiot, S., Votron, L., Resbeut, M., Verry, C., Udrescu, C., Cabelguenne, D., et al.. **Prostate hypofractionated radiation therapy with a rectal spacer comparing moderate hypofractionation (62 Gy at 3.1 Gy per fraction) versus stereotactic irradiation (37.5 Gy at 7.5 Gy per fraction): acute toxicities from the rpah2 randomized trial.** *International journal of radiation oncology biology physics.* 2017. 99:E218-E219 10.1016/j.ijrobp.2017.06.1126	Publication type
Chaudhry, H, Oermann, E, Suy, S, Yu, X, Collins, SP, Barnes, W, Collins, BT. **Stereotactic Body Radiation Therapy (SBRT) for Single Small (< 5 cm) Extracranial Ovarian or Uterine Cancer Metastases: Promising Local Control and Normal Tissue Tolerance With 5 Fraction Approach.** *International Journal of Radiation Oncology, Biology, Physics.* 2012. 84:S448 #DOI#	Publication type

Chaudhuri, A. A., Tang, C., Binkley, M. S., Jin, M., Wynne, J. F., von Eyben, R., Hara, W. Y., Trakul, N., Loo, B. W., Jr., Diehn, M.. **Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.** *Lung Cancer.* 2015. 89:50-6 10.1016/j.lungcan.2015.04.014	Sample size
Chaurasia AR, White J, Beckmann RC, et al. Early-Stage Non-Small Cell Lung Cancer Stereotactic Body Radiation Therapy (SBRT) Outcomes in an Equal Access Military Setting. *Cureus.* 2021;13(2):e13485. doi: https://dx.doi.org/10.7759/cureus.13485.	Population
Chaw, C. L., deSouza, N. M., Khoo, V., Suh, Y. E., van As, N.. **Clinical Outcomes of Stereotactic Body Radiotherapy With Immediate Versus Delayed Hormone Therapy in Men With Oligometastatic Recurrence of Prostate Cancer.** *Clinical oncology.* 2020. #volume#:#pages# 10.1016/j.clon.2020.03.008	Sample size
Chawla, S.,Chen, Y.,Katz, A. W.,Muhs, A. G.,Philip, A.,Okunieff, P.,Milano, M. T.. **Stereotactic body radiotherapy for treatment of adrenal metastases.** *Int J Radiat Oncol Biol Phys.* 2009. 75:71-5 #DOI#	Sample size
Chen LN, Suy S, Wang H, et al. Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. *Radiat Oncol.* 2014;9(1):148. doi: 10.1186/1748-717X-9-148.	Outcomes
Chen X, Chen H, Poon I, et al. Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis. *Cancer Medicine.* 2021;10(18):6189-6198. doi: https://dx.doi.org/10.1002/cam4.4133.	Outcomes
Chen, D., Chang, J. Y., Heymach, J., Tang, C., Nguyen, Q. N., Welsh, J. W.. **Secondary Analysis of a Randomized Phase 1/2 Trial of Pembrolizumab with or without Radiation Therapy for Metastatic Non-small Cell Lung Cancer.** *International journal of radiation oncology biology physics.* 2020. 108:S73- 10.1016/j.ijrobp.2020.07.2216	Publication type
Chen, D., Menon, H., Verma, V., Guo, C., Ramapriyan, R., Barsoumian, H., Younes, A., Hu, Y., Wasley, M., Cortez, M. A., et al.. **Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials.** *Journal for immunotherapy of cancer.* 2020. 8:#pages# 10.1136/jitc-2019-000492	Sample size
Chen, H. H.,Tsai, S. T.,Wang, M. S.,Wu, Y. H.,Hsueh, W. T.,Yang, M. W.,Yeh, I. C.,Lin, J. C.. **Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma.** *Int J Radiat Oncol Biol Phys.* 2006. 66:1408-14 #DOI#	Sample size
Chen, I. M., Johansen, J. S., Theile, S., Hjaltelin, J. X., Novitski, S. I., Brunak, S., Hasselby, J. P., Willemoe, G. L., Lorentzen, T., Madsen, K., et al.. **Randomized phase 2 study of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy in patients with refractory metastatic pancreatic cancer (CHECKPAC).** *Journal of clinical oncology.* 2022. 40:#pages# 10.1200/JCO.2022.40.4_suppl.554	Publication type
Chen, I. M., Johansen, J. S., Theile, S., Hjaltelin, J. X., Novitski, S. I., Brunak, So, Hasselby, J. P., Willemoe, G. L., Lorentzen, T., Madsen, K., et al.. **Randomized Phase II Study of Nivolumab with or Without Ipilimumab Combined with Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC).** *Journal of clinical oncology.* 2022. 71:#pages# 10.1200/JCO.21.02511	Comparator
Chen, L. N.,Suy, S.,Wang, H.,Bhagat, A.,Woo, J. A.,Moures, R. A.,Kim, J. S.,Yung, T. M., Lei, S.,Collins, B. T.,Kowalczyk, K.,Dritschilo, A.,Lynch, J. H.,Collins, S. P.. **Patient-**	Outcomes

reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. *Radiat Oncol.* 2014. 9:148 #DOI#	
Chen, W., Lin, Q., Sun, X., Liu, J., Xu, Y., Chen, Q., Mao, W.. **A propensity-matched analysis of stereotactic body radiotherapy and sublobar resection for stage I non-small cell lung cancer in patients at high risk for lobectomy.** *Journal of clinical oncology.* 2017. 35:#pages# #DOI#	Publication type
Chen, Y.,Guo, W.,Lu, Y.,Zou, B.. **Dose-individualized stereotactic body radiotherapy for T1-3N0 non-small cell lung cancer: long-term results and efficacy of adjuvant chemotherapy.** *Radiother Oncol.* 2008. 88:351-8 #DOI#	Sample size
Cheshier, S. H.,Hanft, S. J.,Adler, J. R.,Chang, S. D.. **CyberKnife radiosurgery for lesions of the foramen magnum.** *Technology in Cancer Research & Treatment.* 2007. 6:329-36 #DOI#	Population
Chetty, I. J., Doemer, A. J., Dolan, J. L., Kim, J. P., Cunningham, J. M., Dragovic, J., Feldman, A., Walker, E. M., Elshaikh, M., Adil, K., Movsas, B., Parikh, P. J.. **MRI-guided Radiotherapy (MRgRT) for Treatment of Oligometastases: Review of Clinical Applications and Challenges.** *International Journal of Radiation Oncology, Biology, Physics.* 2022. 25:25 https://dx.doi.org/10.1016/j.ijrobp.2022.07.027	Publication type
Cheung, P., Faria, S., Ahmed, S., Chabot, P., Greenland, J., Kurien, E., Mohamed, I., Wright, J. R., Hollenhorst, H., de Metz, C., Campbell, H., Vu, T. T., Karvat, A., Wai, E. S., Ung, Y. C., Goss, G., Shepherd, F. A., O'Brien, P., Ding, K., O'Callaghan, C.. **Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25.** *J Natl Cancer Inst.* 2014. 106:dju164 10.1093/jnci/dju164	Sample size
Cheung, Patrick,Patel, Samir,North, Scott A,Sahgal, Arjun,Chu, William,Soliman, Hany, Ahmad, Belal,Winquist, Eric,Niazi, Tamim,Patenaude, Francois. **Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study.** *European Urology.* 2021. 80:693-700 #DOI#	Sample size
Chiang A, Thibault I, Warner A, et al. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): results of a propensity score-matched analysis. *Radiother Oncol.* 2016;118(3):478-484. doi: 10.1016/j.radonc.2015.12.026.	Population
Chihara, Yasuhiro,Ito, Ken,Sugasawa, Keiko,Shin, Masahiro. **Neurological complications after acoustic neurinoma radiosurgery: revised risk factors based on long-term follow-up.** *Acta Oto-Laryngologica.* 2007. 127:65-70 #DOI#	Population
Chipko C, Ojwang J, Gharai LR, Deng X, Mukhopadhyay N, Weiss E. Characterization of chest wall toxicity during long-term follow up after thoracic stereotactic body radiation therapy. *Pract Radiat Oncol.* 2019;9(3):e338-e346. doi: 10.1016/j.prro.2019.01.012 Accessed 20190204//.	Population
Chmura, S. J., Bestvina, C. M., Karrison, T. G., Jelinek, M., Juloori, A., Pointer, K. B., Onderdonk, B. E., Hoffman, P., Melotek, J. M., Gordon, J., et al.. **Safety and Efficacy of a Randomized Phase I Trial to Evaluate Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-small Cell Lung Cancer (COSINR Study).** *International journal of radiation oncology biology physics.* 2020. 108:S72- 10.1016/j.ijrobp.2020.07.2214	Publication type

Chmura, S. J., Winter, K. A., Al-Hallaq, H. A., Borges, V. F., Jaskowiak, N. T., Matuszak, M., Milano, M. T., Salama, J. K., Woodward, W. A., White, J. R.. **NRG-BR002: a phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer (NCT02364557).** *Journal of clinical oncology.* 2019. 37:#pages# 10.1200/JCO.2019.37.15-suppl.TPS1117	Publication type
Chmura, S. J., Winter, K. A., Salama, J. K., Woodward, W. A., Borges, V. F., Al-Hallaq, H. A., Matuszak, M., Jaskowiak, N. T., Milano, M. T., Bandos, H., et al.. **NRG BR002: a phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer.** *Journal of clinical oncology.* 2015. 33:#pages# #DOI#	Publication type
Chmura, S. J., Winter, K. A., Salama, J. K., Woodward, W. W., Borges, V. F., AlHallaq, H., Martuszak, M., Jaskowiak, N. T., Milano, M. T., Bandos, H., et al.. **NRGBR002: a phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) &/or surgical ablation for newly oligo-metastatic breast cancer.** *Cancer research.* 2017. 77:#pages# 10.1158/1538-7445.SABCS16OT1-04-06	Publication type
Chmura, S. J., Winter, K. A., Woodward, W. A., Borges, V. F., Salama, J. K., Al-Hallaq, H. A., Matuszak, M., Milano, M. T., Jaskowiak, N. T., Bandos, H., et al.. **NRG-BR002: a phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557).** *Journal of clinical oncology.* 2022. 40:#pages# 10.1200/JCO.2022.40.16_suppl.1007	Publication type
Chockalingam, A., Konstantinidis, M., Koo, B., Moon, J. T., Tran, A., Nourouzpour, S., Lawson, E., Fox, K., Habibollahi, P., Odisio, B., Loya, M., Bassir, A., Nezami, N.. **Surgical resection, radiotherapy and percutaneous thermal ablation for treatment of stage 1 non-small cell lung cancer: protocol for a systematic review and network meta-analysis.** *BMJ Open.* 2022. 12:e057638 https://dx.doi.org/10.1136/bmjopen-2021-057638	Publication type
Choi, Byung Ock,Choi, Ihl Bohng,Jang, Hong Seok,Kang, Young Nam,Jang, Ji Sun,Bae, Si Hyun,Yoon, Seung Kew,Chai, Gyu Young,Kang, Ki Mun. **Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis.** *BMC cancer.* 2008. 8:1-8 #DOI#	Sample size
Choi, C. W.,Cho, C. K.,Yoo, S. Y.,Kim, M. S.,Yang, K. M.,Yoo, H. J.,Seo, Y. S.,Kang, J. K., Lee, D. H.,Lee, K. H.,Lee, E. D.,Rhu, S. Y.,Choi, S. C.,Kim, M. H.,Kim, B. J.. **Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer.** *Int J Radiat Oncol Biol Phys.* 2009. 74:147-53 #DOI#	Sample size
Chopra, R.,Kondziolka, D.,Niranjan, A.,Lunsford, L. D.,Flickinger, J. C.. **Long-term follow-up of acoustic schwannoma radiosurgery with marginal tumor doses of 12 to 13 Gy.** *International Journal of Radiation Oncology, Biology, Physics.* 2007. 68:845-51 #DOI#	Population
Chung, W. Y.,Liu, K. D.,Shiau, C. Y.,Wu, H. M.,Wang, L. W.,Guo, W. Y.,Ho, D. M.,Pan, D. H.. **Gamma knife surgery for vestibular schwannoma: 10-year experience of 195 cases.** *Journal of Neurosurgery.* 2005. 102 Suppl:87-96 #DOI#	Population
Claude L, Morelle M, Mahe MA, et al. A comparison of two modalities of stereotactic body radiation therapy for peripheral early-stage non-small cell lung cancer: results of	Population

a prospective French study. *British journal of radiology*. 2020;93(1116):20200256-. doi: 10.1259/bjr.20200256.	
Colin, P.,Jovenin, N.,Delemer, B.,Caron, J.,Grulet, H.,Hecart, A. C.,Lukas, C.,Bazin, A., Bernard, M. H.,Scherpereel, B.,Peruzzi, P.,Nakib, I.,Redon, C.,Rousseaux, P.. **Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: a prospective study of 110 patients.** *International Journal of Radiation Oncology, Biology, Physics.* 2005. 62:333-41 #DOI#	Population
Collen, C.,Ampe, B.,Gevaert, T.,Moens, M.,Linthout, N.,De Ridder, M.,Verellen, D., D'Haens, J.,Storme, G.. **Single fraction versus fractionated linac-based stereotactic radiotherapy for vestibular schwannoma: a single-institution experience.** *International Journal of Radiation Oncology, Biology, Physics.* 2011. 81:e503-9 #DOI#	Population
Combs, S. E.,Thilmann, C.,Edler, L.,Debus, J.,Schulz-Ertner, D.. **Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.** *Journal of Clinical Oncology*. 2005. 23:8863-9 #DOI#	Population
Combs, S. E.,Welzel, T.,Schulz-Ertner, D.,Huber, P. E.,Debus, J.. **Differences in clinical results after LINAC-based single-dose radiosurgery versus fractionated stereotactic radiotherapy for patients with vestibular schwannomas.** *International Journal of Radiation Oncology, Biology, Physics.* 2010. 76:193-200 #DOI#	Population
Conibear, J., Chia, B., Ngai, Y., Bates, A. T., Counsell, N., Patel, R., Eaton, D., Faivre-Finn, C., Fenwick, J., Forster, M., et al.. **Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer.** *BMJ open.* 2018. 8:#pages# 10.1136/bmjopen-2017-020690	Publication type
Coon, D.,Gokhale, A. S.,Burton, S. A.,Heron, D. E.,Ozhasoglu, C.,Christie, N.. **Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning.** *Clin Lung Cancer.* 2008. 9:217-21 #DOI#	Sample size
Coppa, N. D.,Raper, D. M.,Zhang, Y.,Collins, B. T.,Harter, K. W.,Gagnon, G. J.,Collins, S. P.,Jean, W. C.. **Treatment of malignant tumors of the skull base with multi-session radiosurgery.** *Journal of hematology & oncology*. 2009. 2:16 #DOI#	Population
Corbin, Kimberly S,Hellman, Samuel,Weichselbaum, Ralph R. **Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy.** *J Clin Oncol.* 2013. 31:1384-1390 #DOI#	Publication type
Cornwell LD, Echeverria AE, Samuelian J, et al. Video-assisted thoracoscopic lobectomy is associated with greater recurrence-free survival than stereotactic body radiotherapy for clinical stage I lung cancer. *J Thorac Cardiovasc Surg*. 2018;155(1):395-402. doi: 10.1016/j.jtcvs.2017.07.065.	Population
Correa RJM, Morton G, Chung HT, et al. Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter? *Radiother Oncol.* 2022;169:51-56. doi: 10.1016/j.radonc.2022.02.007.	Comparator
Correa, R. J. M., Morton, G., Chung, H. T., Tseng, C. L., Cheung, P., Chu, W., Liu, S. K., McGuffin, M., Shahid, A., Davidson, M., et al.. **Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for**	Comparator

localized prostate cancer: does dose heterogeneity matter?. *Radiotherapy and oncology*. 2022. #volume#:#pages# 10.1016/j.radonc.2022.02.007	
Correa, R., Morton, G., Chung, H., Tseng, C., Cheung, P., Chu, W., Liu, S., McGuffin, M., Shahid, A., Davidson, M., et al.. **Two-fraction prostate SABR vs. two-fraction HDR brachytherapy: does dose heterogeneity matter?.** *Radiotherapy and oncology*. 2022. 170:S1193-S1194 10.1016/S0167-8140(22)03372-2	Publication type
Cousins, M. M., Aghdam, N., Dess, R. T., Suy, S., Desai, N. B., Spratt, D. E., Collins, S. P., Jackson, W. C.. **Transient Declines in Serum Testosterone Levels Following Prostate SBRT Do Not Drive Post-treatment Declines in Health-Related Sexual Quality of Life.** *International journal of radiation oncology biology physics*. 2019. 105:E272-10.1016/j.ijrobp.2019.06.1891	Publication type
Crabtree T, Puri V, Timmerman R, et al. Treatment of stage I lung cancer in high-risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033). *J Thorac Cardiovasc Surg*. 2013;145(3):692-699. doi: 10.1016/j.jtcvs.2012.10.038.	Study design
Crabtree TD, Puri V, Robinson C, et al. Analysis of first recurrence and survival in patients with stage I non-small cell lung cancer treated with surgical resection or stereotactic radiation therapy. *J Thorac Cardiovasc Surg*. 2014;147(4):1183-1191; discussion 1191-1182. doi: 10.1016/j.jtcvs.2013.11.057.	Population
Cummings, M. A., Ma, S. J., Hermann, G., Serra, L., Syed, Y., Malhotra, H. K., Chen, Y., Milano, M. T., Gomez-Suescun, J. A., Singh, D. P., Singh, A. K.. **Comparison of Single- and Five-fraction Regimens of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-small-cell Lung Cancer: A Two-institution Propensity-matched Analysis.** *Clin Lung Cancer*. 2018. 19:511-517 10.1016/j.cllc.2018.07.006	Comparator
Curti, B.,Crittenden, M.,Seung, S. K.,Fountain, C. B.,Payne, R.,Chang, S.,Fleser, J., Phillips, K.,Malkasian, I.,Dobrunick, L. B.,Urba, W. J.. **Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma.** *J Immunother Cancer*. 2020. 8:#pages# #DOI#	Sample size
Dagoglu, Nergiz,Callery, Mark,Moser, James,Tseng, Jennifer,Kent, Tara,Bullock, Andrea,Miksad, Rebecca,Mancias, Joseph D,Mahadevan, Anand. **Stereotactic body radiotherapy (SBRT) reirradiation for recurrent pancreas cancer.** *Journal of Cancer*. 2016. 7:283 #DOI#	Sample size
Dagoglu, Nergiz,Callery, Mark,Moser, James,Tseng, Jennifer,Kent, Tara,Bullock, Andrea,Miksad, Rebecca,Mancias, Joseph D,Mahadevan, Anand. **Stereotactic body radiotherapy (SBRT) reirradiation for recurrent pancreas cancer.** *Journal of Cancer*. 2016. 7:283 #DOI#	Sample size
D'Agostino G, Franzese C, De Rose F, et al. High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Low-Intermediate Risk Prostate Cancer. A Mono-institutional Experience with 90 Patients. *Clin Oncol (R Coll Radiol)*. 2016;28(12):e173-e178. doi: 10.1016/j.clon.2016.06.013.	Sample size
D'Agostino, G.,Franzese, C.,De Rose, F.,Franceschini, D.,Comito, T.,Villa, E.,Alongi, F., Liardo, R.,Tomatis, S.,Navarria, P.,Mancosu, P.,Reggiori, G.,Cozzi, L.,Scorsetti, M.. **High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Low-Intermediate Risk Prostate**	Sample size

Cancer. A Mono-institutional Experience with 90 Patients. *Clin Oncol (R Coll Radiol).* 2016. 28:e173-e178 #DOI#	
Dang AT, Levin-Epstein RG, Shabsovich D, et al. Gantry-Mounted Linear Accelerator-Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer. *Advances in radiation oncology.* 2020;5(3):404-411. doi: https://dx.doi.org/10.1016/j.adro.2019.09.010.	Study design
D'Angelillo, R. M., Francolini, G., Ingrosso, G., Ravo, V., Triggiani, L., Magli, A., Mazzeo, E., Arcangeli, S., Alongi, F., Jereczek-Fossa, B. A., Pergolizzi, S., Pappagallo, G. L., Magrini, S. M.. **Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO).** *Critical Reviews in Oncology-Hematology.* 2019. 138:24-28 https://dx.doi.org/10.1016/j.critrevonc.2019.03.014	Aim
Danner M, Hung M-y, Yung TM, et al. Utilization of Patient-Reported Outcomes to Guide Symptom Management during Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer. *Frontiers in Oncology.* 2017;7. doi: 10.3389/fonc.2017.00227.	Outcomes
Dash, Chiranjeev,Demas, Kristina,Uhm, Sunghae,Hanscom, Heather N,Kim, Joy S,Suy, Simeng,Davis, Kimberly M,Sween, Jennifer,Collins, Sean,Adams-Campbell, Lucile L. **Low incidence of fatigue after hypofractionated stereotactic body radiation therapy for localized prostate cancer.** *Frontiers in Oncology.* 2012. 2:142 #DOI#	Sample size
Dash, Chiranjeev,Demas, Kristina,Uhm, Sunghae,Hanscom, Heather N,Kim, Joy S,Suy, Simeng,Davis, Kimberly M,Sween, Jennifer,Collins, Sean,Adams-Campbell, Lucile L. **Low incidence of fatigue after hypofractionated stereotactic body radiation therapy for localized prostate cancer.** *Frontiers in Oncology.* 2012. 2:142 #DOI#	Sample size
David, S., Savas, P., Siva, S., White, M., Neeson, M. W., White, S., Marx, G., Cheuk, R., Grogan, M., Farrell, M., et al.. **A randomised phase II trial of single fraction or multi-fraction SABR (stereotactic ablative body radiotherapy) with atezolizumab in patients with advanced triple negative breast cancer (AZTEC trial).** *Cancer research.* 2022. 82:#pages# 10.1158/1538-7445.SABCS21-PD10-02	Publication type
David, S., Savas, P., Siva, S., White, M., Neeson, M. W., White, S., Marx, G., Cheuk, R., Grogan, M., Farrell, M., et al.. **A randomised phase II trial of single fraction or multi-fraction SABR (stereotactic ablative body radiotherapy) with atezolizumab in patients with advanced triple negative breast cancer (AZTEC trial).** *Cancer research.* 2022. 82:#pages# 10.1158/1538-7445.SABCS21-PD10-02	Publication type
Davis JN, Medbery C, 3rd, Sharma S, Danish A, Mahadevan A. The RSSearch TM Registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy. *Radiation Oncology.* 2013;8:275. doi: https://dx.doi.org/10.1186/1748-717X-8-275.	Outcomes
Dawson LA, Zhu A, Knox J, et al. Radiation Therapy Oncology Group RTOG 1112 randomized phase III study of sorafenib versus stereotactic body radiation therapy followed by sorafenib in hepatocellular carcinoma. *Radiation Oncology Available online: https://www ctsu org.* 2020.	Publication type
De Caluwe, A., Buisseret, L., Poortmans, P., Sotiriou, C., Larsimont, D., Van Gestel, D., Laragione, A., Desmet, A., Van Den Begin, R., Philippson, C., et al.. **84TiP Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer: a randomized phase II trial.** *Annals of oncology.* 2020. 31:S1451- 10.1016/j.annonc.2020.10.571	Publication type

De Caluwé, A., Buisseret, L., Poortmans, P., Van Gestel, D., Salgado, R., Sotiriou, C., Larsimont, D., Paesmans, M., Craciun, L., Stylianos, D., et al.. **Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.** *BMC cancer.* 2021. 21:899 10.1186/s12885-021-08601-1	Publication type
De La Pinta Alonso, C., Vallejo Ocana, C., Hernanz De Lucas, R., Martin Martin, M., Fernandez-Lizarbe, E., Martin Sanchez, M., Dominguez Rullan, J., Munoz Miguelaez, T., Lopez Campos, F., Hervas Moron, A., et al.. **Stereotactic body radiotherapy for oligometastatic and oligoprogression patients.** *Radiotherapy and oncology.* 2018. 127:S913- #DOI#	Publication type
de Vin T, Engels B, Gevaert T, Storme G, De Ridder M. Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. *Annals of Oncology.* 2014;25(2):467-471. doi: https://dx.doi.org/10.1093/annonc/mdt537.	Outcomes
de Vries KC, Wortel RC, Oomen-de Hoop E, Heemsbergen WD, Pos FJ, Incrocci L. Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate-or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial. *International Journal of Radiation Oncology* Biology* Physics.* 2020;106(1):108-115. https://www.redjournal.org/article/S0360-3016(19)33827-1/fulltext.	Intervention
de Vries, Kim C,Wortel, Ruud C,Oomen-de Hoop, Esther,Heemsbergen, Wilma D,Pos, Floris J,Incrocci, Luca. **Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate-or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial.** *International Journal of Radiation Oncology* Biology* Physics.* 2020. 106:108-115 #DOI#	Intervention
Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. *Lancet Oncol.* 2007;8(6):475-487. doi: 10.1016/s1470-2045(07)70143-2.	Comparator
deBettencourt, M., Harris, A. A., Stang, K., Cottler, S., Refaat, T., Molvar, C., Thomas, T. O.. **Stereotactic Body Radiotherapy and Yttrium-90 in the Treatment of Hepatocellular Carcinoma: a Comparison of Outcomes and Costs.** *International journal of radiation oncology biology physics.* 2021. 111:e36-e37 10.1016/j.ijrobp.2021.07.354	Publication type
Deek MP, Taparra K, Dao D, et al. Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. *International Journal of Radiation Oncology, Biology, Physics.* 2021;109(2):387-395. doi: https://dx.doi.org/10.1016/j.ijrobp.2020.08.030.	Outcomes
Deinsberger, R.,Tidstrand, J.,Sabitzer, H.,Lanner, G.. **LINAC radiosurgery in skull base meningiomas.** *Minimally Invasive Neurosurgery.* 2004. 47:333-8 #DOI#	Population
Dess RT, Devasia TP, Aghdam N, et al. Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. *Int J Radiat Oncol Biol Phys.* 2018;101(2):376-386. doi: 10.1016/j.ijrobp.2018.01.055. .	Outcomes
Dess RT, Hartman HE, Aghdam N, et al. Erectile function after stereotactic body radiotherapy for localized prostate cancer. *BJU International.* 2018;121(1):61-68. doi: https://dx.doi.org/10.1111/bju.13962. .	Outcomes
Dess RT, Jackson WC, Suy S, et al. Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.	Outcomes

Cancer. 2017;123(9):1635-1642. https://deepblue.lib.umich.edu/bitstream/handle/2027.42/136687/cncr30519_am.pdf?sequence=1.	
Dess, R. T., Hartman, H. E., Aghdam, N., Jackson, W. C., Soni, P. D., Abugharib, A. E., Suy, S., Desai, N. B., Zumsteg, Z. S., Mehra, R., Morgan, T. M., Feng, F. Y., Hamstra, D. A., Schipper, M. J., Collins, S. P., Spratt, D. E.. **Erectile function after stereotactic body radiotherapy for localized prostate cancer.** *BJU International.* 2018. 121:61-68 https://dx.doi.org/10.1111/bju.13962	Outcomes
Dess, R. T., Hartman, H. E., Soni, P. D., Jackson, W. C., Suy, S., Abugharib, A., Mehra, R., Schipper, M., Feng, F. Y., Hamstra, D. A., et al.. **Erectile function after stereotactic body radiation therapy for prostate cancer: a validated model-based comparison to nerve-sparing prostatectomy, conventional radiation therapy, and brachytherapy.** *International journal of radiation oncology biology physics.* 2017. 99:E228-10.1016/j.ijrobp.2017.06.1148	Publication type
Dess, Robert T,Jackson, William C,Suy, Simeng,Soni, Payal D,Lee, Jae Y,Abugharib, Ahmed E,Zumsteg, Zachary S,Feng, Felix Y,Hamstra, Daniel A,Collins, Sean P. **Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.** *Cancer.* 2017. 123:1635-1642 #DOI#	Outcomes
Detterbeck, F. C., Blasberg, J. D., Woodard, G. A., Decker, R. H., Kumbasar, U., Park, H. S., Mase, V. J., Jr., Bade, B. C., Li, A. X., Brandt, W. S., Madoff, D. C.. **A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 1: a guide to decision-making.** *Journal of Thoracic Disease.* 2022. 14:2340-2356 https://dx.doi.org/10.21037/jtd-21-1823	Publication type
Detterbeck, F. C., Mase, V. J., Jr., Li, A. X., Kumbasar, U., Bade, B. C., Park, H. S., Decker, R. H., Madoff, D. C., Woodard, G. A., Brandt, W. S., Blasberg, J. D.. **A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 2: systematic review of evidence regarding resection extent in generally healthy patients.** *Journal of Thoracic Disease.* 2022. 14:2357-2386 https://dx.doi.org/10.21037/jtd-21-1824	Aim
Detti, B,Bonomo, P,Masi, L,Doro, R,Cipressi, S,Iermano, C,Bonucci, I,Franceschini, D,Di Brina, L,Baki, M. **CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed.** *World journal of urology.* 2016. 34:311-317 #DOI#	Sample size
Detti, B.,Bonomo, P.,Masi, L.,Doro, R.,Cipressi, S.,Iermano, C.,Bonucci, I.,Franceschini, D.,Di Cataldo, V.,Di Brina, L.,Baki, M.,Simontacchi, G.,Meattini, I.,Carini, M.,Serni, S., Nicita, G.,Livi, L.. **Cyberknife treatment for low and intermediate risk prostate cancer.** *Cancer Invest.* 2015. 33:188-92 #DOI#	Sample size
DiBiase, S. J.,Kwok, Y.,Yovino, S.,Arena, C.,Naqvi, S.,Temple, R.,Regine, W. F.,Amin, P., Guo, C.,Chin, L. S.. **Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas.** *International Journal of Radiation Oncology, Biology, Physics.* 2004. 60:1515-9 #DOI#	Population
Didolkar, M. S.,Coleman, C. W.,Brenner, M. J.,Chu, K. U.,Olexa, N.,Stanwyck, E.,Yu, A., Neerchal, N.,Rabinowitz, S.. **Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients.** *J Gastrointest Surg.* 2010. 14:1547-59 #DOI#	Sample size
Dieckmann K, Georg D, Zehetmayer M, Rottenfusser A, Potter R. Stereotactic photon beam irradiation of uveal melanoma: indications and experience at the University of	Outcomes

Vienna since 1997. *Strahlenther Onkol.* 2007;183 Spec No 2:11-13. doi: 10.1007/s00066-007-2005-6.	
Dong, B., Zhu, X., Shu, Z., Ji, Y., Lu, F., Wang, J., Chen, M.. **Video-Assisted Thoracoscopic Lobectomy Versus Stereotactic Body Radiotherapy Treatment for Early-Stage Non-Small Cell Lung Cancer: A Propensity Score-Matching Analysis.** *Front Oncol.* 2020. 10:585709 10.3389/fonc.2020.585709	Setting
Donovan EK, Xie F, Louie AV, et al. Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC). *Clinical Genitourinary Cancer*. 2022.	Setting
Dudani, S., Zhu, X., Yokom, D., Yamada, A., Ho, C., Pantarotto, J., Leighl, N., Zhang, T., Wheatley-Price, P.. **Stage II NSCLC treated with non-surgical approaches: a multi-institution report of outcomes.** *Journal of thoracic oncology.* 2017. 12:S657-S658 #DOI#	Publication type
Dunlap, N. E.,Cai, J.,Biedermann, G. B.,Yang, W.,Benedict, S. H.,Sheng, K.,Schefter, T. E.,Kavanagh, B. D.,Larner, J. M.. **Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy.** *International Journal of Radiation Oncology, Biology, Physics.* 2010. 76:796-801 #DOI#	Sample size
Dunst, J.. **Curative radiotherapy of oligometastatic cancer: long-term results of the SABR-COMET phase II trial.** *Strahlentherapie und Onkologie.* 2021. 197:365-367 10.1007/s00066-021-01745-w	Non-English
Durand-Labrunie, Jérôme,Baumann, Anne-Sophie,Ayav, Ahmet,Laurent, Valérie, Boleslawski, Emmanuel,Cattan, Stéphane,Bogart, Emilie,Le Deley, Marie-Cécile,Steen, Valentine,Lacornerie, Thomas. **Curative irradiation treatment of hepatocellular carcinoma: a multicenter phase 2 trial.** *International Journal of Radiation Oncology* Biology* Physics.* 2020. 107:116-125 #DOI#	Sample size
Duru Birgi, S., Akgun, Z., Hurmuz, P., Akyurek, S., Kaytan Saglam, E., Yilmaz, M. T., Bakirarar, B., Cengiz, M.. **Definitive Chemoradiotherapy Results in Synchronous Oligometastatic Non-small Cell Lung Cancer Patients: Turkish Society for Radiation Oncology Group Study (TROD 10-003).** *American Journal of Clinical Oncology*. 2022. 45:40-47 https://dx.doi.org/10.1097/COC.0000000000000881	Sample size
Duverge, L., Bondiau, P. Y., Claude, L., Supiot, S., Vaugier, L., Thillays, F., Doyen, J., Ricordel, C., Lena, H., Bellec, J., Chajon, E., de Crevoisier, R., Castelli, J.. **Discontinuous stereotactic body radiotherapy schedule increases overall survival in early-stage non-small cell lung cancer.** *Lung Cancer.* 2021. 157:100-108 10.1016/j.lungcan.2021.05.016	Aim
Eba J, Nakamura K, Mizusawa J, et al. Stereotactic body radiotherapy versus lobectomy for operable clinical stage IA lung adenocarcinoma: comparison of survival outcomes in two clinical trials with propensity score analysis (JCOG1313-A). *Jpn J Clin Oncol.* 2016;46(8):748-753. doi: 10.1093/jjco/hyw058.	Study design
El Sayed I, Trifiletti DM, Lehrer EJ, Showalter TN, Dutta SW. Protons versus photons for the treatment of chordoma. *Cochrane Database of Systematic Reviews.* 2021;7:CD013224. doi: https://dx.doi.org/10.1002/14651858.CD013224.pub2.	Population
El Sayed, I., Trifiletti, D. M., Lehrer, E. J., Showalter, T. N., Dutta, S. W.. **Protons versus photons for the treatment of chordoma.** *Cochrane Database of Systematic Reviews.* 2021. 7:CD013224 https://dx.doi.org/10.1002/14651858.CD013224.pub2	Population

Elias, E.,Helou, J.,Zhang, L.,Cheung, P.,Deabreu, A.,D'Alimonte, L.,Sethukavalan, P., Mamedov, A.,Cardoso, M.,Loblaw, A.. **Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy.** *Radiother Oncol.* 2014. 112:83-8 #DOI#	Sample size
Elliott, R. E.,Parker, E. C.,Rush, S. C.,Kalhorn, S. P.,Moshel, Y. A.,Narayana, A.,Donahue, B.,Golfinos, J. G.. **Efficacy of gamma knife radiosurgery for small-volume recurrent malignant gliomas after initial radical resection.** *World Neurosurgery.* 2011. 76:128-40; discussion 61-2 #DOI#	Population
Emara, K.,Weisbrod, D. J.,Sahgal, A.,McGowan, H.,Jaywant, S.,Michaels, H.,Payne, D., Pintilie, M.,Laperriere, N. J.,Simpson, E. R.. **Stereotactic radiotherapy in the treatment of juxtapapillary choroidal melanoma: preliminary results.** *Int J Radiat Oncol Biol Phys.* 2004. 59:94-100 #DOI#	Sample size
English, K., Brodin, N. P., Shankar, V., Zhu, S., Ohri, N., Golowa, Y. S., Cynamon, J., Bellemare, S., Kaubisch, A., Kinkhabwala, M., et al.. **Association of Addition of Ablative Therapy following Transarterial Chemoembolization with Survival Rates in Patients with Hepatocellular Carcinoma.** *JAMA network open.* 2020. 3:#pages# 10.1001/jamanetworkopen.2020.23942	Comparator
Ester, E. C., Jones, D. A., Vernon, M. R., Yuan, J., Weaver, R. D., Shanley, R. M., Andrade, R. S., Cho, L. C.. **Lung reirradiation with stereotactic body radiotherapy (SBRT).** *J Radiosurg SBRT.* 2013. 2:325-331 #DOI#	Sample size
Evans JR, Zhao S, Daignault S, et al. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. *Radiother Oncol.* 2015;116(2):179-184. doi: 10.1016/j.radonc.2015.07.016.	Study design
Evans, J. R.,Zhao, S.,Daignault, S.,Sanda, M. G.,Michalski, J.,Sandler, H. M.,Kuban, D. A., Ciezki, J.,Kaplan, I. D.,Zietman, A. L.,Hembroff, L.,Feng, F. Y.,Suy, S.,Skolarus, T. A., McLaughlin, P. W.,Wei, J. T.,Dunn, R. L.,Finkelstein, S. E.,Mantz, C. A.,Collins, S. P., Hamstra, D. A.,Prostqa Study Consortium. **Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy.** *Radiother Oncol.* 2015. 116:179-84 #DOI#	Study design
Ezer N, Veluswamy RR, Mhango G, Rosenzweig KE, Powell CA, Wisnivesky JP. Outcomes after stereotactic body radiotherapy versus limited resection in older patients with early-stage lung cancer. *J Thorac Oncol.* 2015;10(8):1201-1206. doi: 10.1097/JTO.0000000000000600.	Population
Fakiris, A. J.,McGarry, R. C.,Yiannoutsos, C. T.,Papiez, L.,Williams, M.,Henderson, M. A., Timmerman, R.. **Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study.** *Int J Radiat Oncol Biol Phys.* 2009. 75:677-82 #DOI#	Sample size
Falkson, C. B.,Vella, E. T.,Yu, E.,El-Mallah, M.,Mackenzie, R.,Ellis, P. M.,Ung, Y. C.. **Radiotherapy with curative intent in patients with early-stage, medically inoperable, non-small-cell lung cancer: a systematic review.** *Clin Lung Cancer.* 2017. 18:105-121 e5 #DOI#	Population
Feng, Mary, Suresh, Krithika, Schipper, Matthew J, Bazzi, Latifa, Ben-Josef, Edgar, Matuszak, Martha M, Parikh, Neehar D, Welling, Theodore H, Normolle, Daniel, Ten Haken, Randall K. **Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial.** *JAMA oncology.* 2018. 4:40-47 #DOI#	Sample size

Feng, Z., Ding, K.. **A machine learning method to improve duodenum dose prediction for pancreatic cancer radiotherapy.** *Radiotherapy and oncology.* 2019. 133:S225-10.1016/S0167-8140(19)30849-7	Publication type
Fernandez C, Grills IS, Ye H, et al. Stereotactic Image Guided Lung Radiation Therapy for Clinical Early Stage Non-Small Cell Lung Cancer: A Long-Term Report From a Multi-Institutional Database of Patients Treated With or Without a Pathologic Diagnosis. *Practical Radiation Oncology*. 2020;10(4):e227-e237. doi: https://dx.doi.org/10.1016/j.prro.2019.12.003. .	Outcomes
Fiorica, F., Belluomini, L., Stefanelli, A., Santini, A., Urbini, B., Giorgi, C., Frassoldati, A.. **Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination.** *Am J Clin Oncol.* 2018. 41:1101-1105 10.1097/COC.0000000000000428	Sample size
Fischer-Valuck, B. W., Durci, M., Katz, S. R., Wu, H. T., Syh, J., Syh, J., Patel, B., Rosen, L. R.. **Influence of patient characteristics on survival following treatment with helical stereotactic body radiotherapy (SBRT) in stage I non-small-cell lung cancer.** *Thorac Cancer.* 2013. 4:27-34 10.1111/j.1759-7714.2012.00137.x	Sample size
Flannery, T. J.,Kano, H.,Lunsford, L. D.,Sirin, S.,Tormenti, M.,Niranjan, A.,Flickinger, J. C.,Kondziolka, D.. **Long-term control of petroclival meningiomas through radiosurgery.** *Journal of Neurosurgery*. 2010. 112:957-64 #DOI#	Population
Flickinger, J. C.,Kondziolka, D.,Maitz, A. H.,Lunsford, L. D.. **Gamma knife radiosurgery of imaging-diagnosed intracranial meningioma.** *International Journal of Radiation Oncology, Biology, Physics.* 2003. 56:801-6 #DOI#	Population
Flickinger, J. C.,Kondziolka, D.,Niranjan, A.,Maitz, A.,Voynov, G.,Lunsford, L. D.. **Acoustic neuroma radiosurgery with marginal tumor doses of 12 to 13 Gy.** *International Journal of Radiation Oncology, Biology, Physics.* 2004. 60:225-30 #DOI#	Population
Fodor, A., Lancia, A., Ceci, F., Picchio, M., Hoyer, M., Jereczek-Fossa, B. A., Ost, P., Castellucci, P., Incerti, E., Di Muzio, N., Ingrosso, G.. **Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row : Nodal oligorecurrent prostate cancer.** *World Journal of Urology.* 2019. 37:2607-2613 https://dx.doi.org/10.1007/s00345-018-2322-7	Publication type
Foster, C. C., Sher, D. J., Rusthoven, C. G., Verma, V., Spiotto, M. T., Weichselbaum, R. R., Koshy, M.. **Overall Survival According to Systemic and Radiation Treatment Approaches in Metastatic Non-Small-Cell Lung Cancer: a National Cancer Database Analysis.** *International journal of radiation oncology biology physics.* 2019. 104:244-10.1016/j.ijrobp.2019.01.045	Publication type
Francolini G, Jereczek-Fossa BA, Di Cataldo V, et al. Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series. *BJU international.* 2020;125(3):417-425.	Sample size
Francolini, G., Campi, R., Di Cataldo, V., Detti, B., Loi, M., Triggiani, L., La Mattina, S., Borghetti, P., Magrini, S. M., Nicosia, L., Alongi, F., Ghirardelli, P., Vavassori, V., Allegra, A. G., Aquilano, M., Scoccimarro, E., Peruzzi, A., Pastina, P., Visani, L., Desideri, I., Serni, S., Meattini, I., Livi, L.. **Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience.** *Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societes & of the National Cancer Institute of Mexico.* 2022. 24:2039-2043 https://dx.doi.org/10.1007/s12094-022-02844-5	Sample size

Francolini, G., Detti, B., Cataldo, V. D., Caini, S., Alitto, A. R., Parisi, S., Demofonti, C., Bruni, A., Ingrosso, G., Timon, G., et al.. **ARTO trial-(NCT03449719): early results from a phase II randomized trial testing stereotactic body radiation therapy in patients with oligometastatic castration-resistant prostate cancer undergoing i line treatment with abiraterone acetate.** *Journal of clinical oncology.* 2022. 40:#pages# 10.1200/JCO.2022.40.6_suppl.100	Publication type
Francolini, G., Detti, B., Di Cataldo, V., Caini, S., Alitto, A. R., Parisi, S., Demofonti, C., Bruni, A., Ingrosso, G., Timon, G., et al.. **Early outcomes of a randomized trial of SBRT and Abiraterore in mCPRC: ARTO trial NCT03449719.** *Radiotherapy and oncology*. 2022. 170:S530-S531 10.1016/S0167-8140(22)02627-5	Publication type
Francolini, G., Detti, B., Di Cataldo, V., Caini, S., Alitto, A. R., S, Parisi, Demofonti, C., Bruni, A., Ingrosso, G., Timon, G., et al.. **1369P Biochemical outcomes from ARTO trial (NCT03449719) a phase II randomized trial testing association between abiraterone acetate and stereotactic body radiation therapy in castrate-resistant prostate cancer patients.** *Annals of oncology.* 2022. 33:S1167-S1168 10.1016/j.annonc.2022.07.1501	Publication type
Francolini, G., Garlatti, P., Detti, B., Bruni, A., Mantini, G., Pergolizzi, S., Borghetti, P., D'Angelillo, R. M., Alongi, F., Jereczek-Fossa, B. A., et al.. **Early results from a phase II randomized trial testing stereotactic body radiation therapy in patients with oligometastatic castration resistant prostate cancer undergoing I line treatment with abiraterone acetate (ARTO trial-NCT03449719).** *European urology open science.* 2020. 21:S150- 10.1016/S2666-1683(20)36207-8	Publication type
Franks, K. N., McParland, L., Webster, J., Baldwin, D. R., Sebag-Montefiore, D., Evison, M., Booton, R., Faivre-Finn, C., Naidu, B., Ferguson, J., et al.. **SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection.** *The european respiratory journal.* 2020. 56:#pages# 10.1183/13993003.00118-2020	Study design
Franzin, A.,Vimercati, A.,Medone, M.,Serra, C.,Marzoli, S. B.,Forti, M.,Gioia, L.,Valle, M., Picozzi, P.. **Neuroophthalmological evaluation after Gamma Knife surgery for cavernous sinus meningiomas.** *Neurosurgical Focus.* 2007. 23:E10 #DOI#	Population
Freeman, Debra E,King, Christopher R. **Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes.** *Radiation oncology.* 2011. 6:1-5 #DOI#	Sample size
Friedes, C., Mai, N., Hazell, S., Fu, W., Han, P., Bowers, M., Levy, B., Forde, P. M., Voong, R., Hales, R. K.. **Consolidative Radiotherapy in Oligometastatic Lung Cancer: Patient Selection With a Prediction Nomogram.** *Clinical Lung Cancer.* 2020. 21:e622-e632 https://dx.doi.org/10.1016/j.cllc.2020.05.013	Sample size
Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. *Technol Cancer Res Treat.* 2009;8(5):387-392. doi: 10.1177/153303460900800509.	Outcomes
Friedland, J. L.,Freeman, D. E.,Masterson-McGary, M. E.,Spellberg, D. M.. **Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer.** *Technol Cancer Res Treat.* 2009. 8:387-92 #DOI#	Outcomes
Fritz, P.,Kraus, H. J.,Muhlnickel, W.,Hammer, U.,Dolken, W.,Engel-Riedel, W., Chemaissani, A.,Stoelben, E.. **Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases.** *Radiat Oncol.* 2006. 1:30 #DOI#	Sample size

Fukuoka, S.,Takanashi, M.,Hojyo, A.,Konishi, M.,Tanaka, C.,Nakamura, H.. **Gamma knife radiosurgery for vestibular schwannomas.** *Progress in Neurological Surgery.* 2009. 22:45-62 #DOI#	Population
Fuller DB, Naitoh J, Lee C, Hardy S, Jin H. Virtual HDRSM CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. *International Journal of Radiation Oncology* Biology* Physics.* 2008;70(5):1588-1597. https://www.redjournal.org/article/S0360-3016(07)04756-6/fulltext.	Sample size
Fuller, D. B., Kane, B. L., Medbery, C. A., Underhill, K., Gray, J. R., Peddada, A., Chen, R. C.. **5-year outcomes from a prospective multi-institutional trial of heterogeneous dosing stereotactic body radiotherapy (SBRT) for low-and intermediate-risk prostate cancer.** *Journal of clinical oncology. Conference: 2017 genitourinary cancers symposium. United states.* 2017. 35:#pages# #DOI#	Publication type
Fuller, Donald B,Naitoh, John,Lee, Charles,Hardy, Steven,Jin, Haoran. **Virtual HDRSM CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.** *International Journal of Radiation Oncology* Biology* Physics.* 2008. 70:1588-1597 #DOI#	Sample size
Gabani, P., Robinson, C. G., Ansstas, G., Johanns, T. M., Huang, J.. **Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy.** *Radiotherapy & Oncology.* 2018. 127:310-317 https://dx.doi.org/10.1016/j.radonc.2018.02.022	Outcomes
Ganz, J. C.,Reda, W. A.,Abdelkarim, K.. **Adverse radiation effects after Gamma Knife Surgery in relation to dose and volume.** *Acta Neurochirurgica.* 2009. 151:9-19 #DOI#	Population
Ganz, J. C.,Reda, W. A.,Abdelkarim, K.. **Gamma Knife surgery of large meningiomas: early response to treatment.** *Acta Neurochirurgica.* 2009. 151:1-8 #DOI#	Population
García-Cabezas, S,Bueno, C,Rivin, E,Roldán, JM,Palacios-Eito, A. **Lung metastases in oligometastatic patients: outcome with stereotactic body radiation therapy (SBRT).** *Clinical and Translational Oncology.* 2015. 17:668-672 #DOI#	Sample size
Gerard, M., Lerouge, D., Le Guevelou, J., Thariat, J.. **Stereotaxic ablative radiotherapy in stage 1 non-small-cell lung cancer: results of the phase 3 randomized trial â€œCHISELâ€�.** *Bulletin du cancer.* 2020. 107:145-147 10.1016/j.bulcan.2019.11.001	Non-English
Gill BS, Lin JF, Krivak TC, et al. National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: The impact of new technological advancements. *International Journal of Radiation Oncology, Biology, Physics.* 2014;90(5):1083-1090. doi: http://dx.doi.org/10.1016/j.ijrobp.2014.07.017.	Population
Gill, B. S., Clump, D. A., Burton, S. A., Christie, N. A., Schuchert, M. J., Heron, D. E.. **Salvage stereotactic body radiotherapy for locally recurrent non-small cell lung cancer after sublobar resection and i(125) vicryl mesh brachytherapy.** *Front Oncol.* 2015. 5:109 10.3389/fonc.2015.00109	Sample size
Giuliani M, Hope A, Guckenberger M, et al. Stereotactic Body Radiation Therapy in Octo- and Nonagenarians for the Treatment of Early-Stage Lung Cancer. *Int J Radiat Oncol Biol Phys.* 2017;98(4):893-899. doi: 10.1016/j.ijrobp.2017.01.019.	Population
Giuliani ME, Hope A, Mangona V, et al. Predictors and Patterns of Regional Recurrence Following Lung SBRT: A Report From the Elekta Lung Research Group. *Clin Lung Cancer.* 2017;18(2):162-168. doi: 10.1016/j.cllc.2016.10.006.	Population

Glicksman RM, Kishan AU, Quon H, et al. Absolute Percentage of Pattern 4 Disease as a Prognostic Measure for Intermediate-risk Prostate Cancer Treated with Stereotactic Body Radiotherapy. *Clin Oncol (R Coll Radiol).* 2022;34(9):581-588. doi: 10.1016/j.clon.2022.05.002.	Study design
Glicksman, R. M., Kishan, A. U., Quon, H., Shabsovich, D., Juarez, J., Jiang, T., Steinberg, M. L., Zhang, L., Loblaw, A.. **Absolute Percentage of Pattern 4 Disease as a Prognostic Measure for Intermediate-risk Prostate Cancer Treated with Stereotactic Body Radiotherapy.** *Clinical Oncology (Royal College of Radiologists).* 2022. 34:581-588 https://dx.doi.org/10.1016/j.clon.2022.05.002	Outcomes
Glicksman, R., Liu, S. K., Cheung, P., Vesprini, D., Chu, W., Chung, H. T., Morton, G., Deabreu, A., Davidson, M. T. M., Ravi, A., et al.. **Elective Nodal Ultra Hypofractionated Radiation for Prostate Cancer: safety and Efficacy From Four Prospective Clinical Trials.** *International journal of radiation oncology biology physics.* 2021. 111:S136-10.1016/j.ijrobp.2021.07.307	Publication type
Gogineni, E., Rana, Z., Soberman, D., Sidiqi, B., D'Andrea, V., Lee, L., Potters, L., Parashar, B.. **Biochemical control and toxicity outcomes of SBRT vs LDR brachytherapy in the treatment of low and intermediate risk prostate cancer.** *International journal of radiation oncology, biology, physics.* 2020. #volume#:#pages# 10.1016/j.ijrobp.2020.11.003	Publication type
Gomez, C. L., Xu, X., Qi, X. S., Wang, P. C., Kupelian, P., Steinberg, M., King, C. R.. **Dosimetric parameters predict short-term quality-of-life outcomes for patients receiving stereotactic body radiation therapy for prostate cancer.** *Practical Radiation Oncology.* 2015. 5:257-62 https://dx.doi.org/10.1016/j.prro.2015.01.006	Sample size
Gomez, Daniel R,Tang, Chad,Zhang, Jianjun,Blumenschein Jr, George R,Hernandez, Mike,Lee, J Jack,Ye, Rong,Palma, David A,Louie, Alexander V,Camidge, D Ross. **Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study.** *Journal of Clinical Oncology.* 2019. 37:1558 #DOI#	Sample size
Goodman, Karyn A,Wiegner, Ellen A,Maturen, Katherine E,Zhang, Zhigang,Mo, Qianxing,Yang, George,Gibbs, Iris C,Fisher, George A,Koong, Albert C. **Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.** *International Journal of Radiation Oncology* Biology* Physics.* 2010. 78:486-493 #DOI#	Sample size
Goyal, Kush,Einstein, Douglas,Ibarra, Rafael A,Yao, Min,Kunos, Charles,Ellis, Rod, Brindle, James,Singh, Deepjot,Hardacre, Jeffrey,Zhang, Yuxia. **Stereotactic body radiation therapy for nonresectable tumors of the pancreas.** *Journal of Surgical Research.* 2012. 174:319-325 #DOI#	Sample size
Grabenbauer GG. [Intensity-modulated fractionated radiotherapy vs. stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomized, open-label, phase 3, noninferiority trial]. *Strahlenther Onkol.* 2020;196(7):674-675. doi: 10.1007/s00066-020-01616-w.	Non English
Grabenbauer, G. G.. **Intensity-modulated fractionated radiotherapy vs. stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomized, open-label, phase 3, noninferiority trial.** *Strahlentherapie und Onkologie.* 2020. 196:674-675 10.1007/s00066-020-01616-w	Non-English
Grills, I. S., Hope, A. J., Guckenberger, M., Kestin, L. L., Werner-Wasik, M., Yan, D., Sonke, J. J., Bissonnette, J. P., Wilbert, J., Xiao, Y., Belderbos, J.. **A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell**	Population

lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer.* 2012. 7:1382-93 https://dx.doi.org/10.1097/JTO.0b013e318260e00d	
Grutters, J. P.,Pijls-Johannesma, M.,Ruysscher, D. D.,Peeters, A.,Reimoser, S.,Severens, J. L.,Lambin, P.,Joore, M. A.. **The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research.** *Cancer Treat Rev.* 2010. 36:468-76 #DOI#	Publication Date
Guckenberger M, Allgauer M, Appold S, et al. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer.* 2013;8(8):1050-1058. doi: https://dx.doi.org/10.1097/JTO.0b013e318293dc45.	Population
Guckenberger M, Klement RJ, Kestin LL, et al. Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2013;85(4):1074-1081. doi: 10.1016/j.ijrobp.2012.09.016.	Outcomes
Guckenberger, M., Kestin, L. L., Hope, A. J., Belderbos, J., Werner-Wasik, M., Yan, D., Sonke, J. J., Bissonnette, J. P., Wilbert, J., Xiao, Y., Grills, I. S.. **Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer?.** *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer.* 2012. 7:542-51 https://dx.doi.org/10.1097/JTO.0b013e31824165d7	Population
Guckenberger, M., Klement, R. J., Allgauer, M., Andratschke, N., Blanck, O., Boda-Heggemann, J., Dieckmann, K., Duma, M., Ernst, I., Ganswindt, U., Hass, P., Henkenberens, C., Holy, R., Imhoff, D., Kahl, H. K., Krempien, R., Lohaus, F., Nestle, U., Nevinny-Stickel, M., Petersen, C., Semrau, S., Streblow, J., Wendt, T. G., Wittig, A., Flentje, M., Sterzing, F.. **Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy.** *Radiotherapy & Oncology.* 2016. 118:485-91 https://dx.doi.org/10.1016/j.radonc.2015.09.008	Population
Guckenberger, M.,Baier, K.,Polat, B.,Richter, A.,Krieger, T.,Wilbert, J.,Mueller, G., Flentje, M.. **Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy.** *Radiotherapy & Oncology.* 2010. 97:65-70 #DOI#	Sample size
Guo, J., Guo, J., Cheng, B., Sun, X., Zhang, H., Ma, J.. **Synergistic Effect of Stereotactic Radiotherapy Combined with Karelizumab on Patients with Advanced NSCLC.** *Journal of healthcare engineering.* 2022. 2022:#pages# 10.1155/2022/7875627	Setting
Guss, Z. D.,Batra, S.,Limb, C. J.,Li, G.,Sughrue, M. E.,Redmond, K.,Rigamonti, D.,Parsa, A. T.,Chang, S.,Kleinberg, L.,Lim, M.. **Radiosurgery of glomus jugulare tumors: a meta-analysis.** *Int J Radiat Oncol Biol Phys.* 2011. 81:e497-502 #DOI#	Population
Habraken, S. J. M., Heijmen, B. J. M., Buijsen, J., Verbakel, Wfar, Haasbeek, C. J. A., Ollers, M. C., Westerveld, G. H., Van Wieringen, N., Reerink, O., Seravalli, E., et al.. **QA and dummy-run results of the TRENDY randomized trial on SBRT vs. Chemoembolization for HCC.** *Radiotherapy and oncology.* 2016. 119:S462- #DOI#	Publication type
Habraken, S. J. M., Sharfo, A. W., Buijsen, J., Verbakel, Wfar, Haasbeek, C. J. A., Ollers, M. C., Westerveld, G. H., Van Wieringen, N., Reerink, O., Seravalli, E., et al.. **Automated**	Publication type

treatment planning for prospective QA in the TRENDY randomized trial on liver-SBRT for HCC. *Radiotherapy and oncology.* 2017. 123:S287-S288 #DOI#	
Hadjipanayis, C. G.,Kondziolka, D.,Flickinger, J. C.,Lunsford, L. D.. **The role of stereotactic radiosurgery for low-grade astrocytomas.** *Neurosurgical Focus.* 2003. 14:e15 #DOI#	Population
Haley, Marsha,Gerszten, Peter C. **Stereotactic radiosurgery in the management of cancer pain.** *Current pain and headache reports.* 2009. 13:277-281 #DOI#	Publication type
Hall, W. A., Tsai, S., Banerjee, A., George, B., Ritch, P. S., Thomas, J. P., Paulson, E., Christians, K. K., Clarke, C., Dua, K., et al.. **A randomized, phase II clinical trial of preoperative stereotactic body radiation therapy versus conventionally fractionated chemoradiation for resectable, borderline-resectable, or locally advanced type a pancreatic adenocarcinoma.** *Journal of clinical oncology.* 2019. 37:#pages# 10.1200/JCO.2019.37.15-suppl.TPS4167	Publication type
Hamaji M, Chen F, Matsuo Y, et al. Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer. *Ann Thorac Surg.* 2015;99(4):1122-1129. doi: 10.1016/j.athoracsur.2014.11.009.	Population
Hamaji, M., Matsuo, Y., Chen-Yoshikawa, T. F., Mizowaki, T., Date, H.. **Surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer: review of meta-analyses.** *Journal of Thoracic Disease.* 2019. 11:S1646-S1652 https://dx.doi.org/10.21037/jtd.2018.10.35	Publication type
Hamm, K.,Henzel, M.,Gross, M. W.,Surber, G.,Kleinert, G.,Engenhart-Cabillic, R.. **Radiosurgery/stereotactic radiotherapy in the therapeutical concept for skull base meningiomas.** *Zentralblatt fur Neurochirurgie.* 2008. 69:14-21 #DOI#	Population
Hammer L, Jiang R, Hearn J, et al. A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate Cancer. *International Journal of Radiation Oncology*Biology*Physics.* 2022. doi: https://doi.org/10.1016/j.ijrobp.2022.07.016.	Sample size
Han, J. H.,Kim, D. G.,Chung, H. T.,Park, C. K.,Paek, S. H.,Kim, C. Y.,Jung, H. W.. **Gamma knife radiosurgery for skull base meningiomas: long-term radiologic and clinical outcome.** *International Journal of Radiation Oncology, Biology, Physics.* 2008. 72:1324-32 #DOI#	Population
Hannan, R.,Tumati, V.,Xie, X. J.,Cho, L. C.,Kavanagh, B. D.,Brindle, J.,Raben, D.,Nanda, A.,Cooley, S.,Kim, D. W. N.,Pistenmaa, D.,Lotan, Y.,Timmerman, R.. **Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial.** *Eur J Cancer.* 2016. 59:142-151 #DOI#	Sample size
Hannan, Raquibul,Christensen, Michael,Hammers, Hans,Christie, Alana,Paulman, Brendan,Lin, Dandan,Garant, Aurelie,Arafat, Waddah,Courtney, Kevin,Bowman, Isaac. **Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.** *European Urology Oncology.* 2022. 5:216-224 #DOI#	Sample size
Haque W, Verma V, Polamraju P, Farach A, Butler EB, Teh BS. Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer. *Radiother Oncol.* 2018;129(2):264-269. doi: 10.1016/j.radonc.2018.07.008.	Population
Hara, W.,Loo, B. W., Jr.,Goffinet, D. R.,Chang, S. D.,Adler, J. R.,Pinto, H. A.,Fee, W. E., Kaplan, M. J.,Fischbein, N. J.,Le, Q. T.. **Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal**	Sample size

carcinoma. *International Journal of Radiation Oncology, Biology, Physics.* 2008. 71:393-400 #DOI#	
Harat, A., Harat, M., Martinson, M.. **A Cost-Effectiveness and Quality of Life Analysis of Different Approaches to the Management and Treatment of Localized Prostate Cancer.** *Frontiers in Oncology.* 2020. 10:103 https://dx.doi.org/10.3389/fonc.2020.00103	Intervention
Hasegawa, T.,Fujitani, S.,Katsumata, S.,Kida, Y.,Yoshimoto, M.,Koike, J.. **Stereotactic radiosurgery for vestibular schwannomas: analysis of 317 patients followed more than 5 years.** *Neurosurgery.* 2005. 57:257-65; discussion 257-65 #DOI#	Population
Hasegawa, T.,Kida, Y.,Kobayashi, T.,Yoshimoto, M.,Mori, Y.,Yoshida, J.. **Long-term outcomes in patients with vestibular schwannomas treated using gamma knife surgery: 10-year follow up.** *Journal of Neurosurgery.* 2005. 102:10-6 #DOI#	Population
Hasegawa, T.,Kida, Y.,Yoshimoto, M.,Iizuka, H.,Ishii, D.,Yoshida, K.. **Gamma Knife surgery for convexity, parasagittal, and falcine meningiomas.** *Journal of Neurosurgery.* 2011. 114:1392-8 #DOI#	Population
Hayashi, M.,Chernov, M.,Tamura, N.,Izawa, M.,Muragaki, Y.,Iseki, H.,Okada, Y., Takakura, K.. **Gamma knife robotic microradiosurgery for benign skull base meningiomas: tumor shrinkage may depend on the amount of radiation energy delivered per lesion volume (unit energy).** *Stereotactic & Functional Neurosurgery.* 2011. 89:6-16 #DOI#	Population
Hayashi, M.,Chernov, M.,Tamura, N.,Nagai, M.,Yomo, S.,Ochiai, T.,Amano, K.,Izawa, M., Hori, T.,Muragaki, Y.,Iseki, H.,Okada, Y.,Takakura, K.. **Gamma Knife robotic microradiosurgery of pituitary adenomas invading the cavernous sinus: treatment concept and results in 89 cases.** *Journal of Neuro-Oncology.* 2010. 98:185-94 #DOI#	Sample size
Hayashi, S., Tanaka, H., Hoshi, H.. **Imaging characteristics of local recurrences after stereotactic body radiation therapy for stage I non-small cell lung cancer: Evaluation of mass-like fibrosis.** *Thorac Cancer.* 2015. 6:186-93 10.1111/1759-7714.12162	Sample size
Heal, C., Ding, W., Lamond, J., Wong, M., Lanciano, R., Su, S., Yang, J., Feng, J., Arrigo, S., Markiewicz, D., Hanlon, A., Brady, L.. **Definitive Treatment of Early-Stage Non-Small Cell Lung Cancer with Stereotactic Ablative Body Radiotherapy in a Community Cancer Center Setting.** *Front Oncol.* 2015. 5:146 10.3389/fonc.2015.00146	Population
Hearn, J. W., Videtic, G. M., Djemil, T., Stephans, K. L.. **Salvage stereotactic body radiation therapy (SBRT) for local failure after primary lung SBRT.** *Int J Radiat Oncol Biol Phys.* 2014. 90:402-6 10.1016/j.ijrobp.2014.05.048	Sample size
Hegazy, M. W.,Mahmood, R.. **Stereotactic Hypofractionated Accurate Radiotherapy of the Prostate (SHARP), 36.25 Gy in Five Fractions for Localized Disease: A Case Series Results from King Faisal Specialist Hospital, Saudi Arabia.** *Gulf J Oncolog.* 2016. 1:12-6 #DOI#	Sample size
Hegde JV, Collins SP, Fuller DB, et al. A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy. *Am J Clin Oncol.* 2018;41(5):502-507. doi: 10.1097/COC.0000000000000311.	Study design
Hegde, J. V.,Collins, S. P.,Fuller, D. B.,King, C. R.,Demanes, D. J.,Wang, P. C.,Kupelian, P. A.,Steinberg, M. L.,Kamrava, M.. **A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body**	Study design

Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy. *Am J Clin Oncol.* 2018. 41:502-507 #DOI#	
Helou J, D'Alimonte L, Quon H, et al. Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose? *Radiotherapy & Oncology*. 2017;123(3):478-482. doi: https://dx.doi.org/10.1016/j.radonc.2017.03.006.	Study design
Helou J, Morton G, Kiss A, et al. A comparative study of patient-reported outcomes after contemporary radiation techniques for prostate cancer. *Radiother Oncol.* 2022;171:164-172. doi: 10.1016/j.radonc.2022.04.025.	Study design
Helou, J., Morton, G., Kiss, A., Mittmann, N., Ravi, A., Chung, H., Davidson, M., Cheung, P., Bezjak, A., Loblaw, A.. **A comparative study of patient-reported outcomes after contemporary radiation techniques for prostate cancer.** *Radiotherapy and oncology*. 2022. 171:164-172 10.1016/j.radonc.2022.04.025	Study design
Helou, J.,Torres, S.,Musunuru, H. B.,Raphael, J.,Cheung, P.,Vesprini, D.,Chung, H. T., D'Alimonte, L.,Krahn, M.,Morton, G.,Loblaw, A.. **Stereotactic body radiotherapy versus low dose rate brachytherapy for localised prostate cancer: a cost-utility analysis.** *Clin Oncol (R Coll Radiol).* 2017. 29:718-731 #DOI#	Setting
Helouc, J., Morton, G., Bezjak, A., Kiss, A., Mittmann, N., Ravi, A., Davidson, M., Cheung, P., Loblawc, A.. **A comparative study of quality of life in patients with low- and intermediate-risk prostate cancer: stereotactic radiotherapy vs. high dose-rate brachytherapy monotherapy vs. high dose-rate brachytherapy boost.** *Brachytherapy*. 2018. 17:S57- #DOI#	Publication type
Hemmatazad, H., Mathier, E., Aebersold, D. M., Shelan, M.. **Single dose of 24 Gy or 3-fraction SBRT regimen in the treatment of oligometastatic cancer? : a phase III multi-center trial.** *Strahlentherapie und Onkologie.* 2021. #volume#:#pages# 10.1007/s00066-021-01806-0	Non-English
Hempel, J. M.,Hempel, E.,Wowra, B.,Schichor, Ch,Muacevic, A.,Riederer, A.. **Functional outcome after gamma knife treatment in vestibular schwannoma.** *European Archives of Oto-Rhino-Laryngology*. 2006. 263:714-8 #DOI#	Population
Henderson, Mark,McGarry, Ronald,Yiannoutsos, Constantin,Fakiris, Achilles,Hoopes, David,Williams, Mark,Timmerman, Robert. **Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non–small-cell lung cancer.** *International Journal of Radiation Oncology* Biology* Physics*. 2008. 72:404-409 #DOI#	Population
Henke, L, Green, O, Curcuru, A, Mutic, S, Markovina, S, Schwarz, J, Grigsby, P, Robinson, C, Chundury, A. **EP-1510 phase I trial of stereotactic MR-guided online adaptive radiotherapy for ovarian oligometastases.** *Radiotherapy and Oncology*. 2019. 133:S817-S818 #DOI#	Publication type
Heppner, P. A.,Sheehan, J. P.,Steiner, L. E.. **Gamma knife surgery for low-grade gliomas.** *Neurosurgery*. 2005. 57:1132-9; discussion #DOI#	Population
Hiraoka, M.,Matsuo, Y.,Nagata, Y.. **Stereotactic body radiation therapy (SBRT) for early-stage lung cancer.** *Cancer Radiotherapie.* 2007. 11:32-5 #DOI#	Population
Hodges JC, Lotan Y, Boike TP, Benton R, Barrier A, Timmerman RD. Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation	Date

therapy: an emerging initial radiation treatment option for organ-confined prostate cancer. *J Oncol Pract*. 2012;8(3 Suppl):e31s-37s. doi: 10.1200/JOP.2012.000548.	
Hodges JC, Lotan Y, Boike TP, Benton R, Barrier A, Timmerman RD. Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer. *Am J Manag Care*. 2012;18(5):e186-193. https://www.ncbi.nlm.nih.gov/pubmed/22694113.	Date
Hoffe, S., Frakes, J. M., Aguilera, T. A., Czito, B., Palta, M., Brookes, M., Schweizer, C., Colbert, L., Moningi, S., Bhutani, M. S., et al.. **Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC).** *International journal of radiation oncology, biology, physics.* 2020. 108:1399-1400 10.1016/j.ijrobp.2020.09.022	Publication type
Holy, R.,Piroth, M.,Pinkawa, M.,Eble, M. J.. **Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer.** *Strahlenther Onkol.* 2011. 187:245-51 #DOI#	Sample size
Holyoake, D. L. P., Ward, E., Grose, D., McIntosh, D., Sebag-Montefiore, D., Radhakrishna, G., Patel, N., Silva, M., Mukherjee, S., Strauss, V. Y., et al.. **A phase-I trial of preoperative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.** *BMC cancer.* 2016. 16:#pages# 10.1186/s12885-016-2765-4	Sample size
Hoppe, B. S.,Laser, B.,Kowalski, A. V.,Fontenla, S. C.,Pena-Greenberg, E.,Yorke, E. D., Lovelock, D. M.,Hunt, M. A.,Rosenzweig, K. E.. **Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who's at risk?.** *International Journal of Radiation Oncology, Biology, Physics.* 2008. 72:1283-6 #DOI#	Sample size
Hopstaken, J. S., de Ruiter, J. C., Damhuis, R. A. M., de Langen, A. J., van Diessen, J. N. A., Klomp, H. M., Klompenhouwer, E. G., Hartemink, K. J.. **Stage I non-small cell lung cancer: Treatment modalities, Dutch daily practice and future perspectives.** *Cancer Treatment And Research Communications.* 2021. 28:100404 https://dx.doi.org/10.1016/j.ctarc.2021.100404	Publication type
Horne, Z. D., Dohopolski, M. J., Clump, D. A., Burton, S. A., Heron, D. E.. **Thoracic reirradiation with SBRT for residual/recurrent and new primary NSCLC within or immediately adjacent to a prior high-dose radiation field.** *Pract Radiat Oncol.* 2018. 8:e117-e123 10.1016/j.prro.2017.11.011	Sample size
Hoskin, Md, Frcr, P.. **Pain Response After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases—A Phase 2, Randomized Controlled Trial Within a Prospective Cohort.** *International journal of radiation oncology biology physics.* 2021. 110:368-370 10.1016/j.ijrobp.2021.01.002	Publication type
Hou, X., Wang, W., Zhang, F., Hu, K.. **Stereotactic body radiation therapy for oligometastatic pulmonary tumors from cervical cancer.** *Asia Pac J Clin Oncol.* 2019. 15:e175-e180 10.1111/ajco.13159	Setting
Howington, J. A., Blum, M. G., Chang, A. C., Balekian, A. A., Murthy, S. C.. **Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.** *Chest.* 2013. 143:e278S-e313S https://dx.doi.org/10.1378/chest.12-2359	Publication Date
Hoyer, M.,Roed, H.,Traberg Hansen, A.,Ohlhuis, L.,Petersen, J.,Nellemann, H.,Kiil Berthelsen, A.,Grau, C.,Aage Engelholm, S.,Von der Maase, H.. **Phase II study on**	Sample size

stereotactic body radiotherapy of colorectal metastases. *Acta Oncol.* 2006. 45:823-30 #DOI#	
Hsieh, P. C.,Chandler, J. P.,Bhangoo, S.,Panagiotopoulos, K.,Kalapurakal, J. A., Marymont, M. H.,Cozzens, J. W.,Levy, R. M.,Salehi, S.. **Adjuvant gamma knife stereotactic radiosurgery at the time of tumor progression potentially improves survival for patients with glioblastoma multiforme.** *Neurosurgery.* 2005. 57:684-92; discussion 684-92 #DOI#	Population
Hu, C., Cheng, Y. J., Tsai, H. L., Jing, H., Meyer, J. J.. **Revisiting the role of SBRT in Localized Hepatocellular Carcinoma (HCC): accounting for Selection Biases in National Cancer Database (NCDB) Analyses.** *International journal of radiation oncology biology physics.* 2019. 105:S183-S184 10.1016/j.ijrobp.2019.06.228	Publication type
Hu, Y., Qin, T., Li, S., Zhang, T., Xue, J.. **Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: study Protocol of a Randomized Controlled Trial.** *Frontiers in oncology.* 2020. 10:#pages# 10.3389/fonc.2020.01589	Setting
Huang W-Y, Jen Y-M, Lee M-S, et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. *International Journal of Radiation Oncology* Biology* Physics.* 2012;84(2):355-361. https://www.redjournal.org/article/S0360-3016(11)03616-9/fulltext.	Setting
Huang, W. Y., Shen, P. C., Dai, Y. H., Yang, J. F., Lo, C. H.. **Stereotactic body radiotherapy versus transarterial chemoembolization for medium-sized hepatocellular carcinoma: a propensity score matching analysis.** *Liver cancer.* 2018. 7:214-10.1159/000490877	Publication type
Huang, Wen-Yen,Jen, Yee-Min,Lee, Meei-Shyuan,Chang, Li-Ping,Chen, Chang-Ming, Ko, Kai-Hsiung,Lin, Kuen-Tze,Lin, Jang-Chun,Chao, Hsing-Lung,Lin, Chun-Shu. **Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.** *International Journal of Radiation Oncology* Biology* Physics.* 2012. 84:355-361 #DOI#	Setting
Huertas, A., Baumann, A. S., Saunier-Kubs, F., Salleron, J., Oldrini, G., Croise-Laurent, V., Barraud, H., Ayav, A., Bronowicki, J. P., Peiffert, D.. **Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma.** *Radiother Oncol.* 2015. 115:211-6 10.1016/j.radonc.2015.04.006	Sample size
Ibarra, R. A.,Rojas, D.,Snyder, L.,Yao, M.,Fabien, J.,Milano, M.,Katz, A.,Goodman, K., Stephans, K.,El-Gazzaz, G.,Aucejo, F.,Miller, C.,Fung, J.,Lo, S.,Machtay, M.,Sanabria, J. R.. **Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors.** *Acta Oncol.* 2012. 51:575-83 #DOI#	Sample size
Ibrahim, T., Tselikas, L., Yazbeck, C., Kattan, J.. **Systemic Versus Local Therapies for Colorectal Cancer Pulmonary Metastasis: What to Choose and When?.** *Journal of Gastrointestinal Cancer.* 2016. 47:223-31 https://dx.doi.org/10.1007/s12029-016-9818-4	Publication type
Isfahanian N, Lukka H, Dayes I, et al. A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806). *Clin Genitourin Cancer.* 2020;18(4):e410-e415. doi: 10.1016/j.clgc.2019.12.020. .	Publication type
Isfahanian, N., Lukka, H., Dayes, I., Quan, K., Schnarr, K. L., Douvi, G., Goldberg, M., Wright, J., Swaminath, A., Chow, T., et al.. **A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional**	Study design

Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: the PBS Trial (NCT03380806). *Clinical genitourinary cancer.* 2020. 18:e410-e415 10.1016/j.clgc.2019.12.020	
Ishiyama, H.,Teh, B. S.,Lo, S. S.,Mathews, T.,Blanco, A.,Amato, R.,Ellis, R. J.,Mayr, N. A., Paulino, A. C.,Xu, B.,Butler, B. E.. **Stereotactic body radiation therapy for prostate cancer.** *Future Oncol.* 2011. 7:1077-86 #DOI#	Publication type
Iwai, Y.,Yamanaka, K.,Ikeda, H.. **Gamma Knife radiosurgery for skull base meningioma: long-term results of low-dose treatment.** *Journal of Neurosurgery.* 2008. 109:804-10 #DOI#	Population
Iwai, Y.,Yamanaka, K.,Shiotani, M.,Uyama, T.. **Radiosurgery for acoustic neuromas: results of low-dose treatment.** *Neurosurgery.* 2003. 53:282-87; discussion 287-8 #DOI#	Population
Iwata, H.,Sato, K.,Tatewaki, K.,Yokota, N.,Inoue, M.,Baba, Y.,Shibamoto, Y.. **Hypofractionated stereotactic radiotherapy with CyberKnife for nonfunctioning pituitary adenoma: high local control with low toxicity.** *Neuro-Oncology.* 2011. 13:916-22 #DOI#	Population
Iyengar, P.,Wardak, Z.,Gerber, D. E.,Tumati, V.,Ahn, C.,Hughes, R. S.,Dowell, J. E., Cheedella, N.,Nedzi, L.,Westover, K. D.,Pulipparacharuvil, S.,Choy, H.,Timmerman, R. D.. **Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.** *JAMA Oncol.* 2018. 4:e173501 #DOI#	Sample size
Jabbari, Siavash,Weinberg, Vivian K,Kaprealian, Tania,Hsu, I-Chow,Ma, Lijun,Chuang, Cynthia,Descovich, Martina,Shiao, Stephen,Shinohara, Katsuto,Roach III, Mack. **Stereotactic body radiotherapy as monotherapy or post–external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.** *International Journal of Radiation Oncology* Biology* Physics.* 2012. 82:228-234 #DOI#	Sample size
Jaccard, M., Zilli, T., Dubouloz, A., Escude, L., Jorcano, S., Linthout, N., Bral, S., Verbakel, W., Bruynzeel, A., Björkqvist, M., et al.. **Urethra-Sparing Stereotactic Body Radiation Therapy for Prostate Cancer: quality Assurance of a Randomized Phase 2 Trial.** *International journal of radiation oncology, biology, physics.* 2020. 108:1047-1054 10.1016/j.ijrobp.2020.06.002	Outcomes
Jackson, William C,Dess, Robert T,Litzenberg, Dale W,Li, Pin,Schipper, Matthew, Rosenthal, Seth A,Chang, Garrick C,Horwitz, Eric M,Price, Robert A,Michalski, Jeff M. **A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life.** *Practical Radiation Oncology.* 2018. 8:40-47 #DOI#	Sample size
Jain S, Poon I, Soliman H, et al. Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11 days: a comparison of acute toxicity and quality of life. *Radiother Oncol.* 2013;108(2):320-325. doi: 10.1016/j.radonc.2013.06.045.	Sample size
Jang, W. I., Bae, S. H., Kim, M. S., Han, C. J., Park, S. C., Kim, S. B., Cho, E. H., Choi, C. W., Kim, K. S., Hwang, S., Kim, J. H., Chang, A. R., Park, Y., Kim, E. S., Kim, W. C., Jo, S., Park, H. J.. **A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.** *Cancer.* 2020. 126:363-372 10.1002/cncr.32502	Sample size
Janowski E-M, Kole TP, Chen LN, et al. Dysuria following stereotactic body radiation therapy for prostate cancer. *Frontiers in Oncology.* 2015;5:151. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490223/pdf/fonc-05-00151.pdf. .	Outcomes

Janowski, Einsley,Chen, Leonard N,Kim, Joy S,Lei, Siyuan,Suy, Simeng,Collins, Brian, Lynch, John,Dritschilo, Anatoly,Collins, Sean. **Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥ 50 cm3).** *Radiation Oncology*. 2014. 9:1-10 #DOI#	Sample size
Janowski, Einsley-Marie,Kole, Thomas P,Chen, Leonard N,Kim, Joy S,Yung, Thomas M, Collins, Brian Timothy,Suy, Simeng,Lynch, John H,Dritschilo, Anatoly,Collins, Sean P. **Dysuria following stereotactic body radiation therapy for prostate cancer.** *Frontiers in Oncology*. 2015. 5:151 #DOI#	Outcomes
Janvary, Zsolt Levente,Jansen, Nicolas,Baart, Veronique,Devillers, Magali,Dechambre, David,Lenaerts, Eric,Seidel, Laurence,Barthelemy, Nicole,Berkovic, Patrick,Gulyban, Akos. **Clinical outcomes of 130 patients with primary and secondary lung tumors treated with Cyberknife robotic stereotactic body radiotherapy.** *Radiology and Oncology*. 2017. 51:178-186 #DOI#	Population
Jardel, P., Kammerer, E., Villeneuve, H., Thariat, J.. **Stereotactic radiation therapy for breast cancer in the elderly.** *Translational Cancer Research*. 2020. 9:S86-S96 https://dx.doi.org/10.21037/tcr.2019.07.18	Publication type
Jelinek, M. J., Melotek, J. M., Vokes, E. E., Weichselbaum, R. R., Chmura, S. J., Patel, J. D.. **A phase I trial to evaluate concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in stage IV NSCLC.** *Journal of thoracic oncology*. 2017. 12:S1579-S1580 #DOI#	Publication type
Jeon, W., Ahn, S. J., Kim, Y. C., Oh, I. J., Park, C. K., Jeong, J. U., Yoon, M. S., Song, J. Y., Nam, T. K., Chung, W. K.. **Correlation of biologically effective dose and the tumor control in Stage I (<5 cm) non-small cell lung cancer with stereotactic ablative radiotherapy: a single institutional cohort study.** *Japanese Journal of Clinical Oncology*. 2018. 48:144-152 https://dx.doi.org/10.1093/jjco/hyx172	Sample size
Jeong, Bae-Kwon,Jeong, Hojin,Ha, In Bong,Choi, Hoon Sik,Kam, Sung Chul,Hwa, Jeong Seok,Hyun, Jae Seog,Chung, Ky Hyun,Choi, See Min,Kang, Ki Mun. **Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma.** *jkms*. 2015. 30:710-715 #DOI#	Sample size
Jeppesen SS, Hansen NCG, Schytte T, Hansen O. Survival of localized NSCLC patients without active treatment or treated with SBRT. *Acta Oncol*. 2018;57(2):219-225. doi: 10.1080/0284186X.2017.1374558.	Population
Jeppesen, S., Hansen, O., Matzen, L.. **Does CGA impact QOL and overall survival in NSCLC patients treated with SBRT - Results of a randomized pilot study.** *Journal of thoracic oncology*. 2017. 12:S2403- #DOI#	Publication type
Jereczek-Fossa BA, Rojas DP, Zerini D, et al. Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT). *British Journal of Radiology*. 2019;92(1094):20180494. doi: https://dx.doi.org/10.1259/bjr.20180494.	Sample size
Ji, X., Zhao, Y., He, C., Han, S., Zhu, X., Shen, Z., Chen, C., Chu, X.. **Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer.** *Frontiers in oncology*. 2021. 11:#pages# 10.3389/fonc.2021.659987	Setting
Jia, H., Lv, J., Liang, L.. **Outcomes of radiotherapy combined with systemic therapy for stage IV NSCLC: a real-world study.** *Journal of clinical oncology*. 2021. 39:#pages# 10.1200/JCO.2021.39.15_suppl.e24084	Publication type

Jiang NY, Dang AT, Yuan Y, et al. Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy. *Int J Radiat Oncol Biol Phys.* 2019;105(3):628-636. doi: 10.1016/j.ijrobp.2019.06.2539.	Outcomes
Jiang, N. Y., Dang, A. T., Yuan, Y., Chu, F. I., Shabsovich, D., King, C. R., Collins, S. P., Aghdam, N., Suy, S., Mantz, C. A., Miszczyk, L., Napieralska, A., Namysl-Kaletka, A., Bagshaw, H., Prionas, N., Buyyounouski, M. K., Jackson, W. C., Spratt, D. E., Nickols, N. G., Steinberg, M. L., Kupelian, P. A., Kishan, A. U.. **Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy.** *International Journal of Radiation Oncology, Biology, Physics.* 2019. 105:628-636 https://dx.doi.org/10.1016/j.ijrobp.2019.06.2539	Outcomes
Jiang, W. N., Baker, S., Liu, M., Bergman, A., Schellenberg, D., Mou, B., Alexander, A. S., Carolan, H., Atrchian, S., Chan, E. K., et al.. **Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR): overall Survival Results of the SABR-5 Trial.** *International journal of radiation oncology biology physics.* 2022. 114:S147-S148 10.1016/j.ijrobp.2022.07.621	Publication type
Jin, H., Chalkidou, A., Hawkins, M., Summers, J., Eddy, S., Peacock, J. L., Coker, B., Kartha, M. R., Good, J., Pennington, M., Group, Sabr Data Working. **Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiation Therapy Compared With Surgery and Radiofrequency Ablation in Two Patient Cohorts: Metastatic Liver Cancer and Hepatocellular Carcinoma.** *Clinical Oncology (Royal College of Radiologists).* 2021. 33:e143-e154 https://dx.doi.org/10.1016/j.clon.2020.08.010	Setting
Johnson SB, Soulos PR, Shafman TD, et al. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. *Radiother Oncol.* 2016;121(2):294-298. doi: 10.1016/j.radonc.2016.10.013.	Study design
Johnson, S. B., Stahl, J. M., Miccio, J. A., Kann, B. H., Kelly, J. R., Decker, R.. **Stereotactic body radiation and adjuvant chemotherapy versus surgery and adjuvant chemotherapy for T1-2N0 small cell lung cancer.** *International journal of radiation oncology biology physics.* 2018. 101:E3- #DOI#	Publication type
Johnson, S. B.,Soulos, P. R.,Shafman, T. D.,Mantz, C. A.,Dosoretz, A. P.,Ross, R., Finkelstein, S. E.,Collins, S. P.,Suy, S.,Brower, J. V.,Ritter, M. A.,King, C. R.,Kupelian, P. A.,Horwitz, E. M.,Pollack, A.,Abramowitz, M. C.,Hallman, M. A.,Faria, S.,Gross, C. P.,Yu, J. B.. **Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer.** *Radiother Oncol.* 2016. 121:294-298 #DOI#	Study design
Joyner M, Salter BJ, Papanikolaou N, Fuss M. Stereotactic body radiation therapy for centrally located lung lesions. *Acta Oncol.* 2006;45(7):802-807. doi: 10.1080/02841860600915322.	Outcomes
Ju, Andrew W,Wang, Hongkun,Oermann, Eric K,Sherer, Benjamin A,Uhm, Sunghae, Chen, Viola J,Pendharkar, Arjun V,Hanscom, Heather N,Kim, Joy S,Lei, Siyuan. **Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer.** *Radiation oncology.* 2013. 8:1-10 #DOI#	Sample size
Jumeau, Raphaël,Delouya, Guila,Roberge, David,Donath, David,Béliveau-Nadeau, Dominic,Campeau, Marie-Pierre. **Stereotactic body radiotherapy (SBRT) for patients with locally advanced pancreatic cancer: a single center experience.** *Digestive and Liver Disease.* 2018. 50:396-400 #DOI#	Sample size

Kaidar-Person, Orit,Price, Alex,Schreiber, Eric,Zagar, Timothy M,Chen, Ronald C. **Stereotactic body radiotherapy for large primary renal cell carcinoma.** *Clinical Genitourinary Cancer*. 2017. 15:e851-e854 #DOI#	Sample size
Kajiwara, K.,Saito, K.,Yoshikawa, K.,Kato, S.,Akimura, T.,Nomura, S.,Ishihara, H.,Suzuki, M.. **Image-guided stereotactic radiosurgery with the CyberKnife for pituitary adenomas.** *Minimally Invasive Neurosurgery*. 2005. 48:91-6 #DOI#	Population
Kalogeridi, M. A.,Georgolopoulou, P.,Kouloulias, V.,Kouvaris, J.,Pissakas, G.. **Long-term results of LINAC-based stereotactic radiosurgery for acoustic neuroma: the Greek experience.** *Journal of Cancer Research & Therapeutics*. 2009. 5:8-13 #DOI#	Population
Kang, J. K.,Kim, M. S.,Kim, J. H.,Yoo, S. Y.,Cho, C. K.,Yang, K. M.,Yoo, H. J.,Seo, Y. S., Lee, D. H.,Kang, H. J.,Kim, Y. H.,Shin, U. S.. **Oligometastases confined one organ from colorectal cancer treated by SBRT.** *Clin Exp Metastasis*. 2010. 27:273-8 #DOI#	Sample size
Kang, J., Nie, Q., Du, R., Zhang, L., Zhang, J., Li, Q., Li, J., Qi, W.. **Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis.** *Molecular and clinical oncology*. 2014. 2:43-50 10.3892/mco.2013.196	Setting
Kang, Jin-Kyu,Kim, Mi-Sook,Cho, Chul Koo,Yang, Kwang Mo,Yoo, Hyung Jun,Kim, Jin Ho,Bae, Sun Hyun,Jung, Da Hoon,Kim, Kum Bae,Lee, Dong Han. **Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization.** *Cancer*. 2012. 118:5424-5431 #DOI#	Sample size
Kann BH, Verma V, Stahl JM, et al. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma. *Radiother Oncol*. 2019;134:44-49. doi: 10.1016/j.radonc.2019.01.027. .	Outcomes
Kann, B. H., Miccio, J. A., Stahl, J. M., Ross, R., Verma, V., Dosoretz, A. P., Park, H. S., Shafman, T. D., Gross, C. P., Yu, J. B., Decker, R. H.. **Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.** *Radiotherapy & Oncology*. 2019. 132:188-196 https://dx.doi.org/10.1016/j.radonc.2018.10.017	Comparator
Kano, H.,Iyer, A.,Kondziolka, D.,Niranjan, A.,Flickinger, J. C.,Lunsford, L. D.. **Outcome predictors of gamma knife radiosurgery for renal cell carcinoma metastases.** *Neurosurgery*. 2011. 69:1232-9 #DOI#	Population
Kano, H.,Niranjan, A.,Khan, A.,Flickinger, J. C.,Kondziolka, D.,Lieberman, F.,Lunsford, L. D.. **Does radiosurgery have a role in the management of oligodendrogliomas?.** *Journal of Neurosurgery*. 2009. 110:564-71 #DOI#	Population
Kano, H.,Niranjan, A.,Kondziolka, D.,Flickinger, J. C.,Lunsford, L. D.. **Outcome predictors for intracranial ependymoma radiosurgery.** *Neurosurgery*. 2009. 64:279-87; discussion 287-8 #DOI#	Population
Kano, H.,Yang, H. C.,Kondziolka, D.,Niranjan, A.,Arai, Y.,Flickinger, J. C.,Lunsford, L. D.. **Stereotactic radiosurgery for pediatric recurrent intracranial ependymomas.** *Journal of Neurosurgery. Pediatrics.*. 2010. 6:417-23 #DOI#	Population
Kastelijn EA, El Sharouni SY, Hofman FN, et al. Clinical outcomes in early-stage NSCLC treated with stereotactic body radiotherapy versus surgical resection. *Anticancer Res*. 2015;35(10):5607-5614. https://www.ncbi.nlm.nih.gov/pubmed/26408733.	Population
Kataria S, Koneru H, Guleria S, et al. Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer:	Outcomes

An Ablative Procedure? *Frontiers in Oncology*. 2017;7:157. doi: https://dx.doi.org/10.3389/fonc.2017.00157.	
Katz A, Formenti SC, Kang J. Predicting Biochemical Disease-Free Survival after Prostate Stereotactic Body Radiotherapy: Risk-Stratification and Patterns of Failure. *Frontiers in Oncology*. 2016;6:168. doi: https://dx.doi.org/10.3389/fonc.2016.00168.	Outcomes
Katz, A. J.,Santoro, M.,Ashley, R.,Diblasio, F.,Witten, M.. **Stereotactic body radiotherapy as boost for organ-confined prostate cancer.** *Technol Cancer Res Treat*. 2010. 9:575-82 #DOI#	Sample size
Katz, A. W.,Carey-Sampson, M.,Muhs, A. G.,Milano, M. T.,Schell, M. C.,Okunieff, P.. **Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases.** *Int J Radiat Oncol Biol Phys*. 2007. 67:793-8 #DOI#	Sample size
Katz, A., Formenti, S. C., Kang, J.. **Predicting Biochemical Disease-Free Survival after Prostate Stereotactic Body Radiotherapy: Risk-Stratification and Patterns of Failure.** *Frontiers in Oncology*. 2016. 6:168 https://dx.doi.org/10.3389/fonc.2016.00168	Outcomes
Kawaguchi, Koji,Sato, Kengo,Horie, Akihisa,Iketani, Susumu,Yamada, Hiroyuki, Nakatani, Yasunori,Sato, Junichi,Hamada, Yoshiki. **Stereotactic radiosurgery may contribute to overall survival for patients with recurrent head and neck carcinoma.** *Radiation Oncology*. 2010. 5:1-9 #DOI#	Sample size
Kelley, J., Faulkner, N., Hanna, W., Heidel, R. E., Turner, J. F., Darrow, K.. **PD01.13 Stereotactic Modulating Radiation Therapy (SMRT) For Oligo-Metastatic Non-Small Cell Lung Cancer.** *Journal of thoracic oncology*. 2019. 14:S1138-10.1016/j.jtho.2019.09.050	Publication type
Kepka, L., Tyc-Szczepaniak, D., Osowiecka, K., Sprawka, A., Trabska-Kluch, B., Czeremszynska, B., Olszyna-Serementa, M.. **Quality of life: result from a randomized trial that compared WBRT with radiosurgery of tumor cavity.** *Radiotherapy and oncology*. 2017. 123:S327-S328 #DOI#	Publication type
Kessel, K. A., Fischer, H., Vogel, M. M., Oechsner, M., Bier, H., Meyer, B., Combs, S. E.. **Fractionated vs. single-fraction stereotactic radiotherapy in patients with vestibular schwannoma : hearing preservation and patients' self-reported outcome based on an established questionnaire.** *Strahlentherapie und Onkologie*. 2017. 193:192-199 10.1007/s00066-016-1070-0	Population
Khalifa, J., Pouessel, D., Roumiguie, M., Sargos, P., Loos, G., Schick, U., Salem, N., Mesgouez-Nebout, N., Loriot, Y., Hennequin, C., et al.. **Consolidative radiotherapy for metastatic urothelial bladder cancer patients without progression and with no more than three residual metastatic lesions following first line systemic therapy: a prospective randomized comparative phase II trial (BLAD RAD01/GETUG-AFU V07).** *Journal of clinical oncology*. 2021. 39:#pages# 10.1200/JCO.2021.39.15_suppl.TPS4588	Publication type
Khalladi, N., Dejean, C., Bosset, M., Pointreau, Y., Kinj, R., Racadot, S., Castelli, J., Huguet, F., Renard, S., Guihard, S., et al.. **A priori quality assurance using a benchmark case of the randomized phase 2 GORTEC 2014-14 in oligometastatic head and neck cancer patients.** *Cancer/radiotherapie*. 2021. 25:755-762 10.1016/j.canrad.2021.04.005	Aim
Khoo, V., Ahmed, M., McDonald, F., Kirby, A., Van As, N., Hawkins, M., Syndikis, I., Franks, K., Jain, S., Tree, A., et al.. **CORE: a randomised trial of COnventional care**	Publication type

versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases. *Lung cancer (Amsterdam, Netherlands).* 2017. 103:S55-S56 #DOI#	
Khorprasert C, Thonglert K, Alisanant P, Amornwichet N. Advanced radiotherapy technique in hepatocellular carcinoma with portal vein thrombosis: feasibility and clinical outcomes. *PloS one.* 2021;16(9 September). doi: 10.1371/journal.pone.0257556.	Interventio n
Kilburn, J. M., Kuremsky, J. G., Blackstock, A. W., Munley, M. T., Kearns, W. T., Hinson, W. H., Lovato, J. F., Miller, A. A., Petty, W. J., Urbanic, J. J.. **Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment.** *Radiother Oncol.* 2014. 110:505-10 10.1016/j.radonc.2013.11.017	Sample size
Kim H, Gill B, Beriwal S, Huq MS, Roberts MS, Smith KJ. Cost-effectiveness analysis of stereotactic body radiation therapy compared with radiofrequency ablation for inoperable colorectal liver metastases. *Int J Radiat Oncol Biol Phys.* 2016;95(4):1175-1183. doi: 10.1016/j.ijrobp.2016.02.045.	Date
Kim, Chae-Yong,Paek, Sun Ha,Jeong, Sang Soon,Chung, Hyun-Tai,Han, Jung Ho,Park, Chul-Kee,Jung, Hee-Won,Kim, Dong Gyu. **Gamma knife radiosurgery for central neurocytoma.** *Cancer.* 2007. 110:2276-2284 #DOI#	Population
Kim, DW Nathan,Straka, Christopher,Cho, L Chinsoo,Timmerman, Robert D. **Stereotactic body radiation therapy for prostate cancer: review of experience of a multicenter phase I/II dose-escalation study.** *Frontiers in Oncology.* 2014. 4:319 #DOI#	Sample size
Kim, Hun Jung,Phak, Jeong Hoon,Kim, Woo Chul. **Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma.** *Radiat Oncol J.* 2016. 34:260-264 #DOI#	Sample size
Kim, J. H.,Kim, M. S.,Yoo, S. Y.,Lim, S. M.,Lee, G. H.,Yi, K. H.. **Stereotactic body radiotherapy for refractory cervical lymph node recurrence of nonanaplastic thyroid cancer.** *Otolaryngol Head Neck Surg.* 2010. 142:338-43 #DOI#	Sample size
Kim, Mi-Sook,Choi, ChulWon,Yoo, SungYul,Cho, ChulKoo,Seo, YoungSeok,Ji, YoungHoon,Lee, DongHan,Hwang, DaeYong,Moon, SunMi,Kim, Min Suk. **Stereotactic body radiation therapy in patients with pelvic recurrence from rectal carcinoma.** *Japanese journal of clinical oncology.* 2008. 38:695-700 #DOI#	Sample size
Kim, S., Wuthrick, E., Blakaj, D. M., Eroglu, Z., Verschraegen, C., Thapa, R., Mills, M., Dibs, K., Liveringhouse, C., Russell, J., et al.. **LBA42 Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma.** *Annals of oncology.* 2022. 33:S1409-S1410 10.1016/j.annonc.2022.08.041	Publication type
Kim, Y. J., Ahn, H., Kim, C. S., Lee, J. L., Kim, Y. S.. **Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial.** *Trials.* 2018. 19:#pages# 10.1186/s13063-018-2574-y	Sample size
Kimura, T., Aikata, H., Takahashi, S., Takahashi, I., Nishibuchi, I., Doi, Y., Kenjo, M., Murakami, Y., Honda, Y., Kakizawa, H., Awai, K., Chayama, K., Nagata, Y.. **Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies.** *Hepatol Res.* 2015. 45:378-86 10.1111/hepr.12359	Sample size
Kimura, T., Takeda, A., Tsurugai, Y., Kawano, R., Doi, Y., Oku, Y., Hioki, K., Miura, H., Nagata, Y.. **A Multi-Institutional Retrospective Study of Repeated Stereotactic Body**	Sample size

Radiation Therapy for Intrahepatic Recurrent Hepatocellular Carcinoma. *International Journal of Radiation Oncology, Biology, Physics.* 2020. 108:1265-1275 https://dx.doi.org/10.1016/j.ijrobp.2020.07.034	
King C. Stereotactic body radiotherapy for prostate cancer: current results of a phase II trial. *IMRT, IGRT, SBRT*. Vol 43: Karger Publishers; 2011:428-437.	Sample size
King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC, Jr. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. *Int J Radiat Oncol Biol Phys*. 2009;73(4):1043-1048. doi: 10.1016/j.ijrobp.2008.05.059.	Sample size
King CR, Brooks JD, Gill H, Presti JC, Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. *Int J Radiat Oncol Biol Phys*. 2012;82(2):877-882. doi: 10.1016/j.ijrobp.2010.11.054.	Sample size
King CR, Collins S, Fuller D, et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. *International Journal of Radiation Oncology, Biology, Physics*. 2013;87(5):939-945. doi: https://dx.doi.org/10.1016/j.ijrobp.2013.08.019. .	Outcomes
King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. *Radiotherapy and Oncology*. 2013;109(2):217-221. https://www.thegreenjournal.com/article/S0167-8140(13)00430-1/pdf	Outcomes
King, C. R., Collins, S., Fuller, D., Wang, P. C., Kupelian, P., Steinberg, M., Katz, A.. **Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials.** *International Journal of Radiation Oncology, Biology, Physics.* 2013. 87:939-45 https://dx.doi.org/10.1016/j.ijrobp.2013.08.019	Outcomes
King, C. R.,Brooks, J. D.,Gill, H.,Pawlicki, T.,Cotrutz, C.,Presti, J. C., Jr.. **Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.** *Int J Radiat Oncol Biol Phys.* 2009. 73:1043-8 #DOI#	Sample size
King, C. R.,Brooks, J. D.,Gill, H.,Presti, J. C., Jr.. **Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.** *Int J Radiat Oncol Biol Phys.* 2012. 82:877-82 #DOI#	Sample size
King, Christopher R,Freeman, Debra,Kaplan, Irving,Fuller, Donald,Bolzicco, Giampaolo, Collins, Sean,Meier, Robert,Wang, Jason,Kupelian, Patrick,Steinberg, Michael. **Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials.** *Radiotherapy and Oncology.* 2013. 109:217-221 #DOI#	Outcomes
King, Christopher. **Stereotactic body radiotherapy for prostate cancer: current results of a phase II trial.** *IMRT, IGRT, SBRT.* 2011. 43:428-437 #DOI#	Sample size
Kishan A, Ruan D, Dang A, Chu F, Steinberg M, Weidhaas J. MicroRNA-based biomarkers predicting long-term toxicity to prostate SBRT. *International Journal of Radiation Oncology, Biology, Physics*. 2019;105(1):S39-S40.	Publication type
Kishan AU, Dang A, Katz AJ, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. *JAMA network open*. 2019;2(2):e188006-e188006. https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2723641/kishan_2019_oi_180332.pdf.	Study design

Kishan AU, Marco N, Schulz-Jaavall MB, et al. Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. *Radiotherapy & Oncology*. 2022;167:226-232. doi: https://dx.doi.org/10.1016/j.radonc.2021.12.040.	Study design
Kishan, A. U., Lamb, J., Casado, M., Wang, X., Ma, T. M., Low, D., Sheng, K., Yang, Y., Gao, Y., Basehart, V., et al.. **Magnetic resonance imaging-guided versus computed tomography-guided stereotactic body radiotherapy for prostate cancer (MIRAGE): interim analysis of a phase III randomized trial.** *Journal of clinical oncology*. 2022. 40:#pages# 10.1200/JCO.2022.40.6_suppl.255	Publication type
Kishan, A. U., Ma, T. M., Lamb, J. M., Casado, M., Wilhame, H., Low, D., Yang, Y., Gao, Y., Neylon, J. P., Basehart, V., et al.. **Magnetic Resonance Imaging-Guided vs. Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer (MIRAGE): primary Endpoint Analysis of a Phase III Randomized Trial.** *International journal of radiation oncology biology physics*. 2022. 114:S92-S93 10.1016/j.ijrobp.2022.07.507	Publication type
Kishan, Amar U,Dang, Audrey,Katz, Alan J,Mantz, Constantine A,Collins, Sean P, Aghdam, Nima,Chu, Fang-I,Kaplan, Irving D,Appelbaum, Limor,Fuller, Donald B. **Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer.** *JAMA network open*. 2019. 2:e188006-e188006 #DOI#	Study design
Kishan, Amar U.,King, Christopher R.. **Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer.** *Seminars in Radiation Oncology*. 2017. 27:268-278 #DOI#	Publication type
Klement, R. J., Guckenberger, M., Alheid, H., Allgauer, M., Becker, G., Blanck, O., Boda-Heggemann, J., Brunner, T., Duma, M., Gerum, S., Habermehl, D., Hildebrandt, G., Lewitzki, V., Ostheimer, C., Papachristofilou, A., Petersen, C., Schneider, T., Semrau, R., Wachter, S., Andratschke, N.. **Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control.** *Radiotherapy & Oncology*. 2017. 123:227-233 https://dx.doi.org/10.1016/j.radonc.2017.01.013	Outcomes
Koh, Dong-Hoon,Kim, Jin-Bum,Kim, Hong-Wook,Chang, Young-Seop,Kim, Hyung Joon. **Clinical outcomes of CyberKnife radiotherapy in prostate cancer patients: short-term, single-center experience.** *Korean Journal of Urology*. 2014. 55:172-177 #DOI#	Sample size
Koh, E. S.,Millar, B. A.,Menard, C.,Michaels, H.,Heydarian, M.,Ladak, S.,McKinnon, S., Rutka, J. A.,Guha, A.,Pond, G. R.,Laperriere, N. J.. **Fractionated stereotactic radiotherapy for acoustic neuroma: single-institution experience at The Princess Margaret Hospital.** *Cancer*. 2007. 109:1203-10 #DOI#	Population
Koiwai, K., Endo, Y., Mizuhata, K., Ina, H., Fukazawa, A., Ozawa, T., Fujinaga, Y.. **Ten-Year Experience of Stereotactic Body Radiotherapy at a Single Institution: Impact of Technological Development on the Outcome of Patients With Early Lung Cancer.** *Technology in Cancer Research & Treatment*. 2020. 19:1533033820979163 https://dx.doi.org/10.1177/1533033820979163	Aim
Kole TP, Tong M, Wu B, et al. Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer. *Acta Oncologica*. 2016;55(1):52-58. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986047/pdf/nihms806303.pdf. *.	Outcomes
Kole, Thomas P,Tong, Michael,Wu, Binbin,Lei, Siyuan,Obayomi-Davies, Olusola,Chen, Leonard N,Suy, Simeng,Dritschilo, Anatoly,Yorke, Ellen,Collins, Sean P. **Late urinary**	Outcomes

toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer. *Acta Oncologica.* 2016. 55:52-58 #DOI#	
Kondziolka, D.,Mathieu, D.,Lunsford, L. D.,Martin, J. J.,Madhok, R.,Niranjan, A., Flickinger, J. C.. **Radiosurgery as definitive management of intracranial meningiomas.** *Neurosurgery.* 2008. 62:53-8; discussion 58-60 #DOI#	Population
Koneru H, Cyr R, Feng LR, et al. The impact of obesity on patient reported outcomes following stereotactic body radiation therapy for prostate cancer. *Cureus*. 2016;8(7).	Outcomes
Koneru, Harsha,Cyr, Robyn,Feng, Li Rebekah,Bae, Edward,Danner, Malika T,Ayoob, Marilyn,Yung, Thomas M,Lei, Siyuan,Collins, Brian T,Saligan, Leorey. **The impact of obesity on patient reported outcomes following stereotactic body radiation therapy for prostate cancer.** *Cureus.* 2016. 8:#pages# #DOI#	Outcomes
Kong, D. S.,Lee, J. I.,Lim, D. H.,Kim, K. W.,Shin, H. J.,Nam, D. H.,Park, K.,Kim, J. H.. **The efficacy of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas: long-term results of 125 consecutive patients treated in a single institution.** *Cancer.* 2007. 110:854-60 #DOI#	Population
Kong, D. S.,Lee, J. I.,Park, K.,Kim, J. H.,Lim, D. H.,Nam, D. H.. **Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas.** *Cancer.* 2008. 112:2046-51 #DOI#	Population
Kong, F. M., Zang, Y., Pi, W., Long, D., Ellsworth, S., Saito, N., Ghabril, M., Lacerda, M. A., Agarwal, D. M., O'Neil, B., et al.. **Stereotactic body radiation therapy to generate comparable survival to surgery in treating hepatocellular carcinoma (HCC): results of 756 patients.** *Journal of clinical oncology.* 2017. 35:#pages# #DOI#	Publication type
Kong, F. Ms, He, C., Zang, Y., Althouse, S. K., Tim, L., Kesler, K.. **Long-term survival comparison of stereotactic radiotherapy versus surgery for elderly patients with clinical stage T1-T2 nonsmall cell lung cancer.** *Journal of clinical oncology.* 2018. 36:#pages# 10.1200/JCO.2018.36.15-suppl.8511	Publication type
Koong, Albert C,Le, Quynh T,Ho, Anthony,Fong, Bryan,Fisher, George,Cho, Cheryl, Ford, Jim,Poen, Joseph,Gibbs, Iris C,Mehta, Vivek K. **Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer.** *International Journal of Radiation Oncology* Biology* Physics.* 2004. 58:1017-1021 #DOI#	Sample size
Korytko, T.,Radivoyevitch, T.,Colussi, V.,Wessels, B. W.,Pillai, K.,Maciunas, R. J., Einstein, D. B.. **12 Gy gamma knife radiosurgical volume is a predictor for radiation necrosis in non-AVM intracranial tumors.** *International Journal of Radiation Oncology, Biology, Physics.* 2006. 64:419-24 #DOI#	Population
Koshy, M.,Malik, R.,Mahmood, U.,Husain, Z.,Sher, D. J.. **Stereotactic body radiotherapy and treatment at a high volume facility is associated with improved survival in patients with inoperable stage I non-small cell lung cancer.** *Radiother Oncol.* 2015. 114:148-54 #DOI#	Population
Koto, M.,Takai, Y.,Ogawa, Y.,Matsushita, H.,Takeda, K.,Takahashi, C.,Britton, K. R., Jingu, K.,Takai, K.,Mitsuya, M.,Nemoto, K.,Yamada, S.. **A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer.** *Radiother Oncol.* 2007. 85:429-34 #DOI#	Sample size
Kougioumtzopoulou, A., Zygogianni, A., Liakouli, Z., Kypraiou, E., Kouloulias, V.. **The role of radiotherapy in bone metastases: A critical review of current literature.** *European Journal of Cancer Care.* 2017. 26:#pages# https://dx.doi.org/10.1111/ecc.12724	Study design

Kountouri, M., Zilli, T., Bruynzeel, A., Minn, H., Sanchez-Saugar, E., Oliveira, A., Bral, S., Jorcano, S., Abacioglu, U., Symon, Z., et al.. **Short vs protracted urethra-sparing prostate SBRT: feasibility and early toxicity from a randomized phase II trial.** *Strahlentherapie und Onkologie.* 2015. 191:902- 10.1007/s00066-015-0903-6	Publication type
Koyi H, Hillerdal G, Kolbeck KG, Brodin D, Liv P, Branden E. Non-small cell lung cancer (NSCLC) in octogenarians in clinical practice. *Anticancer Res.* 2016;36(10):5397-5402. doi: 10.21873/anticanres.11115.	Population
Kreil, W.,Luggin, J.,Fuchs, I.,Weigl, V.,Eustacchio, S.,Papaefthymiou, G.. **Long term experience of gamma knife radiosurgery for benign skull base meningiomas.** *Journal of Neurology, Neurosurgery & Psychiatry*. 2005. 76:1425-30 #DOI#	Population
Krema, H.,Somani, S.,Sahgal, A.,Xu, W.,Heydarian, M.,Payne, D.,McGowan, H.,Michaels, H.,Simpson, E. R.,Laperriere, N.. **Stereotactic radiotherapy for treatment of juxtapapillary choroidal melanoma: 3-year follow-up.** *Br J Ophthalmol.* 2009. 93:1172-6 #DOI#	Sample size
Krishnan, S.,Foote, R. L.,Brown, P. D.,Pollock, B. E.,Link, M. J.,Garces, Y. I.. **Radiosurgery for cranial base chordomas and chondrosarcomas.** *Neurosurgery*. 2005. 56:777-84; discussion 777-84 #DOI#	Population
Kroese TE, Christ SM, van Rossum PSN, et al. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study. *Radiotherapy & Oncology*. 2022;173:269-276. doi: https://dx.doi.org/10.1016/j.radonc.2022.06.012.	Population
Kroese, T. E., Christ, S. M., van Rossum, P. S. N., Burger, M. D. L., Buijs, G. S., Muhlematter, U., Andratschke, N., Ruurda, J. P., Hullner, M., Gutschow, C. A., van Hillegersberg, R., Guckenberger, M.. **Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.** *Radiotherapy & Oncology*. 2022. 173:269-276 https://dx.doi.org/10.1016/j.radonc.2022.06.012	Outcomes
Kroese, T. E., Jorritsma, N. K. N., van Laarhoven, H. W. M., Verhoeven, R. H. A., Mook, S., Haj Mohammad, N., Ruurda, J. P., van Rossum, P. S. N., van Hillegersberg, R.. **Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study.** *Clinical and Translational Radiation Oncology*. 2022. 37:109-115 https://dx.doi.org/10.1016/j.ctro.2022.08.012	Intervention
Kroeze, S. G. C., Henkenberens, C., Schmidt-Hegemann, N. S., Vogel, M. M. E., Kirste, S., Becker, J., Burger, I. A., Derlin, T., Bartenstein, P., Eiber, M., Mix, M., la Fougere, C., Christiansen, H., Belka, C., Combs, S. E., Grosu, A. L., Muller, A. C., Guckenberger, M.. **Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.** *European Urology Focus.* 2021. 7:309-316 https://dx.doi.org/10.1016/j.euf.2019.08.012	Outcomes
Krug, D., Fabian, A., Pyschny, F., Blanck, O., Dellas, K., Maass, N., Dunst, J.. **Radiotherapy in patients with oligometastatic breast cancer.** *Der Gynakologe.* 2019. #volume#:#pages# 10.1007/s00129-019-04496-z	Non-English
Kubo, K., Kimura, T., Aikata, H., Takahashi, S., Takeuchi, Y., Takahashi, I., Nishibuchi, I., Murakami, Y., Chayama, K., Nagata, Y.. **Long-term outcome of stereotactic body radiotherapy for patients with small hepatocellular carcinoma.** *Hepatol Res.* 2018. 48:701-707 10.1111/hepr.13063	Sample size

Kulik, L.. **Locoregenional Therapy for Hepatocellular Carcinoma: transarterial Chemoembolization Versus Transarterial Radioembolization Versus Stereotactic Body Radiotherapy.** *Clinical liver disease.* 2019. 13:26-28 10.1002/cld.801	Publication type
Kumar A, Straka CA, Vitzthum L, et al. Cost-effectiveness analysis of stereotactic ablative radiotherapy in patients with oligometastatic cancer. *Journal of clinical oncology*. 2020;38(15). doi: 10.1200/JCO.2020.38.15-suppl.7085.	Publication type
Kunos, C. A., Brindle, J., Waggoner, S., Zanotti, K., Resnick, K., Fusco, N., Adams, R., Debernardo, R.. **Phase II Clinical Trial of Robotic Stereotactic Body Radiosurgery for Metastatic Gynecologic Malignancies.** *Front Oncol.* 2012. 2:181 10.3389/fonc.2012.00181	Sample size
Kunos, C. A., Sherertz, T. M., Mislmani, M., Ellis, R. J., Lo, S. S., Waggoner, S. E., Zanotti, K. M., Herrmann, K., Debernardo, R. L.. **Phase I Trial of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Ablative Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer.** *Front Oncol.* 2015. 5:126 10.3389/fonc.2015.00126	Sample size
Kwon, J. H.,Bae, S. H.,Kim, J. Y.,Choi, B. O.,Jang, H. S.,Jang, J. W.,Choi, J. Y.,Yoon, S. K., Chung, K. W.. **Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer.** *BMC Cancer.* 2010. 10:475 #DOI#	Sample size
Lagerwaard, F. J., Aaronson, N. K., Gundy, C. M., Haasbeek, C. J., Slotman, B. J., Senan, S.. **Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer.** *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer.* 2012. 7:1148-54 https://dx.doi.org/10.1097/JTO.0b013e318252cfef	Population
Laliscia, C., Fabrini, M. G., Delishaj, D., Morganti, R., Greco, C., Cantarella, M., Tana, R., Paiar, F., Gadducci, A.. **Clinical Outcomes of Stereotactic Body Radiotherapy in Oligometastatic Gynecological Cancer.** *Int J Gynecol Cancer.* 2017. 27:396-402 10.1097/IGC.0000000000000885	Sample size
Lamanna, G., Jorcano, S., Bral, S., Rubio, C., Oliveira, A., Bottero, M., Abacioglu, U., Achard, V., Minn, H., Symon, Z., et al.. **Does the dose to penile bulb/internal pudendal arteries matter for erectile dysfunction post-SBRT?.** *Radiotherapy and oncology.* 2020. 152:S25- 10.1016/S0167-8140(21)00087-6	Publication type
Lamanna, G.. **Urethra-sparing prostate cancer SBRT: 18-months results from a once-a-week vs. every-other-day randomized phase II trial.** *Strahlentherapie und Onkologie.* 2019. 195:589- 10.1007/s00066-019-01459-0	Publication type
Landau, D. B., Hughes, L., Ngai, Y., Hanna, G. G., Conibear, J., Farrelly, L., Counsell, N.. **SARON: stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer (NSCLC). A UK randomised phase III trial.** *Lung cancer (Amsterdam, Netherlands).* 2017. 103:S54- #DOI#	Publication type
Lanni, T. B., Jr.,Grills, I. S.,Kestin, L. L.,Robertson, J. M.. **Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer.** *American Journal of Clinical Oncology.* 2011. 34:494-8 #DOI#	Population
Laviana AA, Ilg AM, Veruttipong D, et al. Utilizing time-driven activity-based costing to understand the short-and long-term costs of treating localized, low-risk prostate cancer. *Cancer.* 2016;122(3):447-455.	Date

https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.29743?download=true.	
Lawler, G.. **A review of surface guidance in extracranial stereotactic body radiotherapy (SBRT/SABR) for set-up and intra-fraction motion management.** *Technical Innovations and Patient Support in Radiation Oncology*. 2022. 21:23-26 https://dx.doi.org/10.1016/j.tipsro.2022.01.001	Aim
Lee, J. Y.,Niranjan, A.,McInerney, J.,Kondziolka, D.,Flickinger, J. C.,Lunsford, L. D.. **Stereotactic radiosurgery providing long-term tumor control of cavernous sinus meningiomas.** *Journal of Neurosurgery*. 2002. 97:65-72 #DOI#	Population
Lee, M. T.,Kim, J. J.,Dinniwell, R.,Brierley, J.,Lockwood, G.,Wong, R.,Cummings, B., Ringash, J.,Tse, R. V.,Knox, J. J.,Dawson, L. A.. **Phase I study of individualized stereotactic body radiotherapy of liver metastases.** *J Clin Oncol*. 2009. 27:1585-91 #DOI#	Sample size
Lee, S., Song, S. Y., Kim, S. S., Choi, W., Je, H. U., Back, G. M., Cho, B., Jeong, S. Y., Choi, E. K.. **Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.** *Clin Lung Cancer*. 2018. 19:e253-e261 10.1016/j.cllc.2017.11.001	Outcomes
Leeman JE, Rimner A, Montecalvo J, et al. Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy. *International Journal of Radiation Oncology, Biology, Physics*. 2017;97(1):138-145. doi: https://dx.doi.org/10.1016/j.ijrobp.2016.09.037.	Population
Lei, Q., Wang, Y., Sui, J., Luo, Q., Jin, F., Long, B., Shu, X., Li, S., Huang, L., Zhong, M., et al.. **CAMRESBRT: randomized Phase II Trial of Camrelizumab with Stereotactic Body Radiotherapy vs. Camrelizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.** *International journal of radiation oncology biology physics*. 2022. 114:e282- 10.1016/j.ijrobp.2022.07.1302	Publication type
Lesueur, P., Escande, A., Thariat, J., Vauleon, E., Monnet, I., Cortot, A., Lerouge, D., Danhier, S., Do, P., Dubos-Arvis, C., Chouaid, C., Gervais, R.. **Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC.** *Cancer Med*. 2018. 7:5505-5513 10.1002/cam4.1825	Aim
Leung HW, Chan AL, Muo CH. Cost-effectiveness of gemcitabine plus modern radiotherapy in locally advanced pancreatic cancer. *Clin Ther*. 2016;38(5):1174-1183. doi: 10.1016/j.clinthera.2016.03.005.	Date
Leung HW, Liu CF, Chan AL. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma. *Radiat Oncol*. 2016;11:69. doi: 10.1186/s13014-016-0644-4.	Date
LeVasseur, N., Willemsma, K., Lohrisch, C. A., Lalani, N., Chia, S. K. L., Liu, M., Gelmon, K. A.. **Impact of oligometastatic disease on survival in ER positive breast cancer: a population-based analysis.** *Journal of clinical oncology*. 2020. 38:#pages# 10.1200/JCO.2020.38.15_suppl.e19109	Publication type
Levin-Epstein R, Qiao-Guan G, Juarez JE, et al. Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer. *Frontiers in Oncology*. 2020;10:539. doi: https://dx.doi.org/10.3389/fonc.2020.00539.	Aim

Li J, Dai J, Xian P, et al. Efficacy and safety of Prostate stereotactic body radiotherapy for metastatic castration-resistant prostate cancer: A prospective cohort study. *Cancer Treat Res Commun.* 2021;27:100368. doi: 10.1016/j.ctarc.2021.100368.	Setting
Li, G. J., Arifin, A. J., Al-Shafa, F., Cheung, P., Rodrigues, G. B., Palma, D. A., Louie, A. V.. **A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.** *Annals of Palliative Medicine.* 2021. 10:6045-6051 https://dx.doi.org/10.21037/apm-20-847	Aim
Li, G., Xia, Y. F., Huang, Y. X., Okat, D., Qiu, B., Doyen, J., Bondiau, P. Y., Benezery, K., Gao, J., Qian, C. N.. **Better preservation of erectile function in localized prostate cancer patients with modern proton therapy: Is it cost-effective?.** *Prostate.* 2022. 82:1438-1446 https://dx.doi.org/10.1002/pros.24417	Setting
Li, J., Dai, J., Xian, P., Xiong, L., Song, Y., Tang, X., Li, Y., Wu, Y., Zhou, H., Liu, N.. **Efficacy and safety of Prostate stereotactic body radiotherapy for metastatic castration-resistant prostate cancer: a prospective cohort study.** *Cancer treatment and research communications.* 2021. 27:#pages# 10.1016/j.ctarc.2021.100368	Setting
Li, X., Niu, C., Chen, Q., Chen, X.. **Comparison of efficacy of stereotactic body radiotherapy and thoracoscopic surgery in the treatment of early-stage non-small cell lung cancer.** *Journal of B.U.On..* 2020. 25:1497-1503 #DOI#	Setting
Lievens, Y., Obyn, C., Mertens, A. S., Van Halewyck, D., Hulstaert, F.. **Stereotactic body radiotherapy for lung cancer: how much does it really cost?.** *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer.* 2015. 10:454-61 https://dx.doi.org/10.1097/JTO.0000000000000421	Setting
Lieverse, R. I. Y., Van Limbergen, E. J., Oberije, C. J. G., Troost, E. G. C., Hadrup, S. R., Dingemans, A. Mc, Hendriks, L. E. L., Eckert, F., Hiley, C., Dooms, C., et al.. **Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.** *BMC cancer.* 2020. 20:#pages# 10.1186/s12885-020-07055-1	Intervention
Lin, J. C.,Jen, Y. M.,Li, M. H.,Chao, H. L.,Tsai, J. T.. **Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer.** *Eur J Gastroenterol Hepatol.* 2015. 27:259-64 #DOI#	Sample size
Lin, Q., Sun, X., Zhou, N., Wang, Z., Xu, Y., Wang, Y.. **Outcomes of stereotactic body radiotherapy versus lobectomy for stage I non-small cell lung cancer: a propensity score matching analysis.** *BMC Pulm Med.* 2019. 19:98 10.1186/s12890-019-0858-y	Setting
Lischalk, Jonathan W,Burke, Aidan,Chew, Jessica,Elledge, Christen,Gurka, Marie, Marshall, John,Pishvaian, Michael,Collins, Sean,Unger, Keith. **Five-fraction stereotactic body radiation therapy (SBRT) and chemotherapy for the local management of metastatic pancreatic cancer.** *Journal of gastrointestinal cancer.* 2018. 49:116-123 #DOI#	Sample size
Lischalk, Jonathan W,Malik, Ryan M,Collins, Sean P,Collins, Brian T,Matus, Ismael A, Anderson, Eric D. **Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases.** *Radiation Oncology.* 2016. 11:1-10 #DOI#	Sample size
Liu, D.,Xu, D.,Zhang, Z.,Zhang, Y.,Zheng, L.. **Long-term outcomes after Gamma Knife surgery for vestibular schwannomas: a 10-year experience.** *Journal of Neurosurgery.* 2006. 105 Suppl:149-53 #DOI#	Population

Liu, H. Y., Lee, Y., McLean, K., Leggett, D., Hodgkinson, P., Fawcett, J., Mott, R., Stuart, K., Pryor, D.. **Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma - Initial Experience From an Australian Liver Cancer Service.** *Clin Oncol (R Coll Radiol).* 2020. 32:e194-e202 10.1016/j.clon.2020.04.004	Sample size
Liu, H., Zhang, X., Vinogradskiy, Y. Y., Swisher, S. G., Komaki, R., Chang, J. Y.. **Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy.** *Int J Radiat Oncol Biol Phys.* 2012. 84:1017-23 10.1016/j.ijrobp.2012.02.020	Sample size
Lo, C. H., Yang, J. F., Liu, M. Y., Jen, Y. M., Lin, C. S., Chao, H. L., Huang, W. Y.. **Survival and prognostic factors for patients with advanced hepatocellular carcinoma after stereotactic ablative radiotherapy.** *PLoS ONE [Electronic Resource].* 2017. 12:e0177793 https://dx.doi.org/10.1371/journal.pone.0177793	Sample size
Lo, S. S.,Cho, K. H.,Hall, W. A.,Kossow, R. J.,Hernandez, W. L.,McCollow, K. K.,Gerbi, B. J.,Higgins, P. D.,Lee, C. K.,Dusenbery, K. E.. **Single dose versus fractionated stereotactic radiotherapy for meningiomas.** *Canadian Journal of Neurological Sciences.* 2002. 29:240-8 #DOI#	Population
Lo, Simon S,Fakiris, Achilles J,Chang, Eric L,Mayr, Nina A,Wang, Jian Z,Papiez, Lech, Teh, Bin S,McGarry, Ronald C,Cardenes, Higinia R,Timmerman, Robert D. **Stereotactic body radiation therapy: a novel treatment modality.** *Nature reviews Clinical oncology.* 2010. 7:44-54 #DOI#	Sample size
Lobato-Polo, J.,Kondziolka, D.,Zorro, O.,Kano, H.,Flickinger, J. C.,Lunsford, L. D.. **Gamma knife radiosurgery in younger patients with vestibular schwannomas.** *Neurosurgery.* 2009. 65:294-300; discussion 300-1 #DOI#	Population
Loblaw A, Cheung P, D'Alimonte L, et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. *Radiotherapy & Oncology*. 2013;107(2):153-158. doi: https://dx.doi.org/10.1016/j.radonc.2013.03.022.	Sample size
Loblaw, A., Cheung, P., Vesprini, D., Liu, S. K., Chu, W., Chung, H. T., Morton, G., Musunuru, B., Deabreu, A., Davidson, M., et al.. **Stereotactic radiotherapy +/- HDR boost for unfavorable-risk prostate cancer: comparison of efficacy, survival, and late toxicity outcomes.** *Journal of clinical oncology.* 2020. 38:#pages# 10.1200/JCO.2020.38.6_suppl.372	Publication type
Loblaw, D. A., Quon, H. C., Ong, A. T., Alayed, Y., Cheung, P., Chu, W., Chung, H. T., Vesprini, D., Chowdhury, A., Panjwani, D., et al.. **Accelerating Prostate Stereotactic Ablative Body Radiotherapy (SABR): efficacy and Toxicity of a Randomized Phase II Study of 11 Versus 29 Days Overall Treatment Time (PATRIOT Study; ClinicalTrials.gov NCT01423474).** *International journal of radiation oncology biology physics.* 2019. 105:S56- 10.1016/j.ijrobp.2019.06.491	Publication type
Loi M, Di Cataldo V, Simontacchi G, et al. Robotic Stereotactic Retreatment for Biochemical Control in Previously Irradiated Patients Affected by Recurrent Prostate Cancer. *Clinical Oncology (Royal College of Radiologists).* 2018;30(2):93-100. doi: https://dx.doi.org/10.1016/j.clon.2017.11.007.	Sample size
Losa, M.,Valle, M.,Mortini, P.,Franzin, A.,da Passano, C. F.,Cenzato, M.,Bianchi, S., Picozzi, P.,Giovanelli, M.. **Gamma knife surgery for treatment of residual nonfunctioning pituitary adenomas after surgical debulking.** *Journal of Neurosurgery.* 2004. 100:438-44 #DOI#	Population

Louie AV, Haasbeek CJ, Mokhles S, et al. Predicting Overall Survival After Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model. *Int J Radiat Oncol Biol Phys*. 2015;93(1):82-90. doi: 10.1016/j.ijrobp.2015.05.003. *EXC - not aim of interest	Aim
Louie, A. V.,van Werkhoven, E.,Chen, H.,Smit, E. F.,Paul, M. A.,Widder, J.,Groen, H. J., van den Borne, B. E.,De Jaeger, K.,Slotman, B. J.,Senan, S.. **Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: results from the ROSEL multicenter randomized trial.** *Radiother Oncol*. 2015. 117:44-8 #DOI#	Sample size
Lu, X. J.,Dong, J.,Ji, L. J.,Xiao, L. X.,Ling, C. Q.,Zhou, J.. **Tolerability and efficacy of Gamma knife radiosurgery on hepatocellular carcinoma with portal vein tumor thrombosis.** *Oncotarget*. 2016. 7:3614-22 #DOI#	Setting
Lucas JT, Jr., Kuremsky JG, Soike M, et al. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for stage 1 and node negative stage 2 non-small cell lung cancer (NSCLC). *Lung Cancer*. 2014;85(1):59-65. doi: 10.1016/j.lungcan.2014.04.003.	Population
Luke, J. J., Chmura, S. J., Allred, J. B., Salama, J. K., Al-Hallaq, H. A., Hsu, C., Yom, S. S., Kozloff, M., Munster, P. N., Schwartz, G. K.. **A randomized phase II study of anti-PD1 antibody [MK-3475 (Pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605).** *Journal of clinical oncology*. 2018. 36:#pages# 10.1200/JCO.2018.36.15-suppl.TPS9599	Publication type
Luke, J. J., Lemons, J. M., Karrison, T. G., Pitroda, S. P., Melotek, J. M., Zha, Y., Al-Hallaq, H. A., Arina, A., Khodarev, N. N., Janisch, L., Chang, P., Patel, J. D., Fleming, G. F., Moroney, J., Sharma, M. R., White, J. R., Ratain, M. J., Gajewski, T. F., Weichselbaum, R. R., Chmura, S. J.. **Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.** *J Clin Oncol*. 2018. 36:1611-1618 10.1200/JCO.2017.76.2229	Sample size
Lunsford, L. D.,Niranjan, A.,Martin, J. J.,Sirin, S.,Kassam, A.,Kondziolka, D.,Flickinger, J. C.. **Radiosurgery for miscellaneous skull base tumors.** *Progress in Neurological Surgery*. 2007. 20:192-205 #DOI#	Population
Ma, S. J., Cummings, M., Serra, L. M., Syed, Y. A., Hermann, G. M., Chen, Y., Milano, M. T., Singh, A. K., Gomez-Suescun, J. A., Singh, D. P.. **Three- Versus Five-Fraction Regimens of Stereotactic Body Radiotherapy for Peripheral Early-Stage Non-Small-Cell Lung Cancer: A Two-Institution Propensity Score-Matched Analysis.** *Clinical Lung Cancer*. 2018. 19:e297-e302 https://dx.doi.org/10.1016/j.cllc.2017.11.007	Comparator
Macbeth, F., Treasure, T.. **Stereotactic Ablative Radiotherapy for Oligometastatic Disease: Great Enthusiasm but Scant Evidence.** *Clinical Oncology (Royal College of Radiologists)*. 2022. 34:313-317 https://dx.doi.org/10.1016/j.clon.2022.02.008	Publication type
Macias, Victor A,Blanco, Manuel L,Barrera, Inmaculada,Garcia, Rafael. **A phase II study of stereotactic body radiation therapy for low-intermediate-high-risk prostate cancer using helical tomotherapy: dose-volumetric parameters predicting early toxicity.** *Frontiers in Oncology*. 2014. 4:336 #DOI#	Sample size
Madsen, Berit L,Hsi, R Alex,Pham, Huong T,Fowler, Jack F,Esagui, Laura,Corman, John. **Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.** *International Journal of Radiation Oncology* Biology* Physics*. 2007. 67:1099-1105 #DOI#	Sample size

Mahadevan, Anand,Jain, Sanjay,Goldstein, Michael,Miksad, Rebecca,Pleskow, Douglas, Sawhney, Mandeep,Brennan, Darren,Callery, Mark,Vollmer, Charles. **Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.** *International Journal of Radiation Oncology* Biology* Physics.* 2010. 78:735-742 #DOI#	Sample size
Mahadevan, Anand,Miksad, Rebecca,Goldstein, Michael,Sullivan, Ryan,Bullock, Andrea, Buchbinder, Elizabeth,Pleskow, Douglas,Sawhney, Mandeep,Kent, Tara,Vollmer, Charles. **Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer.** *International Journal of Radiation Oncology* Biology* Physics.* 2011. 81:e615-e622 #DOI#	Sample size
Mak, K. M., McDonald, F., Teague, J., Faivre-Finn, C., Forster, M., Hanna, G., Moinuddin, S., Conibear, J., Harden, S., Popat, S., et al.. **SARON: stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer (NSCLC).** *Lung cancer (Amsterdam, Netherlands).* 2022. 165:S71- 10.1016/S0169-5002(22)00202-1	Publication type
Malik, I.,Rowe, J. G.,Walton, L.,Radatz, M. W.,Kemeny, A. A.. **The use of stereotactic radiosurgery in the management of meningiomas.** *British Journal of Neurosurgery.* 2005. 19:13-20 #DOI#	Population
Mampuya, W. A., Matsuo, Y., Ueki, N., Nakamura, M., Mukumoto, N., Nakamura, A., Iizuka, Y., Kishi, T., Mizowaki, T., Hiraoka, M.. **The impact of abdominal compression on outcome in patients treated with stereotactic body radiotherapy for primary lung cancer.** *Journal of Radiation Research.* 2014. 55:934-9 https://dx.doi.org/10.1093/jrr/rru028	Sample size
Mandl, E. S.,Meijer, O. W.,Slotman, B. J.,Vandertop, W. P.,Peerdeman, S. M.. **Stereotactic radiation therapy for large vestibular schwannomas.** *Radiotherapy & Oncology.* 2010. 95:94-8 #DOI#	Population
Mangona, V. S., Aneese, A. M., Marina, O., Hymas, R. V., Ionascu, D., Robertson, J. M., Gallardo, L. J., Grills, I. S.. **Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis.** *Int J Radiat Oncol Biol Phys.* 2015. 91:124-32 10.1016/j.ijrobp.2014.08.345	Population
Marcus, K. J.,Goumnerova, L.,Billett, A. L.,Lavally, B.,Scott, R. M.,Bishop, K.,Xu, R., Young Poussaint, T.,Kieran, M.,Kooy, H.,Pomeroy, S. L.,Tarbell, N. J.. **Stereotactic radiotherapy for localized low-grade gliomas in children: final results of a prospective trial.** *International Journal of Radiation Oncology, Biology, Physics.* 2005. 61:374-9 #DOI#	Population
Mark, R. J., Gorman, V., McCullough, S.. **Five day accelerated partial breast irradiation (APBI) using stereotactic body radiation therapy (SBRT) in stage 0-II breast cancer: a report of 135 cases with up to two-year follow-up.** *Journal of clinical oncology.* 2020. 38:#pages# 10.1200/JCO.2020.38.15-suppl.e12596	Publication type
Mark, R. J., Gorman, V., Wolski, M., McCullough, S.. **Five Day Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT) in Stage 0-II Breast Cancer: a Report of 218 Cases With Up to 39 Month Follow-Up.** *International journal of radiation oncology biology physics.* 2021. 111:e208-10.1016/j.ijrobp.2021.07.735	Publication type
Mark, R., Gorman, V., McCoullough, S.. **Five Day Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT) in Stage 0-II Breast Cancer: a Report of 114 Patients with up to 2 Year Follow-up.** *International journal of radiation oncology biology physics.* 2020. 108:E27- 10.1016/j.ijrobp.2020.02.526	Publication type

Martin, A,Gaya, Antoni. **Stereotactic body radiotherapy: a review.** *Clinical Oncology*. 2010. 22:157-172 #DOI#	Publication type
Martin, J., Keall, P., Siva, S., Greer, P., Christie, D., Moore, K., Dowling, J., Pryor, D., Chong, P., McLeod, N., et al.. **TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol.** *BMJ open.* 2019. 9:#pages# 10.1136/bmjopen-2019-030731	Publication type
Marvaso, G., Ciardo, D., Corrao, G., Gandini, S., Fodor, C., Zerini, D., Rojas, D. P., Augugliaro, M., Bonizzi, G., Pece, S., et al.. **Radioablation +/- hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159).** *BMC cancer.* 2019. 19:903 10.1186/s12885-019-6117-z	Publication type
Mathieu, D., Campeau, M. P., Bahig, H., Larrivee, S., Vu, T., Lambert, L., Lavoie, C., Roberge, D., Doucet, R., Carrier, J. F., Gorgos, A., Fortin, B., Filion, E.. **Long-term quality of life in early-stage non-small cell lung cancer patients treated with robotic stereotactic ablative radiation therapy.** *Pract Radiat Oncol.* 2015. 5:e365-73 10.1016/j.prro.2014.12.002	Population
Mathieu, D.,Kondziolka, D.,Flickinger, J. C.,Niranjan, A.,Williamson, R.,Martin, J. J., Lunsford, L. D.. **Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates.** *Neurosurgery*. 2007. 60:460-8; discussion 468-70 #DOI#	Population
Matsuo Y, Chen F, Hamaji M, et al. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: a propensity score matching analysis. *Eur J Cancer*. 2014;50(17):2932-2938. doi: 10.1016/j.ejca.2014.09.006.	Population
Matsuo, Y.,Shibuya, K.,Nagata, Y.,Takayama, K.,Norihisa, Y.,Mizowaki, T.,Narabayashi, M.,Sakanaka, K.,Hiraoka, M.. **Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer.** *International Journal of Radiation Oncology, Biology, Physics*. 2011. 79:1104-11 #DOI#	Population
Mazzola, R., Francolini, G., Triggiani, L., Napoli, G., Cuccia, F., Nicosia, L., Giaj-Levra, N., Figlia, V., Ricchetti, F., Rigo, M., et al.. **Metastasis-directed Stereotactic Body Radiotherapy (SBRT)-guided by pet-ct 18f-choline versus pet-ct 68ga-psma in castration sensitive oligorecurrent prostate cancer: a comparative effectiveness analysis.** *European urology open science.* 2020. 21:S140- 10.1016/S2666-1683(20)36197-8	Publication type
McBride SM, Wong DS, Dombrowski JJ, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial. *Cancer*. 2012;118(15):3681-3690. https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.26699?download=true.	Sample size
McBride, S. M., Lee, N. Y., Pfister, D. G., Sherman, E. J., Tsai, C. J., Aghalar, J., Eng, J., Zhi, W. I., McFarland, D. C., Michel, L. S., et al.. **Biomarker predictors of outcome from a randomized trial of nivolumab +/- stereotactic body radiotherapy (SBRT) in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).** *Journal of clinical oncology*. 2019. 37:#pages# 10.1200/JCO.2019.37.15-suppl.6063	Publication type
McBride, S. M., Sherman, E. J., Tsai, C. J., Baxi, S. S., Aghalar, J., Eng, J., Zhi, W. I., McFarland, D. C., Michel, L. S., Spielsinger, D., et al.. **A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in**	Publication type

metastatic (M1) head and neck squamous cell carcinoma (HNSCC). *Journal of clinical oncology*. 2018. 36:#pages# 10.1200/JCO.2018.36.15_suppl.6009	
McBride, Sean M,Wong, Douglas S,Dombrowski, John J,Harkins, Bonnie,Tapella, Patricia,Hanscom, Heather N,Collins, Sean P,Kaplan, Irving D. **Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial.** *Cancer*. 2012. 118:3681-3690 #DOI#	Sample size
McDonald, F., Guckenberger, M., Popat, S., Andratschke, N., Kilburn, L., Toms, C., Bliss, J.. **HALT: targeted therapy beyond progression with or without dose-intensified radiotherapy in oligoprogressive disease in oncogene addicted lung tumours.** *Lung cancer (Amsterdam, Netherlands)*. 2017. 103:S57- #DOI#	Publication type
McDonald, F., Guckenberger, M., Popat, S., Faivre-Finn, C., Andratschke, N., Riddell, A., Hanna, G., Franks, K., Harrow, S., Miles, E., et al.. **HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours.** *Lung cancer (Amsterdam, Netherlands)*. 2020. 139:S92-10.1016/S0169-5002(20)30244-0	Publication type
McDonald, F., Guckenberger, M., Popat, S., Faivre-Finn, C., Andratschke, N., Riddell, A., Hanna, G., Hiley, C., Prakash, V., Nair, A., et al.. **HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours.** *Lung cancer (Amsterdam, Netherlands)*. 2022. 165:S70-S71 10.1016/S0169-5002(22)00201-X	Publication type
McDonald, F., Guckenberger, M., Popat, S., Faivre-Finn, C., Andratschke, N., Riddell, A., Hanna, G., Prakash, V., Nair, A., Diez, P., et al.. **171 HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours.** *Lung cancer (Amsterdam, Netherlands)*. 2021. 156:S70-S71 10.1016/S0169-5002(21)00370-6	Publication type
McDonald, F., Mak, K. M., Teague, J., Landau, D., Hanna, G., Farrelly, L., Counsell, N.. **SARON: stereotactic Ablative Radiotherapy for Oligometastatic Non-small cell lung cancer (NSCLC): a randomised phase III trial.** *Lung cancer (Amsterdam, Netherlands)*. 2020. 139:S91- 10.1016/S0169-5002(20)30243-9	Publication type
Medina-Rico, Mauricio,Ramos, Hugo López,Lobo, Manuel,Romo, Jorge,Prada, Juan Guillermo. **Epidemiology of renal cancer in developing countries: Review of the literature.** *Canadian Urological Association Journal*. 2018. 12:E154 #DOI#	Aim
Mendez Romero, A.,Wunderink, W.,Hussain, S. M.,De Pooter, J. A.,Heijmen, B. J., Nowak, P. C.,Nuyttens, J. J.,Brandwijk, R. P.,Verhoef, C.,Ijzermans, J. N.,Levendag, P. C.. **Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study.** *Acta Oncol*. 2006. 45:831-7 #DOI#	Sample size
Menoux, I., Antoni, D., Truntzer, P., Keller, A., Massard, G., Noel, G.. **Stereotactic body radiation therapy for stage I non-small cell lung carcinomas: Moderate hypofractionation optimizes outcome.** *Lung Cancer*. 2018. 126:201-207 10.1016/j.lungcan.2018.11.013	Sample size
Mercado C, Kress MA, Cyr RA, et al. Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience. *Frontiers in Oncology*. 2016;6:114. doi: https://dx.doi.org/10.3389/fonc.2016.00114.	Outcomes
Mesko, S., Sandler, K., Cohen, J., Konecny, G., Steinberg, M., Kamrava, M.. **Clinical Outcomes for Stereotactic Ablative Radiotherapy in Oligometastatic and**	Sample size

Oligoprogressive Gynecological Malignancies. *Int J Gynecol Cancer.* 2017. 27:403-408 10.1097/IGC.0000000000000869	
Metellus, P.,Regis, J.,Muracciole, X.,Fuentes, S.,Dufour, H.,Nanni, I.,Chinot, O.,Martin, P. M.,Grisoli, F.. **Evaluation of fractionated radiotherapy and gamma knife radiosurgery in cavernous sinus meningiomas: treatment strategy.** *Neurosurgery.* 2005. 57:873-86; discussion 873-86 #DOI#	Population
Milano, M. T.,Chen, Y.,Katz, A. W.,Philip, A.,Schell, M. C.,Okunieff, P.. **Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy.** *Radiotherapy & Oncology.* 2009. 91:301-6 #DOI#	Sample size
Milano, Michael T,Zhang, Hong,Metcalfe, Su K,Muhs, Ann G,Okunieff, Paul. **Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy.** *Breast cancer research and treatment.* 2009. 115:601-608 #DOI#	Sample size
Milker-Zabel, S.,Zabel-du Bois, A.,Huber, P.,Schlegel, W.,Debus, J.. **Fractionated stereotactic radiation therapy in the management of benign cavernous sinus meningiomas : long-term experience and review of the literature.** *Strahlenther Onkol.* 2006. 182:635-40 #DOI#	Population
Mills, M, Reddy, AV, Reshko, LB, Richardson, KM, Kersh, CR. **Clinical outcomes of stereotactic body radiation therapy for extracranial oligometastatic ovarian cancer.** *International Journal of Radiation Oncology, Biology, Physics.* 2019. 105:E569 #DOI#	Publication type
Mingione, V.,Yen, C. P.,Vance, M. L.,Steiner, M.,Sheehan, J.,Laws, E. R.,Steiner, L.. **Gamma surgery in the treatment of nonsecretory pituitary macroadenoma.** *Journal of Neurosurgery.* 2006. 104:876-83 #DOI#	Population
Mitchell, K. G., Farooqi, A., Ludmir, E. B., Corsini, E. M., Zhang, J., Sepesi, B., Vaporciyan, A. A., Swisher, S. G., Heymach, J. V., Zhang, J., Gomez, D. R., Antonoff, M. B.. **Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer.** *Clinical Lung Cancer.* 2020. 21:37-46.e7 https://dx.doi.org/10.1016/j.cllc.2019.07.007	Intervention
Mitchell, P., O'Byrne, K. J., Brown, C., Jurkovic, H., Karapetis, C. S., Kok, P. S., Lao, L., Le, H. V., Pavlakis, N., Ab Rahman, A. S., et al.. **A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiotherapy (SABR) in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD).** *International journal of radiation oncology, biology, physics.* 2021. 111:S10-S11 10.1016/j.ijrobp.2021.07.056	Publication type
Mitchell, R. A., Diamantopoulos, S., Dunlop, A., Alexander, S., Goodwin, E., Herbert, T., Jones, S., Mohajer, J., Nill, S., Smith, G. A., et al.. **Two-fraction prostate radiotherapy using high field MR-linac: technique and initial experience.** *Radiotherapy and oncology.* 2022. 170:S1460-S1461 10.1016/S0167-8140(22)03626-X	Publication type
Miyakawa, A., Shibamoto, Y., Baba, F., Manabe, Y., Murai, T., Sugie, C., Yanagi, T., Takaoka, T.. **Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study.** *Radiation Oncology.* 2017. 12:152 https://dx.doi.org/10.1186/s13014-017-0888-7	Sample size
Miyamoto, S., Nomura, R., Sato, K., Awano, N., Kuse, N., Inomata, M., Izumo, T., Terada, Y., Furuhata, Y., Bae, Y., Kunitoh, H.. **Nivolumab and stereotactic radiation therapy for the treatment of patients with Stage IV non-small-cell lung cancer.** *Jpn J Clin Oncol.* 2019. 49:160-164 10.1093/jjco/hyy171	Sample size

Miyazaki T, Yamazaki T, Nakamura D, et al. Surgery or stereotactic body radiotherapy for elderly stage I lung cancer? A propensity score matching analysis. *Surg Today*. 2017;47(12):1476-1483. doi: 10.1007/s00595-017-1536-4.	Population
Modorati, G.,Miserocchi, E.,Galli, L.,Picozzi, P.,Rama, P.. **Gamma knife radiosurgery for uveal melanoma: 12 years of experience.** *Br J Ophthalmol.* 2009. 93:40-4 #DOI#	Sample size
Mohamed, M., Katz, A. W., Tejani, M. A., Sharma, A. K., Kashyap, R., Noel, M. S., Qiu, H., Hezel, A. F., Ramaraju, G. A., Dokus, M. K., Orloff, M. S.. **Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma.** *Advances in radiation oncology*. 2016. 1:35-42 https://dx.doi.org/10.1016/j.adro.2015.12.003	Sample size
Mokhles S, Verstegen N, Maat AP, et al. Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis. *Lung Cancer*. 2015;87(3):283-289. doi: 10.1016/j.lungcan.2015.01.005.	Population
Mokhles, S.,Nuyttens, J. J.,Maat, A. P.,Birim, O.,Aerts, J. G.,Bogers, A. J.,Takkenberg, J. J.. **Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.** *Ann Surg Oncol.* 2015. 22:316-23 #DOI#	Intervention
Mortezaee, K., Motallebzadeh, E., Milajerdi, A., Farhood, B., Najafi, M., Sahebkar, A.. **The Effect of Prostate Cancer Radiotherapy on Testosterone Level: A Systematic Review and Meta-analysis.** *Current Medicinal Chemistry - Anti-Cancer Agents*. 2020. 20:636-642 https://dx.doi.org/10.2174/1871520620666200128112558	Outcomes
Motta, M.,del Vecchio, A.,Attuati, L.,Picozzi, P.,Perna, L.,Franzin, A.,Bolognesi, A., Cozzarini, C.,Calandrino, R.,Mortini, P.,di Muzio, N.. **Gamma knife radiosurgery for treatment of cerebral metastases from non-small-cell lung cancer.** *International Journal of Radiation Oncology, Biology, Physics*. 2011. 81:e463-8 #DOI#	Population
Muller, K.,Nowak, P. J.,Naus, N.,de Pan, C.,van Santen, C. A.,Levendag, P.,Luyten, G. P.. **Lacrimal gland radiosensitivity in uveal melanoma patients.** *Int J Radiat Oncol Biol Phys*. 2009. 74:497-502 #DOI#	Sample size
Murai T, Shibamoto Y, Nishiyama T, et al. Organizing pneumonia after stereotactic ablative radiotherapy of the lung. *Radiation Oncology*. 2012;7:123. doi: https://dx.doi.org/10.1186/1748-717X-7-123.	Population
Murphy JD, Chang DT, Abelson J, et al. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. *Cancer*. 2012;118(4):1119-1129. doi: 10.1002/cncr.26365.	Date
Murthy V, Gupta M, Mulye G, et al. Early Results of Extreme Hypofractionation Using Stereotactic Body Radiation Therapy for High-risk, Very High-risk and Node-positive Prostate Cancer. *Clinical Oncology (Royal College of Radiologists)*. 2018;30(7):442-447. doi: https://dx.doi.org/10.1016/j.clon.2018.03.004.	Setting
Murthy, V., Mallick, I., Gavarraju, A., Sinha, S., Krishnatry, R., Telkhade, T., Moses, A., Kannan, S., Prakash, G., Pal, M., et al.. **Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL).** *BMJ open*. 2020. 10:e034623 10.1136/bmjopen-2019-034623	Publication type

Musunuru HB, Davidson M, Cheung P, et al. Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer. *Int J Radiat Oncol Biol Phys.* 2016;94(5):1043-1051. doi: 10.1016/j.ijrobp.2015.12.010.	Study design
Musunuru HB, Quon H, Davidson M, et al. Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials. *Radiotherapy and Oncology*. 2016;118(1):112-117. https://www.thegreenjournal.com/article/S0167-8140(15)00681-7/fulltext.	Study design
Musunuru, H Bindu,Quon, Harvey,Davidson, Melanie,Cheung, Patrick,Zhang, Liying, D'Alimonte, Laura,Deabreu, Andrea,Mamedov, Alexandre,Loblaw, Andrew. **Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials.** *Radiotherapy and Oncology*. 2016. 118:112-117 #DOI#	Study design
Musunuru, H. B., Davidson, M., Cheung, P., Vesprini, D., Liu, S., Chung, H., Chu, W., Mamedov, A., Ravi, A., D'Alimonte, L., et al.. **Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer.** *International journal of radiation oncology, biology, physics.* 2016. 94:1043-1051 10.1016/j.ijrobp.2015.12.010	Study design
Myrehaug, S., Soliman, H., Tseng, C., Heyn, C., Sahgal, A.. **Re-irradiation of Vertebral Body Metastases: Treatment in the Radiosurgery Era.** *Clinical Oncology (Royal College of Radiologists).* 2018. 30:85-92 https://dx.doi.org/10.1016/j.clon.2017.11.005	Population
Nagata, Y., Hiraoka, M., Shibata, T., Onishi, H., Kokubo, M., Karasawa, K., Shioyama, Y., Onimaru, R., Kozuka, T., Kunieda, E., Saito, T., Nakagawa, K., Hareyama, M., Takai, Y., Hayakawa, K., Mitsuhashi, N., Ishikura, S.. **Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403.** *International Journal of Radiation Oncology, Biology, Physics.* 2015. 93:989-96 https://dx.doi.org/10.1016/j.ijrobp.2015.07.2278	Population
Nakagawa T, Negoro Y, Matsuoka T, Okumura N, Dodo Y. Comparison of the outcomes of stereotactic body radiotherapy and surgery in elderly patients with cT1-2N0M0 non-small cell lung cancer. *Respir Investig.* 2014;52(4):221-226. doi: 10.1016/j.resinv.2014.01.002.	Population
Nambu A, Onishi H, Aoki S, et al. Rib fracture after stereotactic radiotherapy on follow-up thin-section computed tomography in 177 primary lung cancer patients. *Radiat Oncol.* 2011;6:137. doi: 10.1186/1748-717X-6-137. *	Population
Nanda RH, Liu Y, Gillespie TW, et al. Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: a National Cancer Data Base analysis. *Cancer.* 2015;121(23):4222-4230. doi: 10.1002/cncr.29640.	Population
Nanda, R. H.,Liu, Y.,Gillespie, T. W.,Mikell, J. L.,Ramalingam, S. S.,Fernandez, F. G., Curran, W. J.,Lipscomb, J.,Higgins, K. A.. **Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: a National Cancer Data Base analysis.** *Cancer.* 2015. 121:4222-30 #DOI#	Population
Navarria, Pierina,Ascolese, Anna Maria,Tomatis, Stefano,Cozzi, Luca,De Rose, Fiorenza, Mancosu, Pietro,Alongi, Filippo,Clerici, Elena,Lobefalo, Francesca,Tozzi, Angelo. **Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments.** *Radiation Oncology.* 2014. 9:1-8 #DOI#	Sample size

Navarro-Martin, Arturo, Aso, Samantha, Cacicedo, Jon, Arnaiz, Maria, Navarro, Valentin, Rosales, Samuel, de Blas, Rodolfo, Ramos, Ricard, Guedea, Ferran. **Phase II trial of SBRT for stage I NSCLC: survival, local control, and lung function at 36 months.** *Journal of Thoracic Oncology.* 2016. 11:1101-1111 #DOI#	Population
Newman, N. B., Anderson, J. L., Shinohara, E. T., Michael, P., Attia, A., Osmundson, E. C.. **Neoadjuvant Stereotactic Ablative and Hypofractionated Radiotherapy for Oligometastatic NSCLC.** *International journal of radiation oncology biology physics.* 2019. 104:1196- 10.1016/j.ijrobp.2019.05.059	Publication type
Ngai, Y., Hanna, G., Conibear, J., Counsell, N., Hughes, L., Farrelly, L., Landau, D.. **SARON: stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer (NSCLC). A UK randomized phase III trial.** *Journal of thoracic oncology.* 2017. 12:S1425-S1426 #DOI#	Publication type
Nguyen, K. N. B., Hause, D. J., Novak, J., Monjazeb, A. M., Daly, M. E.. **Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors.** *Pract Radiat Oncol.* 2019. 9:e196-e202 10.1016/j.prro.2018.11.005	Sample size
Nguyen, Q. N., Chow, E., Chun, S. G., Komaki, R. U., Liao, Z., Fnu, R. Z., Szeto, B., Hahn, S. M., Fuller, C. D., Moon, B., et al.. **Single-Fraction Stereotactic versus Conventional Multifraction Radiation for Predominantly Non-Spine Bone Metastases: a Randomized Phase II Trial.** *International journal of radiation oncology biology physics.* 2019. 105:S49- 10.1016/j.ijrobp.2019.06.479	Publication type
Nguyen, Q., Chow, E., Chun, S. G., Liao, Z. X., Fnu, R., Welsh, J. W., Hahn, S., Fuller, C. D., Moon, B., Bird, J. E., et al.. **Single-fraction stereotactic versus standard conventional multifraction radiation for predominantly non-spine bone metastases: a randomized phase II trial.** *Journal of clinical oncology.* 2019. 37:#pages# 10.1200/JCO.2019.37.15_suppl.11578	Publication type
Nicosia L, Franceschini D, Perrone-Congedi F, et al. A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study. *Radiother Oncol.* 2022;166:92-99. doi: 10.1016/j.radonc.2021.10.023.	Outcomes
Nieder, C., Andratschke, N. H., Guckenberger, M.. **A pooled analysis of stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small cell lung cancer: is failure to recruit patients into randomized trials also an answer to the research question?.** *Annals of Translational Medicine.* 2015. 3:148 https://dx.doi.org/10.3978/j.issn.2305-5839.2015.06.05	Publication type
Nieuwenhuizen, S., Puijk, R. S., van den Bemd, B., Aldrighetti, L., Arntz, M., van den Boezem, P. B., Bruynzeel, A. M. E., Burgmans, M. C., de Cobelli, F., Coolsen, M. M. E., et al.. **Resectability and ablatability criteria for the treatment of liver only colorectal metastases: multidisciplinary consensus document from the COLLISION trial group.** *Cancers.* 2020. 12:1-17 10.3390/cancers12071779	Aim
Ning, M. S., Ahobila, V., Jhingran, A., Stecklein, S. R., Frumovitz, M., Schmeler, K. M., Eifel, P. J., Klopp, A. H.. **Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer.** *Gynecol Oncol.* 2018. 148:132-138 10.1016/j.ygyno.2017.10.017	Sample size
No, H. J., Raja, N., Von Eyben, R., Das, M., Roy, M., Myall, N., Neal, J., Wakelee, H., Chin, A., Diehn, M., Loo, B. W., Chang, D. T., Pollom, E. L., Vitzthum, L. K.. **Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.** *International Journal of*	Aim

Radiation Oncology, Biology, Physics. 2022. 114:603-610 https://dx.doi.org/10.1016/j.ijrobp.2022.04.050	
Nonikov, S., Ilin, N., Melnik, Y., Novikov, R., Merezhko, Y., Kanaev, S.. **OC-0041 Dosimetric comparison of SBRT and HDR brachytherapy in patients from randomized study.** *Radiotherapy and oncology.* 2021. 158:S28-S29 10.1016/S0167-8140(21)06283-6	Publication type
Norihisa, Y.,Nagata, Y.,Takayama, K.,Matsuo, Y.,Sakamoto, T.,Sakamoto, M.,Mizowaki, T.,Yano, S.,Hiraoka, M.. **Stereotactic body radiotherapy for oligometastatic lung tumors.** *Int J Radiat Oncol Biol Phys.* 2008. 72:398-403 #DOI#	Sample size
Nugent SM, Golden SE, Hooker ER, et al. Longitudinal Health-related Quality of Life among Individuals Considering Treatment for Stage I Non-Small-Cell Lung Cancer. *Ann Am Thorac Soc.* 2020;17(8):988-997. doi: 10.1513/AnnalsATS.202001-029OC.	Population
Nugent, F. W., Gunturu, K., Stuart, K. E., Flacke, S., Molgaard, C., Hunter, K., Qamar, A., Iqbal, S., Gordon, F., Galuski, K., et al.. **A randomized phase II study of individualized stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) as a bridge to transplant in hepatocellular carcinoma (HCC).** *Journal of clinical oncology.* 2017. 35:#pages# #DOI#	Publication type
Nugent, F. W., Hunter, K., Molgaard, C., Qamar, A., Gunturu, K., Stuart, K. E., Gordon, F., Flacke, S.. **A randomized phase II feasibility study of individualized stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) with DEBDOX beads as a bridge to transplant in hepatocellular carcinoma (HCC).** *Journal of clinical oncology.* 2020. 38:#pages# 10.1200/JCO.2020.38.15_suppl.4586	Publication type
Nwokedi, E. C.,DiBiase, S. J.,Jabbour, S.,Herman, J.,Amin, P.,Chin, L. S.. **Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme.** *Neurosurgery.* 2002. 50:41-6; discussion 46-7 #DOI#	Population
Nyman, J.,Hallqvist, A.,Lund, J. A.,Brustugun, O. T.,Bergman, B.,Bergstrom, P.,Friesland, S.,Lewensohn, R.,Holmberg, E.,Lax, I.. **SPACE - a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC.** *Radiother Oncol.* 2016. 121:1-8 #DOI#	Population
Oar, A., Kneebone, A., Lee, M., Goldstein, D., Sjoquist, K. M., Le, H., Chu, J., Barbour, A., Gholamrezaei, L., Lynam, J. F., et al.. **Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.** *Journal of clinical oncology.* 2021. 39:#pages# 10.1200/JCO.2021.39.15_suppl.TPS4172	Publication type
Oar, A., Lee, M., Le, H., Wilson, K., Aiken, C., Chantrill, L., Simes, J., Nguyen, N., Barbour, A., Samra, J., et al.. **AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.** *BMC cancer.* 2021. 21:#pages# 10.1186/s12885-021-08666-y	Publication type
Obayomi-Davies O, Chen LN, Bhagat A, et al. Potency preservation following stereotactic body radiation therapy for prostate cancer. *Radiation Oncology.* 2013;8(1):1-10. .	Outcomes
Obayomi-Davies, Olusola,Chen, Leonard N,Bhagat, Aditi,Wright, Henry C,Uhm, Sunghae,Kim, Joy S,Yung, Thomas M,Lei, Siyuan,Batipps, Gerald P,Pahira, John.	Outcomes

Potency preservation following stereotactic body radiation therapy for prostate cancer. *Radiation Oncology.* 2013. 8:1-10 #DOI#	
O'Connor, John K,Trotter, James,Davis, Gary L,Dempster, Jane,Klintmalm, Goran B, Goldstein, Robert M. **Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation.** *Liver Transplantation.* 2012. 18:949-954 #DOI#	Sample size
Oermann, Eric K,Suy, Simeng,Hanscom, Heather N,Kim, Joy S,Lei, Sue,Yu, Xia,Zhang, Guowei,Ennis, Brook,Rohan, JoyAnn P,Piel, Nathaniel. **Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low-to intermediate-risk prostate cancer.** *Journal of Hematology & Oncology.* 2011. 4:1-9 #DOI#	Sample size
Ogawa, Y., Shibamoto, Y., Hashizume, C., Kondo, T., Iwata, H., Tomita, N., Ogino, H.. **Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT.** *Radiation Oncology.* 2018. 13:136 https://dx.doi.org/10.1186/s13014-018-1080-4	Sample size
Okunaga, T.,Matsuo, T.,Hayashi, N.,Hayashi, Y.,Shabani, H. K.,Kaminogo, M.,Ochi, M., Nagata, I.. **Linear accelerator radiosurgery for vestibular schwannoma: measuring tumor volume changes on serial three-dimensional spoiled gradient-echo magnetic resonance images.** *Journal of Neurosurgery.* 2005. 103:53-8 #DOI#	Population
Olsen, J. R.,Robinson, C. G.,El Naqa, I.,Creach, K. M.,Drzymala, R. E.,Bloch, C.,Parikh, P. J.,Bradley, J. D.. **Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer.** *International Journal of Radiation Oncology, Biology, Physics.* 2011. 81:e299-303 #DOI#	Population
Olson RA, LaPointe V, Benny A, Chan M, Lefresne S, McKenzie M. Evaluation of Patient-Reported Outcome Differences by Radiotherapy Techniques for Bone Metastases in A Population-Based Healthcare System. *Current Oncology.* 2022;29(3):2073-2080. doi: https://dx.doi.org/10.3390/curroncol29030167.	Population
Olson, R. A., Jiang, W., Liu, M. C., Bergman, A., Schellenberg, D., Mou, B., Alexander, A. S., Carolan, H., Hsu, F., Miller, S., et al.. **Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for up to 5 Oligometastases: preliminary Results of the SABR-5 Trial.** *International journal of radiation oncology biology physics.* 2021. 111:S4-10.1016/j.ijrobp.2021.07.044	Publication type
Olson, R. A., LaPointe, V., Benny, A., Chan, M., Lefresne, S., McKenzie, M.. **Evaluation of Patient-Reported Outcome Differences by Radiotherapy Techniques for Bone Metastases in A Population-Based Healthcare System.** *Current Oncology.* 2022. 29:2073-2080 https://dx.doi.org/10.3390/curroncol29030167	Population
Olson, R. A., Senan, S., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M. I., Rodrigues, G., Yaremko, B. P., et al.. **Quality of Life Outcomes after Stereotactic Ablative Radiotherapy (SABR) vs. Standard of Care Palliative Treatments: a Secondary Analysis of the SABR-COMET Randomized Trial.** *International journal of radiation oncology biology physics.* 2019. 105:S72-S73 10.1016/j.ijrobp.2019.06.527	Publication type
Olson, R., Senan, S., Harrow, S., Gaede, S., Louie, A., Haasbeek, N., Mulroy, L., Lock, M., Rodriques, G., Yaremko, B., et al.. **QUALITY OF LIFE OUTCOMES AFTER STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) VERSUS STANDARD OF CARE PALLIATIVE TREATMENTS: a SECONDARY ANALYSIS OF THE SABR-COMET RANDOMIZED TRIAL.** *Radiotherapy and oncology.* 2019. 139:S41- 10.1016/S0167-8140(19)33383-3	Publication type

Onishi, H.,Shirato, H.,Nagata, Y.,Hiraoka, M.,Fujino, M.,Gomi, K.,Karasawa, K., Hayakawa, K.,Niibe, Y.,Takai, Y.,Kimura, T.,Takeda, A.,Ouchi, A.,Hareyama, M.,Kokubo, M.,Kozuka, T.,Arimoto, T.,Hara, R.,Itami, J.,Araki, T.. **Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?.** *International Journal of Radiation Oncology, Biology, Physics.* 2011. 81:1352-8 #DOI#	Sample size
Ost, P., Reynders, D., Decaestecker, K., Fonteyne, V., Lumen, N., De Bruycker, A., Lambert, B., Delrue, L., Bultijnck, R., Claeys, T., et al.. **Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: a Prospective, Randomized, Multicenter Phase II Trial.** *Journal of clinical oncology.* 2018. 36:446-453 10.1200/JCO.2017.75.4853	Intervention
Ost, P., Reynders, D., Decaestecker, K., Fonteyne, V., Lumen, N., De Bruycker, A., Lambert, B., Delrue, L., Bultijnck, R., Goetghebeur, E., et al.. **Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence.** *Radiotherapy and oncology.* 2018. 127:S191-S192 #DOI#	Publication type
Ottaviani, F.,Neglia, C. B.,Ventrella, L.,Giugni, E.,Motti, E.. **Hearing loss and changes in transient evoked otoacoustic emissions after gamma knife radiosurgery for acoustic neurinomas.** *Archives of Otolaryngology -- Head & Neck Surgery.* 2002. 128:1308-12 #DOI#	Population
Owen, D., Olivier, K. R., Song, L., Mayo, C. S., Miller, R. C., Nelson, K., Bauer, H., Brown, P. D., Park, S. S., Ma, D. J., Garces, Y. I.. **Safety and Tolerability of SBRT after High-Dose External Beam Radiation to the Lung.** *Front Oncol.* 2014. 4:376 10.3389/fonc.2014.00376	Sample size
Paix, A.,Noel, G.,Falcoz, P. E.,Levy, P.. **Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer.** *Radiother Oncol.* 2018. 128:534-540 #DOI#	Setting
Palma, D., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., et al.. **Stereotactic radiation for treatment of oligometastases (SABR-COMET) – Extended long-term outcomes.** *Radiotherapy and oncology.* 2022. 170:S88- 10.1016/S0167-8140(22)02480-X	Publication type
Palma, D., Olson, R., Harrow, S., Gaede, S., Louie, A., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G., Yaremko, B., et al.. **STEREOTACTIC ABLATIVE RADIOTHERAPY FOR THE COMPREHENSIVE TREATMENT OF OLIGOMETASTATIC CANCERS: LONG-TERM RESULTS OF THE SABR-COMET RANDOMIZED TRIAL.** *Radiotherapy and oncology.* 2020. 150:S7- 10.1016/S0167-8140(20)30900-2	Publication type
Pang, J. W. S., Bashir, U., Glover, T., Ahmed, M., Fotiadis, N. I.. **Ablative techniques for lung metastases: baseline characteristics and outcomes of stereotactic radiotherapy versus radiofrequency ablation at the royal marsden.** *Cardiovascular and interventional radiology.* 2019. 42:S285- 10.1007/s00270-019-02282-x	Publication type
Parashar B, Port J, Arora S, et al. Analysis of stereotactic radiation vs. wedge resection vs. wedge resection plus cesium-131 brachytherapy in early stage lung cancer. *Brachytherapy.* 2015;14(5):648-654. doi: 10.1016/j.brachy.2015.04.001.	Population
Parikh, N. D., Marshall, V. D., Green, M., Feng, M.. **Use of radiofrequency ablation and stereotactic body radiotherapy for the treatment of hepatocellular carcinoma: an analysis of the SEER-Medicare database.** *Hepatology (Baltimore, Md.).* 2016. 64:641A- #DOI#	Publication type

Parikh, N. R., Clark, M. A., Patel, P., Kafka-Peterson, K., Zaide, L., Ma, T. M., Steinberg, M. L., Cao, M., Raldow, A. C., Lamb, J., Kishan, A. U.. **Time-Driven Activity-Based Costing of CT-Guided vs MR-Guided Prostate SBRT.** *Applied Radiation Oncology*. 2021. 10:33-40 #DOI#	Publication type
Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. *The Lancet*. 2018;392(10162):2353-2366. https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(18)32486-3.pdf.	Intervention
Parker, Christopher C,James, Nicholas D,Brawley, Christopher D,Clarke, Noel W,Hoyle, Alex P,Ali, Adnan,Ritchie, Alastair WS,Attard, Gerhardt,Chowdhury, Simon,Cross, William. **Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.** *The Lancet*. 2018. 392:2353-2366 #DOI#	Intervention
Parks, J., Kloecker, G., Woo, S., Dunlap, N. E.. **Stereotactic Body Radiation Therapy as Salvage for Intrathoracic Recurrence in Patients With Previously Irradiated Locally Advanced Non-Small Cell Lung Cancer.** *Am J Clin Oncol*. 2016. 39:147-53 10.1097/COC.0000000000000039	Sample size
Parthan A, Pruttivarasin N, Davies D, et al. Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer. *Frontiers in Oncology*. 2012;2:81. doi: https://dx.doi.org/10.3389/fonc.2012.00081.	Date
Patel SA, Switchenko JM, Fischer-Valuck B, et al. Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer. *Radiation Oncology*. 2020;15(1):217. doi: https://dx.doi.org/10.1186/s13014-020-01658-5	Duplicate
Patil, C. G.,Hoang, S.,Borchers, D. J., 3rd,Sakamoto, G.,Soltys, S. G.,Gibbs, I. C.,Harsh, G. R. th,Chang, S. D.,Adler, J. R., Jr.. **Predictors of peritumoral edema after stereotactic radiosurgery of supratentorial meningiomas.** *Neurosurgery*. 2008. 63:435-40; discussion 440-2 #DOI#	Population
Paul S, Lee PC, Mao J, Isaacs AJ, Sedrakyan A. Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis. *BMJ*. 2016;354:i3570. doi: 10.1136/bmj.i3570.	Population
Peng, P., Chen, Y., Han, G., Meng, R., Zhang, S., Liao, Z., Zhang, Y., Gong, J., Xiao, C., Liu, X., et al.. **MA01.09 Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: a Multicenter, Randomized Phase II Study.** *Journal of thoracic oncology*. 2019. 14:S250-S251 10.1016/j.jtho.2019.08.499	Publication type
Pennathur, A.,Luketich, J. D.,Burton, S.,Abbas, G.,Heron, D. E.,Fernando, H. C.,Gooding, W. E.,Ozhasoglu, C.,Ireland, J.,Landreneau, R. J.,Christie, N. A.. **Stereotactic radiosurgery for the treatment of lung neoplasm: initial experience.** *Annals of Thoracic Surgery*. 2007. 83:1820-4; discussion 1824-5 #DOI#	Sample size
Petrovich, Z.,Yu, C.,Giannotta, S. L.,Zee, C. S.,Apuzzo, M. L.. **Gamma knife radiosurgery for pituitary adenoma: early results.** *Neurosurgery*. 2003. 53:51-9; discussion 59-61 #DOI#	Population

Peulen, H.,Karlsson, K.,Lindberg, K.,Tullgren, O.,Baumann, P.,Lax, I.,Lewensohn, R., Wersall, P.. **Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy.** *Radiotherapy & Oncology*. 2011. 101:260-6 #DOI#	Sample size
Pham, HT,Song, G,Badiozamani, K,Yao, M,Corman, J,Hsi, RA,Madsen, B. **Five-year outcome of stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP) for patients with low-risk prostate cancer.** *International Journal of Radiation Oncology, Biology, Physics*. 2010. 78:S58 #DOI#	Publication type
Phillips I, Sandhu S, Luchtenborg M, Harden S. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer. *Clin Oncol (R Coll Radiol)*. 2019;31(10):681-687. doi: 10.1016/j.clon.2019.07.013.	Population
Phillips R, Lim SJ, Shi WY, et al. Primary Outcomes of a Phase II Randomized Trial of Observation Versus Stereotactic Ablative RadiatIon for OLigometastatic Prostate CancEr (ORIOLE). *International Journal of Radiation Oncology*Biology*Physics*. 2019;105(3):681-. doi: 10.1016/j.ijrobp.2019.08.031.	Publication type
Phillips R, Radwan N, Ross A, et al. A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE). *Journal of clinical oncology*. 2017;35(15). https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01781812/full.	Publication type
Phillips, R., Lim, S. J., Shi, W. Y., Antonarakis, E. S., Rowe, S., Gorin, M., Deville, C., Greco, S. C., Denmeade, S., Paller, C., et al.. **Primary Outcomes of a Phase II Randomized Trial of Observation Versus Stereotactic Ablative RadiatIon for OLigometastatic Prostate CancEr (ORIOLE).** *International journal of radiation oncology biology physics*. 2019. 105:681- 10.1016/j.ijrobp.2019.08.031	Publication type
Phillips, R., Radwan, N., Ross, A., Rowe, S. P., Gorin, M. A., Antonarakis, E. S., Deville, C., Greco, S. C., Denmeade, S. R., Paller, C. J., et al.. **A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE).** *Journal of clinical oncology*. 2017. 35:#pages# #DOI#	Publication type
Pielkenrood BJ, van der Velden JM, van der Linden YM, et al. Pain response after stereotactic body radiation therapy versus conventional radiation therapy in patients with bone metastases-a phase 2 randomized controlled trial within a prospective cohort. *Int J Radiat Oncol Biol Phys*. 2021;110(2):358-367. https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02247481/full.	Population
Pielkenrood, B. J., Gal, R., Kasperts, N., Verhoeff, J. J. C., Bartels, Mmtj, Seravalli, E., van der Linden, Y. M., Monninkhof, E. M., Verlaan, J. J., van der Velden, J. M., et al.. **Quality of Life After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases.** *International journal of radiation oncology, biology, physics*. 2022. 112:1203-1215 10.1016/j.ijrobp.2021.12.163	Population
Pielkenrood, B. J.,van der Velden, J. M.,van der Linden, Y. M.,Bartels, M. M. T.,Kasperts, N.,Verhoeff, J. J. C.,Eppinga, W. S. C.,Gal, R.,Verlaan, J. J.,Verkooijen, H. M. L.. **Pain response after stereotactic body radiation therapy versus conventional radiation therapy in patients with bone metastases-a phase 2 randomized controlled trial within a prospective cohort.** *Int J Radiat Oncol Biol Phys*. 2021. 110:358-367 #DOI#	Population
Pielkenrood, B., Van der Velden, J., Van der Linden, Y., Bartels, M., Kasperts, N., Verhoeff, J., Eppinga, W., Gal, R., Verlaan, J., Verkooijen, H.. **Phase 2 RCT comparing conventional radiotherapy with SBRT in patients with bone metastases.** *Radiotherapy and oncology*. 2020. 152:S201-S202 10.1016/S0167-8140(21)00396-0	Publication type

Plathow, C.,Schulz-Ertner, D.,Thilman, C.,Zuna, I.,Lichy, M.,Weber, M. A.,Schlemmer, H. P.,Wannenmacher, M.,Debus, J.. **Fractionated stereotactic radiotherapy in low-grade astrocytomas: long-term outcome and prognostic factors.** *International Journal of Radiation Oncology, Biology, Physics*. 2003. 57:996-1003 #DOI#	Population
Polistina, Francesco,Costantin, Giorgio,Casamassima, Franco,Francescon, Paolo, Guglielmi, Rosabianca,Panizzoni, Gino,Febbraro, Antonio,Ambrosino, Giovanni. **Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration.** *Annals of surgical oncology*. 2010. 17:2092-2101 #DOI#	Sample size
Pollack A, Walker G, Horwitz EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. *J Clin Oncol*. 2013;31(31):3860-3868. doi: 10.1200/jco.2013.51.1972.	Intervention
Pollock, B. E.,Foote, R. L.,Stafford, S. L.. **Stereotactic radiosurgery: the preferred management for patients with nonvestibular schwannomas?.** *International Journal of Radiation Oncology, Biology, Physics*. 2002. 52:1002-7 #DOI#	Population
Pollock, B. E.. **Radiosurgery for pituitary adenomas.** *Progress in Neurological Surgery*. 2007. 20:164-171 #DOI#	Population
Pollom EL, Lee K, Durkee BY, et al. **Cost-effectiveness of stereotactic body radiation therapy versus radiofrequency ablation for hepatocellular carcinoma: a Markov modeling study**. *Radiology*. 2017;283(2):460-468. doi: 10.1148/radiol.2016161509.	Date
Ponsky, Lee,Lo, Simon S,Zhang, Yuxia,Schluchter, Mark,Liu, Yiying,Patel, Ravi, Abouassaly, Robert,Welford, Scott,Gulani, Vikas,Haaga, John Robert. **Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma.** *Radiotherapy and Oncology*. 2015. 117:183-187 #DOI#	Sample size
Pontoriero, A,Iatì, G,Mondello, S,Midili, F,Siragusa, C,Brogna, A,Ielo, I,Anastasi, G, Magno, C,Pergolizzi, S. **High-dose robotic stereotactic body radiotherapy in the treatment of patients with prostate cancer: preliminary results in 26 patients.** *Technology in cancer research & treatment*. 2016. 15:179-185 #DOI#	Sample size
Poon, D. M. C., Lam, D., Wong, K. C. W., Chu, C. M., Mo, F., Suen, J., Ng, C. F., Chan, A. T. C.. **Stereotactic body radiotherapy (SBRT) versus conventional fractionated intensity-modulated radiotherapy (CF-IMRT) for patients with earlystage localized prostate cancer: one-year late toxicity results from a prospective randomized phase II study.** *Journal of clinical oncology*. 2019. 37:#pages# #DOI#	Publication type
Poon, D. M., Lam, D., Wong, K., Mok, F., Mo, F., Chu, C. M., Ng, A. C. F., Suen, J., Chan, A. T. C.. **Stereotactic body radiotherapy (SBRT) versus conventional fractionated intensity-modulated radiotherapy (CF-IMRT) for Asian patients with early-stage localized prostate cancer: acute toxicity results from a prospective randomized phase II study.** *Annals of oncology*. 2018. 29:#pages# 10.1093/annonc/mdy434	Publication type
Port JL, Parashar B, Osakwe N, et al. A propensity-matched analysis of wedge resection and stereotactic body radiotherapy for early stage lung cancer. *Annals of Thoracic Surgery*. 2014;98(4):1152-1159. doi: https://dx.doi.org/10.1016/j.athoracsur.2014.04.128. *EXC - not clear if people treated with SBRT were candidates for surgery or not	Population

Pouratian, N.,Sheehan, J.,Jagannathan, J.,Laws, E. R., Jr.,Steiner, L.,Vance, M. L.. **Gamma knife radiosurgery for medically and surgically refractory prolactinomas.** *Neurosurgery*. 2006. 59:255-66; discussion 255-66 #DOI#	Population
Powell, C.,Micallef, C.,Gonsalves, A.,Wharram, B.,Ashley, S.,Brada, M.. **Fractionated stereotactic radiotherapy in the treatment of vestibular schwannoma (acoustic neuroma): predicting the risk of hydrocephalus.** *International Journal of Radiation Oncology, Biology, Physics*. 2011. 80:1143-50 #DOI#	Population
Presley CJ, Soulos PR, Tinetti M, Montori VM, Yu JB, Gross CP. Treatment burden of Medicare beneficiaries with stage I non-small-cell lung cancer. *J Oncol Pract*. 2017;13(2):e98-e107. doi: 10.1200/JOP.2016.014100.	Population
Price, Tracy R,Perkins, Susan M,Sandrasegaran, Kumar,Henderson, Mark A,Maluccio, Mary A,Zook, Jennifer E,Tector, A Joseph,Vianna, Rodrigo M,Johnstone, Peter AS, Cardenes, Higinia R. **Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma.** *Cancer*. 2012. 118:3191-3198 #DOI#	Sample size
Pryor, D., Sidhom, M., Arumugam, S., Bucci, J., Smart, J., Grand, M., Greer, P., Keats, S., Wilton, L., O'Neill, M., et al.. **Early Results of a Phase 2 Multicentre Study of Linac-based Stereotactic Boost for Prostate Cancer.** *Radiotherapy and oncology*. 2019. 133:S832-S833 10.1016/S0167-8140(19)31963-2	Publication type
Puataweepong, P., Dhanachai, M., Dangprasert, S., Narkwong, L., Sitathanee, C., Sawangsilpa, T., Janwityanujit, T., Yongvithisatid, P.. **Linac-based stereotactic radiosurgery and fractionated stereotactic radiotherapy for vestibular schwannomas: comparative observations of 139 patients treated at a single institution.** *Journal of radiation research*. 2014. 55:351-358 10.1093/jrr/rrt121	Population
Puataweepong, P.,Dhanachai, M.,Dangprasert, S.,Laothamatas, J.,Theerapancharoen, V.,Yongvithisatid, P.. **Comparison of conventional external radiotherapy and stereotactic radiotherapy in the treatment of pituitary adenoma.** *Journal of the Medical Association of Thailand*. 2009. 92:382-9 #DOI#	Population
Puri V, Crabtree TD, Bell JM, et al. Treatment outcomes in stage I lung cancer: a comparison of surgery and stereotactic body radiation therapy. *J Thorac Oncol*. 2015;10(12):1776-1784. doi: 10.1097/JTO.0000000000000680.	Population
Puri V, Crabtree TD, Kymes S, et al. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis. *Journal of Thoracic & Cardiovascular Surgery*. 2012;143(2):428-436. doi: https://dx.doi.org/10.1016/j.jtcvs.2011.10.078.	Date
Putz, F., Müller, J., Wimmer, C., Goerig, N., Knippen, S., Iro, H., Grundtner, P., Eyüpoglu, I., Rössler, K., Semrau, S., et al.. **Stereotactic radiotherapy of vestibular schwannoma : hearing preservation, vestibular function, and local control following primary and salvage radiotherapy.** *Strahlentherapie und Onkologie*. 2017. 193:200-212 10.1007/s00066-016-1086-5	Population
Qi, X Sharon,Wang, Jason P,Gomez, Caitlin L,Shao, Weber,Xu, Xiaoqing,King, Christopher,Low, Daniel A,Steinberg, Michael,Kupelian, Patrick. **Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy.** *Radiotherapy and Oncology*. 2016. 121:113-117 #DOI#	Sample size
Qing, S. W., Ju, X. P., Cao, Y. S., Zhang, H. J.. **Dose escalation of Stereotactic Body Radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer patients**	Publication type

with CyberKnife: protocol of a phase I study. *Radiation oncology (London, England).* 2017. 12:#pages# 10.1186/s13014-016-0760-1	
Qu, M. X., Chen, Y., Zaric, G., Senan, S., Olson, R. A., Harrow, S., John-Baptiste, A., Gaede, S., Mulroy, L., Schellenberg, D., et al.. **Cost-Effectiveness of SABR in Oligometastatic Cancer: an Economic Analysis Based on Long-Term Results of the SABR-COMET Trial.** *International journal of radiation oncology, biology, physics.* 2021. 111:e344- 10.1016/j.ijrobp.2021.07.1038	Publication type
Qu, M., Chen, Y., Zaric, G., Senan, S., Olson, R., Harrow, S., John-Baptiste, A., Gaede, S., Mulroy, L., Schellenberg, D., et al.. **23 COST-EFFECTIVENESS OF SABR IN OLIGOMETASTATIC CANCER: AN ECONOMIC ANALYSIS BASED ON LONG-TERM RESULTS OF THE SABR-COMET RANDOMIZED TRIAL.** *Radiotherapy and oncology.* 2021. 163:S13- 10.1016/S0167-8140(21)08901-5	Publication type
Qu, M., Chen, Y., Zaric, G., Senan, S., Olson, R., Harrow, S., John-Baptiste, A., Gaede, S., Mulroy, L., Schellenberg, D., et al.. **IS SABR COST-EFFECTIVE IN OLIGOMETASTATIC CANCER? AN ECONOMIC ANALYSIS OF SABR-COMET.** *Radiotherapy and oncology.* 2019. 139:S41-S42 10.1016/S0167-8140(19)33384-5	Publication type
Qu, X. M., Chen, Y., Zaric, G. S., Senan, S., Olson, R. A., Harrow, S., John-Baptiste, A., Gaede, S., Mulroy, L. A., Schellenberg, D., et al.. **Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial.** *International journal of radiation oncology biology physics.* 2021. 109:1176-1184 10.1016/j.ijrobp.2020.12.001	Setting
Que, J., Kuo, H. T., Lin, L. C., Lin, K. L., Lin, C. H., Lin, Y. W., Yang, C. C.. **Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma.** *BMC Cancer.* 2016. 16:451 https://dx.doi.org/10.1186/s12885-016-2512-x	Setting
Que, J., Wu, H. C., Lin, C. H., Huang, C. I., Li, L. C., Ho, C. H.. **Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis.** *Medicine.* 2020. 99:e19660- 10.1097/MD.0000000000019660	Comparator
Que, Jenny,Lin, Chia-Hui,Lin, Li-Ching,Ho, Chung-Han. **Challenges of BCLC stage C hepatocellular carcinoma: Results of a single-institutional experience on stereotactic body radiation therapy.** *Medicine.* 2020. 99:#pages# #DOI#	Setting
Quon HC, Musunuru HB, Cheung P, et al. Dose-escalated stereotactic body radiation therapy for prostate cancer: Quality-of-life comparison of two prospective trials. *Frontiers in oncology.* 2016;6:185. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002986/pdf/fonc-06-00185.pdf.	Study design
Quon HC, Ong A, Cheung P, et al. Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial. *Radiother Oncol.*2018;127(2):206-212. doi: 10.1016/j.radonc.2018.02.029. *	Comparator
Quon, H. C., Ong, A., Cheung, P., Chu, W., Chung, H. T., Vesprini, D., Chowdhury, A., Panjwani, D., Pang, G., Korol, R., et al.. **Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): a phase 2 randomized trial.** *Radiotherapy and oncology.* 2018. 127:206-212 10.1016/j.radonc.2018.02.029	Aim
Quon, H. C., Ong, A., Cheung, P., Chu, W., Chung, H. T., Vesprini, D., Chowdhury, A., Panjwani, D., Pang, G., Korol, R., et al.. **PATRIOT Trial: randomized phase II study of**	Study design

prostate stereotactic body radiotherapy comparing 11 versus 29 days overall treatment time. *Journal of clinical oncology*. 2015. 33:#pages# #DOI#	
Quon, Harvey C,Musunuru, Hima Bindu,Cheung, Patrick,Pang, Geordi,Mamedov, Alexandre,D'Alimonte, Laura,Deabreu, Andrea,Zhang, Liying,Loblaw, Andrew. **Dose-escalated stereotactic body radiation therapy for prostate cancer: Quality-of-life comparison of two prospective trials.** *Frontiers in oncology*. 2016. 6:185 #DOI#	Study design
Rades, D.,Schild, S. E.. **Value of postoperative stereotactic radiosurgery and conventional radiotherapy for incompletely resected typical neurocytomas.** *Cancer*. 2006. 106:1140-3 #DOI#	Population
Radwan N, Phillips R, Ross A, et al. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). *BMC Cancer*. 2017;17(1):453. doi: 10.1186/s12885-017-3455-6.	Duplicate
Rahman, M.,Neal, D.,Baruch, W.,Bova, F. J.,Frentzen, B. H.,Friedman, W. A.. **The risk of malignancy anywhere in the body after linear accelerator (LINAC) stereotactic radiosurgery.** *Stereotact Funct Neurosurg*. 2014. 92:323-33 #DOI#	Population
Raman S, Yau V, Pineda S, et al. Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience. *Clin Lung Cancer*. 2018;19(5):e803-e810. doi: 10.1016/j.cllc.2018.06.001.	Population
Rana Z, Cyr RA, Chen LN, et al. Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer. *Frontiers in Oncology*. 2014;4:290. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204455/pdf/fonc-04-00290.pdf.	Outcomes
Rana, Zaker,Cyr, Robyn A,Chen, Leonard N,Kim, Brian S,Moures, Rudy A,Yung, Thomas M,Lei, Siyuan,Collins, Brian T,Suy, Simeng,Dritschilo, Anatoly. **Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer.** *Frontiers in Oncology*. 2014. 4:290 #DOI#	Outcomes
Ratko, T. A., Douglas, G. W., de Souza, J. A., Belinson, S. E., Aronson, N.. **.** *Agency for Healthcare Research and Quality*. 2014. #volume#:12 #DOI#	Publication Date
Raymakers, A. J. N., Cameron, D., Tyldesley, S., Regier, D. A.. **Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care.** *Current Oncology*. 2021. 28:1857-1866 https://dx.doi.org/10.3390/curroncol28030172	Setting
Repka MC, Guleria S, Cyr RA, et al. Acute urinary morbidity following stereotactic body radiation therapy for prostate cancer with prophylactic alpha-adrenergic antagonist and urethral dose reduction. *Frontiers in oncology*. 2016;6:122. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870496/pdf/fonc-06-00122.pdf.	Outcomes
Repka, M. C., Aghdam, N., Kataria, S. K., Campbell, L., Suy, S., Collins, S. P., Anderson, E., Lischalk, J. W., Collins, B. T.. **Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation.** *Radiation Oncology*. 2017. 12:162 https://dx.doi.org/10.1186/s13014-017-0897-6	Sample size
Repka, Michael C,Guleria, Shan,Cyr, Robyn A,Yung, Thomas M,Koneru, Harsha,Chen, Leonard N,Lei, Siyuan,Collins, Brian T,Krishnan, Pranay,Suy, Simeng. **Acute urinary morbidity following stereotactic body radiation therapy for prostate cancer with prophylactic alpha-adrenergic antagonist and urethral dose reduction.** *Frontiers in oncology*. 2016. 6:122 #DOI#	Outcomes

Reyngold, M., O'Reilly, E. M., Varghese, A. M., Fiasconaro, M., Zinovoy, M., Romesser, P. B., Wu, A., Hajj, C., Cuaron, J. J., Tuli, R., et al.. **Association of Ablative Radiation Therapy with Survival among Patients with Inoperable Pancreatic Cancer.** *JAMA oncology*. 2021. #volume#:#pages# 10.1001/jamaoncol.2021.0057	Aim
Reyngold, M., Wu, A. J., McLane, A., Zhang, Z., Hsu, M., Stein, N. F., Zhou, Y., Ho, A. Y., Rosenzweig, K. E., Yorke, E. D., Rimner, A.. **Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT).** *Radiation Oncology*. 2013. 8:99 https://dx.doi.org/10.1186/1748-717X-8-99	Sample size
Ricardi U, Frezza G, Filippi AR, et al. Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study. *Lung Cancer*. 2014;84(3):248-253. doi: https://dx.doi.org/10.1016/j.lungcan.2014.02.015.	Population
Ricardi, U.,Filippi, A. R.,Guarneri, A.,Giglioli, F. R.,Mantovani, C.,Fiandra, C.,Anglesio, S., Ragona, R.. **Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy.** *Acta Oncologica*. 2009. 48:571-7 #DOI#	Sample size
Ricco A, Davis J, Rate W, et al. Lung metastases treated with stereotactic body radiotherapy: the RSSearch R patient Registry's experience. *Radiation Oncology*. 2017;12(1):35. doi: https://dx.doi.org/10.1186/s13014-017-0773-4. .	Outcomes
Rieber, J., Abbassi-Senger, N., Adebahr, S., Andratschke, N., Blanck, O., Duma, M., Eble, M. J., Ernst, I., Flentje, M., Gerum, S., Hass, P., Henkenberens, C., Hildebrandt, G., Imhoff, D., Kahl, H., Klass, N. D., Krempien, R., Lohaus, F., Lohr, F., Petersen, C., Schrade, E., Streblow, J., Uhlmann, L., Wittig, A., Sterzing, F., Guckenberger, M.. **Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease.** *International Journal of Radiation Oncology, Biology, Physics*. 2017. 98:511-520 https://dx.doi.org/10.1016/j.ijrobp.2016.09.026	Outcomes
Ritter, T. A., Chao, H. H., Chang, M. G., Katsoulakis, E., Padilla, L., Xiao, Y., Kang, H., Al-Hallaq, H. A., Moghanaki, D., Palta, J. R., et al.. **Enhancing Radiation Therapy Plan Quality in a Multi-Site Randomized Clinical Trial with a Benchmark Credentialing Exercise: the VA STARPORT Experience.** *International journal of radiation oncology biology physics*. 2022. 114:S95-S96 10.1016/j.ijrobp.2022.07.514	Publication type
Roberge, D.,Souhami, L.,Olivier, A.,Leblanc, R.,Podgorsak, E.. **Hypofractionated stereotactic radiotherapy for low grade glioma at McGill University: long-term follow-up.** *Technology in Cancer Research & Treatment*. 2006. 5:1-8 #DOI#	Population
Robinson CG, DeWees TA, El Naqa IM, et al. Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer. *J Thorac Oncol*. 2013;8(2):192-201. doi: 10.1097/JTO.0b013e31827ce361	Population
Roche, P. H.,Khalil, M.,Soumare, O.,Regis, J.. **Hydrocephalus and vestibular schwannomas: considerations about the impact of gamma knife radiosurgery.** *Progress in Neurological Surgery*. 2008. 21:200-206 #DOI#	Population
Rodrigues, I.,Figueiredo, T.,Gagean, J.,Ferreira, C.,Laranja, A.,Ramos, T.,Conde, S., Moreira, D.,Cardia, J.. **Prognostic factors and clinical outcomes after stereotactic radiotherapy for primary lung tumors.** *Rep Pract Oncol Radiother*. 2020. 25:943-950 #DOI#	Population
Romero, Alejandra Méndez,Wunderink, Wouter,van Os, Rob M,Nowak, Peter JCM, Heijmen, Ben JM,Nuyttens, Joost J,Brandwijk, Rene P,Verhoef, Cornelis,IJzermans, Jan	Sample size

NM,Levendag, Peter C. **Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors.** *International Journal of Radiation Oncology* Biology* Physics.* 2008. 70:1447-1452 #DOI#	
Roos, D. E.,Brophy, B. P.,Bhat, M. K.,Katsilis, E. S.. **Update of radiosurgery at the Royal Adelaide Hospital.** *Australasian Radiology.* 2006. 50:158-67 #DOI#	Population
Rosenberg, S. A., Mak, R., Kotecha, R., Loo, B. W., Senan, S.. **The Nordic-HILUS Trial: ultracentral Lung Stereotactic Ablative Radiotherapy and a Narrow Therapeutic Window.** *Journal of thoracic oncology.* 2021. 16:e79-e80 10.1016/j.jtho.2021.06.030	Publication type
Rossi, Linda,Breedveld, Sebastiaan,Heijmen, Ben JM,Voet, Peter WJ,Lanconelli, Nico, Aluwini, Shafak. **On the beam direction search space in computerized non-coplanar beam angle optimization for IMRT—prostate SBRT.** *Physics in Medicine & Biology.* 2012. 57:5441 #DOI#	Sample size
Rowe, J. G.,Radatz, M. W.,Walton, L.,Hampshire, A.,Seaman, S.,Kemeny, A. A.. **Gamma knife stereotactic radiosurgery for unilateral acoustic neuromas.** *Journal of Neurology, Neurosurgery & Psychiatry.* 2003. 74:1536-42 #DOI#	Population
Rowe, J.,Grainger, A.,Walton, L.,Radatz, M.,Kemeny, A.. **Safety of radiosurgery applied to conditions with abnormal tumor suppressor genes.** *Neurosurgery.* 2007. 60:860-4; discussion 860-4 #DOI#	Population
Rowe, J.,Grainger, A.,Walton, L.,Silcocks, P.,Radatz, M.,Kemeny, A.. **Risk of malignancy after gamma knife stereotactic radiosurgery.** *Neurosurgery.* 2007. 60:60-5; discussion 65-6 #DOI#	Population
Rowe, J.,Radatz, M.,Kemeny, A.. **Radiosurgery for type II neurofibromatosis.** *Progress in Neurological Surgery.* 2008. 21:176-182 #DOI#	Population
Royce, T. J., Switchenko, J. M., Zhang, C., Spratt, D. E., Chen, R. C., Jani, A. B., Patel, S. A.. **Utilization of androgen deprivation therapy (ADT) and stereotactic body radiation therapy (SBRT) for localized prostate cancer (PC) in the United States (US).** *Journal of clinical oncology.* 2020. 38:#pages# 10.1200/JCO.2020.38.6_suppl.370	Publication type
Rucinska, Monika,Kieszkowska-Grudny, Anna,Nawrocki, Sergiusz. **SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer.** *Strahlentherapie und Onkologie.* 2016. 192:449-457 #DOI#	Sample size
Rusthoven, K. E.,Kavanagh, B. D.,Cardenes, H.,Stieber, V. W.,Burri, S. H.,Feigenberg, S. J.,Chidel, M. A.,Pugh, T. J.,Franklin, W.,Kane, M.,Gaspar, L. E.,Schefter, T. E.. **Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.** *J Clin Oncol.* 2009. 27:1572-8 #DOI#	Sample size
Rusthoven, Kyle E,Kavanagh, Brian D,Burri, Stuart H,Chen, Changhu,Cardenes, Higinia, Chidel, Mark A,Pugh, Thomas J,Kane, Madeleine,Gaspar, Laurie E,Schefter, Tracey E. **Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases.** *Journal of Clinical Oncology.* 2009. 27:1579-1584 #DOI#	Sample size
Rwigema, J. C.,Heron, D. E.,Ferris, R. L.,Andrade, R. S.,Gibson, M. K.,Yang, Y., Ozhasoglu, C.,Argiris, A. E.,Grandis, J. R.,Burton, S. A.. **The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy.** *American Journal of Clinical Oncology.* 2011. 34:372-9 #DOI#	Sample size
Rwigema, J. C.,Heron, D. E.,Ferris, R. L.,Gibson, M.,Quinn, A.,Yang, Y.,Ozhasoglu, C., Burton, S.. **Fractionated stereotactic body radiation therapy in the treatment of previously-irradiated recurrent head and neck carcinoma: updated report of the**	Sample size

University of Pittsburgh experience. *American Journal of Clinical Oncology*. 2010. 33:286-93 #DOI#	
Rwigema, J. C.,Parikh, S. D.,Heron, D. E.,Howell, M.,Zeh, H.,Moser, A. J.,Bahary, N., Quinn, A.,Burton, S. A.. **Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas.** *Am J Clin Oncol*. 2011. 34:63-9 #DOI#	Sample size
Ryu, S.,Rock, J.,Jain, R.,Lu, M.,Anderson, J.,Jin, J. Y.,Rosenblum, M.,Movsas, B.,Kim, J. H.. **Radiosurgical decompression of metastatic epidural compression.** *Cancer*. 2010. 116:2250-7 #DOI#	Sample size
Sadozye, A. H.. **Re-irradiation in Gynaecological Malignancies: A Review.** *Clinical Oncology (Royal College of Radiologists)*. 2018. 30:110-115 https://dx.doi.org/10.1016/j.clon.2017.11.013	Publication type
Safi, S., Rauch, G., op den Winkel, J., Kunz, J., Schneider, T., Bischof, M., Heussel, C. P., Huber, P. E., Herth, F. J., Dienemann, H., Hoffmann, H.. **Sublobar Resection, Radiofrequency Ablation or Radiotherapy in Stage I Non-Small Cell Lung Cancer.** *Respiration*. 2015. 89:550-7 10.1159/000381555	Population
Samper Ots PM, Vallejo Ocana C, Martin Martin M, et al. Stereotactic body radiotherapy for early-stage non-small cell lung cancer: a multicentre study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). *Clin Transl Oncol*. 2022;24(2):342-349. doi: 10.1007/s12094-021-02697-4.	Population
Samson, P., Keogan, K., Crabtree, T., Colditz, G., Broderick, S., Puri, V., Meyers, B.. **Interpreting survival data from clinical trials of surgery versus stereotactic body radiation therapy in operable Stage I non-small cell lung cancer patients.** *Lung cancer (Amsterdam, Netherlands)*. 2017. 103:6-10 10.1016/j.lungcan.2016.11.005	Aim
Santacroce, A.,Walier, M.,Regis, J.,Liscak, R.,Motti, E.,Lindquist, C.,Kemeny, A.,Kitz, K., Lippitz, B.,Martinez Alvarez, R.,Pedersen, P. H.,Yomo, S.,Lupidi, F.,Dominikus, K., Blackburn, P.,Mindermann, T.,Bundschuh, O.,van Eck, A. T.,Fimmers, R.,Horstmann, G. A.. **Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patients.** *Neurosurgery*. 2012. 70:32-9; discussion 39 #DOI#	Population
Sanuki, N., Takeda, A., Oku, Y., Mizuno, T., Aoki, Y., Eriguchi, T., Iwabuchi, S., Kunieda, E.. **Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients.** *Acta Oncologica*. 2014. 53:399-404 https://dx.doi.org/10.3109/0284186X.2013.820342	Comparator
Sapir, E., Tao, Y., Lin, J., Kollar, L., Schipper, M., Chugh, R., Schuetze, S. M., Biermann, J. S., Lawrence, T. S., Feng, M.. **Surgical resection or stereotactic body radiation therapy for sarcoma patients with pulmonary metastases.** *International journal of radiation oncology*. 2016. 96:S26- 10.1016/j.ijrobp.2016.06.075	Publication type
Satoh, Y., Onishi, H., Nambu, A., Araki, T.. **Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.** *Radiology*. 2014. 270:275-81 10.1148/radiol.13130652	Sample size
Schellenberg, D.,Goodman, K. A.,Lee, F.,Chang, S.,Kuo, T.,Ford, J. M.,Fisher, G. A., Quon, A.,Desser, T. S.,Norton, J.,Greco, R.,Yang, G. P.,Koong, A. C.. **Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.** *Int J Radiat Oncol Biol Phys*. 2008. 72:678-86 #DOI#	Sample size
Schmid, S., Becker, H., Fritsch, R., Bausch, J., Hunter, N., Jenkner, C., Hassan, M., Passlick, B.. **Study Protocol for a Randomised Controlled Trial on Pulmonary**	Intervention

Metastasectomy vs. Standard of Care in Colorectal Cancer Patients With ≥ 3 Lung Metastases (PUCC-Trial). *Frontiers in oncology*. 2022. 12:#pages# 10.3389/fonc.2022.913896	
Schneider, B. J., Daly, M. E., Kennedy, E. B., Antonoff, M. B., Broderick, S., Feldman, J., Jolly, S., Meyers, B., Rocco, G., Rusthoven, C., Slotman, B. J., Sterman, D. H., Stiles, B. M.. **Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline.** *Journal of Clinical Oncology*. 2018. 36:710-719 https://dx.doi.org/10.1200/JCO.2017.74.9671	Publication type
Schuffenegger, P. M., Barry, A. S., Atenafu, E., Kim, J., Brierley, J., Ringash, J. G., Brade, A., Wong, R., Cho, C. Y., Sapisochin, G., et al.. **Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma with Macrovascular Invasion.** *International journal of radiation oncology biology physics.* 2019. 105:S157- 10.1016/j.ijrobp.2019.06.171	Publication type
Scorsetti, M.,Bignardi, M.,Alongi, F.,Fogliata, A.,Mancosu, P.,Navarria, P.,Castiglioni, S., Pentimalli, S.,Tozzi, A.,Cozzi, L.. **Stereotactic body radiation therapy for abdominal targets using volumetric intensity modulated arc therapy with RapidArc: feasibility and clinical preliminary results.** *Acta Oncol.* 2011. 50:528-38 #DOI#	Sample size
Scorsetti, Marta,Alongi, Filippo,Clerici, Elena,Comito, Tiziana,Fogliata, Antonella,Iftode, Cristina,Mancosu, Pietro,Navarria, Piera,Reggiori, Giacomo,Tomatis, Stefano. **Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer: assessment of patient-reported quality of life.** *Journal of cancer research and clinical oncology*. 2014. 140:1795-1800 #DOI#	Sample size
Scorsetti, Marta,Alongi, Filippo,Filippi, Andrea Riccardo,Pentimalli, Sara,Navarria, Pierina,Clerici, Elena,Castiglioni, Simona,Tozzi, Angelo,Reggiori, Giacomo,Mancosu, Pietro. **Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients.** *Acta Oncologica.* 2012. 51:618-623 #DOI#	Sample size
Sebastian N, Merritt RE, Abdel-Rasoul M, et al. Recurrence after Stereotactic Body Radiation Therapy versus Lobectomy for Non-Small Cell Lung Cancer. *Annals of thoracic surgery*. 2020. doi: 10.1016/j.athoracsur.2020.03.073.	Population
Seisen, T., Drouin, S. J., Phe, V., Parra, J., Mozer, P., Bitker, M. O., Cussenot, O., Roupret, M.. **Current role of image-guided robotic radiosurgery (Cyberknife(R)) for prostate cancer treatment.** *BJU International.* 2013. 111:761-6 https://dx.doi.org/10.1111/bju.12000	Publication type
Selch, M. T.,Pedroso, A.,Lee, S. P.,Solberg, T. D.,Agazaryan, N.,Cabatan-Awang, C., DeSalles, A. A.. **Stereotactic radiotherapy for the treatment of acoustic neuromas.** *Journal of Neurosurgery*. 2004. 101 Suppl 3:362-72 #DOI#	Population
Senan, S., Olson, R., Harrow, S., Gaede, S., Louie, A., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G., Yaremko, B.. **Stereotactic ablative radiotherapy for oligometastatic cancers: efficacy and toxicity results from the randomized SABR-COMET Trial.** *Annals of oncology*. 2018. 29:#pages# 10.1093/annonc/mdy433	Publication type
Senan, S., Verstegen, N. E., Palma, D., Rodrigues, G., Lagerwaard, F. J., Van Der Elst, A., Mollema, R., Van Tets, W. F., Warner, A., Joosten, J. J. A., et al.. **Stages I-II non-small cell lung cancer treated using either lobectomy by video-assisted thoracoscopic surgery (VATS) or stereotactic ablative radiotherapy (SABR): outcomes of a propensity score-matched analysis.** *Journal of clinical oncology.* 2012. 30:#pages# #DOI#	Publication type

Senger, C,Conti, A,Kluge, A,Pasemann, D,Kufeld, M,Acker, G,Lukas, M,Grün, A, Kalinauskaite, G,Budach, V. **Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function.** *BMC urology.* 2019. 19:1-9 #DOI#	Sample size
Seo, Y. S., Kim, M. S., Cho, C. K., Yoo, H. J., Jang, W. I., Kim, K. B., Lee, D. H., Moon, S. M., Lee, H. R.. **Stereotactic body radiotherapy for oligometastases confined to the para-aortic region: clinical outcomes and the significance of radiotherapy field and dose.** *Cancer Invest.* 2015. 33:180-7 10.3109/07357907.2015.1019678	Sample size
Seo, Y.,Kim, M. S.,Yoo, S.,Cho, C.,Yang, K.,Yoo, H.,Choi, C.,Lee, D.,Kim, J.,Kim, M. S., Kang, H.,Kim, Y.. **Stereotactic body radiation therapy boost in locally advanced pancreatic cancer.** *Int J Radiat Oncol Biol Phys.* 2009. 75:1456-61 #DOI#	Sample size
Seymour, Zachary A,Chang, Albert J,Zhang, Li,Kirby, Neil,Descovich, Martina,Roach III, Mack,Hsu, I-Chow,Gottschalk, Alexander R. **Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer.** *Practical radiation oncology.* 2015. 5:e465-e472 #DOI#	Sample size
Shah A, Hahn SM, Stetson RL, Friedberg JS, Pechet TT, Sher DJ. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. *Cancer.* 2013;119(17):3123-3132. doi: 10.1002/cncr.28131.	Date
Shah C, Ward MC, Tendulkar RD, Cherian S, Vicini F, Singer ME. Cost and Cost-Effectiveness of Image Guided Partial Breast Irradiation in Comparison to Hypofractionated Whole Breast Irradiation. *Int J Radiat Oncol Biol Phys.* 2019;103(2):397-402. doi: 10.1016/j.ijrobp.2018.09.021.	Intervention
Shan, G. P.,Wang, B. B.,Zheng, P.,Du, F. L.,Yang, Y. W.. **Efficacy and safety of chemotherapy combined with stereotactic radiotherapy in the treatment of nasopharyngeal carcinoma.** *Med Sci Monit.* 2017. 23:5630-5636 #DOI#	Setting
Shaverdian N, Verruttipong D, Wang PC, et al. Exploring value from the patient's perspective between modern radiation therapy modalities for localized prostate cancer. *Int J Radiat Oncol Biol Phys.* 2017;97(3):516-525. doi: 10.1016/j.ijrobp.2016.11.007.	Study design
Shaverdian N, Wang PC, Steinberg M, Lee P. The patient's perspective on stereotactic body radiation therapy (SBRT) vs. surgery for treatment of early stage non-small cell lung cancer (NSCLC). *Lung Cancer.* 2015;90(2):230-233. doi: 10.1016/j.lungcan.2015.07.009.	Outcomes
Shaverdian, N., Lisberg, A. E., Bornazyan, K., Veruttipong, D., Goldman, J. W., Formenti, S. C., Garon, E. B., Lee, P.. **Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.** *Lancet Oncol.* 2017. 18:895-903 10.1016/S1470-2045(17)30380-7	Intervention
Shaverdian, N.,Verruttipong, D.,Wang, P. C.,Kishan, A. U.,Demanes, D. J.,McCloskey, S., Kupelian, P.,Steinberg, M. L.,King, C. R.. **Exploring value from the patient's perspective between modern radiation therapy modalities for localized prostate cancer.** *Int J Radiat Oncol Biol Phys.* 2017. 97:516-525 #DOI#	Study design
Sheehan, J. P.,Pouratian, N.,Steiner, L.,Laws, E. R.,Vance, M. L.. **Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes.** *J Neurosurg.* 2011. 114:303-9 #DOI#	Population
Sheehan, J.,Lopes, M. B.,Laws, E.. **Pathological findings following radiosurgery of pituitary adenomas.** *Progress in Neurological Surgery.* 2007. 20:172-179 #DOI#	Population

Shen J, Zhuang W, Xu C, et al. Surgery or Non-surgical Treatment of <=8 mm Non-small Cell Lung Cancer: A Population-Based Study. *Frontiers in Surgery*. 2021;8:632561. doi: https://dx.doi.org/10.3389/fsurg.2021.632561.	Intervention
Shen PC, Chang WC, Lo CH, et al. Comparison of stereotactic body radiation therapy and transarterial chemoembolization for unresectable medium-sized hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2019;105(2):307-318. doi: 10.1016/j.ijrobp.2019.05.066 Accessed 20190605//.	Setting
Shen, L., Xi, M., Zhao, L., Zhang, X., Wang, X., Huang, Z., Chen, Q., Zhang, T., Shen, J., Liu, M., Huang, J.. **Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib.** *Cancers*. 2018. 10:14 https://dx.doi.org/10.3390/cancers10120516	Setting
Shen, Ze-Tian,Zhou, Han,Li, Ao-Mei,Ji, Xiao-Qin,Jiang, Chang-Chen,Yuan, Xi,Li, Bing, Zhu, Xi-Xu,Huang, Gui-Chun. **Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.** *Journal of Cancer Research and Clinical Oncology*. 2020. 146:417-428 #DOI#	Sample size
Sher DJ, Parikh RB, Mays-Jackson S, Punglia RS. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer. *Am J Clin Oncol*. 2014;37(3):215-221. doi: 10.1097/COC.0b013e31827a7d2a.	Date
Sher, D. J.,Wee, J. O.,Punglia, R. S.. **Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer.** *International Journal of Radiation Oncology, Biology, Physics*. 2011. 81:e767-74 #DOI#	Publication Date
Shibamoto, Y., Hashizume, C., Baba, F., Ayakawa, S., Manabe, Y., Nagai, A., Miyakawa, A., Murai, T., Iwata, H., Mori, Y., et al.. **Stereotactic body radiotherapy using a radiobiology-based regimen for stage i nonsmall cell lung cancer: a multicenter study.** *Cancer*. 2012. 118:2078-2084 10.1002/cncr.26470	Population
Shirata, Y., Jingu, K., Koto, M., Kubozono, M., Takeda, K., Sugawara, T., Kadoya, N., Matsushita, H.. **Prognostic factors for local control of stage I non-small cell lung cancer in stereotactic radiotherapy: a retrospective analysis.** *Radiat Oncol*. 2012. 7:182 10.1186/1748-717X-7-182	Sample size
Shirvani SM, Jiang J, Chang JY, et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. *Int J Radiat Oncol Biol Phys*. 2012;84(5):1060-1070. doi: 10.1016/j.ijrobp.2012.07.2354.	Population
Shirvani SM, Jiang J, Chang JY, et al. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. *JAMA Surg*. 2014;149(12):1244-1253. doi: 10.1001/jamasurg.2014.556.	Population
Showalter, T. N.,Werner-Wasik, M.,Curran, W. J., Jr.,Friedman, D. P.,Xu, X.,Andrews, D. W.. **Stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of nonacoustic cranial nerve schwannomas.** *Neurosurgery*. 2008. 63:734-40; discussion 740 #DOI#	Population
Shun, S. C.,Chiou, J. F.,Lai, Y. H.,Yu, P. J.,Wei, L. L.,Tsai, J. T.,Kao, C. Y.,Hsiao, Y. L.. **Changes in quality of life and its related factors in liver cancer patients receiving stereotactic radiation therapy.** *Support Care Cancer*. 2008. 16:1059-65 #DOI#	Sample size

Shuto, T.,Inomori, S.,Fujino, H.,Nagano, H.,Hasegawa, N.,Kakuta, Y.. **Cyst formation following gamma knife surgery for intracranial meningioma.** *Journal of Neurosurgery*. 2005. 102 Suppl:134-9 #DOI#	Population
Siva S, Bressel M, Mai T, et al. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): the Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. *JAMA oncology*. 2021;7(10):1476-1485. doi: 10.1001/jamaoncol.2021.2939.	Comparator
Siva, S., Bressel, M., Kron, T., Mai, T., Le, H. V., Montgomery, R., Hardcastle, N., Rezo, A., Gill, S., Higgs, B. G., et al.. **Stereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the Lung: a Randomized Phase II Trial.** *International journal of radiation oncology biology physics*. 2020. 108:S3-S4 10.1016/j.ijrobp.2020.07.2072	Publication type
Siva, S., Bressel, M., Mai, T., Le, H., Vinod, S., De Silva, H., Macdonald, S., Skala, M., Hardcastle, N., Rezo, A., et al.. **Final results of TROG 13.01 SAFRON II: single vs multi-fraction SABR for pulmonary oligometastases.** *Radiotherapy and oncology*. 2021. 161:S247-S249 10.1016/S0167-8140(21)06868-7	Publication type
Siva, S., Louie, A. V., Warner, A., Muacevic, A., Gandhidasan, S., Ponsky, L., Ellis, R., Kaplan, I., Mahadevan, A., Chu, W., Swaminath, A., Onishi, H., Teh, B., Correa, R. J., Lo, S. S., Staehler, M.. **Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).** *Cancer*. 2018. 124:934-942 https://dx.doi.org/10.1002/cncr.31156	Aim
Siva, S.,Ellis, R. J.,Ponsky, L.,Teh, B. S.,Mahadevan, A.,Muacevic, A.,Staehler, M.,Onishi, H.,Wersall, P.,Nomiya, T.,Lo, S. S.. **Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma.** *Future Oncol*. 2016. 12:637-45 #DOI#	Study design
Siva, S.,Kothari, G.,Muacevic, A.,Louie, A. V.,Slotman, B. J.,Teh, B. S.,Lo, S. S.. **Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach.** *Nat Rev Urol*. 2017. 14:549-563 #DOI#	Publication type
Smith BD, Jiang J, Chang JY, et al. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults. *J Geriatr Oncol*. 2015;6(4):324-331. doi: 10.1016/j.jgo.2015.05.002.	Date
Smith, K. A.,Ashby, L. S.,Gonzalez, L. F.,Brachman, D. G.,Thomas, T.,Coons, S. W.,Battaglia, M.,Scheck, A.. **Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme.** *Journal of Neurosurgery*. 2008. 109 Suppl:106-17 #DOI#	Population
Solberg, Timothy D,Balter, James M,Benedict, Stanley H,Fraass, Benedick A,Kavanagh, Brian,Miyamoto, Curtis,Pawlicki, Todd,Potters, Louis,Yamada, Yoshiya. **Quality and safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy: Executive summary.** *Practical radiation oncology*. 2012. 2:2-9 #DOI#	Publication type
Somani, S.,Sahgal, A.,Krema, H.,Heydarian, M.,McGowan, H.,Payne, D.,Xu, W.,Michaels, H.,Laperriere, N.,Simpson, E. R.. **Stereotactic radiotherapy in the treatment of juxtapapillary choroidal melanoma: 2-year follow-up.** *Can J Ophthalmol*. 2009. 44:61-5 #DOI#	Sample size

Song, Andrew,Lu, Bo. **Utility of stereotactic ablative radiotherapy/stereotactic body radiation therapy in the setting of oligometastatic non-small cell lung cancer.** *Journal of thoracic disease*. 2018. 10:657 #DOI#	Publication type
Song, Y., Yuan, Z., Li, F., Dong, Y., Zhuang, H., Wang, J., Chen, H., Wang, P.. **Analysis of clinical efficacy of CyberKnife((R)) treatment for locally advanced pancreatic cancer.** *Onco Targets Ther*. 2015. 8:1427-31 10.2147/OTT.S81939	Setting
Sood, Sumit,Ju, Andrew W,Wang, Honkung,Lei, Siyuan,Uhm, Sunghae,Zhang, Guowei, Suy, Simeng,Carroll, John,Lynch, John,Dritschilo, Anatoly. **Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer.** *Radiation Oncology*. 2013. 8:1-6 #DOI#	Sample size
Souhami, L.,Seiferheld, W.,Brachman, D.,Podgorsak, E. B.,Werner-Wasik, M.,Lustig, R., Schultz, C. J.,Sause, W.,Okunieff, P.,Buckner, J.,Zamorano, L.,Mehta, M. P.,Curran, W. J., Jr.. **Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol.** *International Journal of Radiation Oncology, Biology, Physics*. 2004. 60:853-60 #DOI#	Population
Spaas, M., Sundahl, N., Rottey, S., Kruse, V., De Maeseneer, D., Duprez, F., Dirix, P., Surmont, V., Lievens, Y., Van den Begin, R., et al.. **Immuno-radiotherapy in solid tumors: preliminary results of the randomized phase 2 CHEERS trial.** *Radiotherapy and oncology*. 2021. 161:S490-S491 10.1016/S0167-8140(21)06981-4	Publication type
Spiegelmann, R.,Cohen, Z. R.,Nissim, O.,Alezra, D.,Pfeffer, R.. **Cavernous sinus meningiomas: a large LINAC radiosurgery series.** *Journal of Neuro-Oncology*. 2010. 98:195-202 #DOI#	Population
Spiegelmann, R.,Nissim, O.,Menhel, J.,Alezra, D.,Pfeffer, M. R.. **Linear accelerator radiosurgery for meningiomas in and around the cavernous sinus.** *Neurosurgery*. 2002. 51:1373-79; discussion 1379-80 #DOI#	Population
Spindler, N. J., Felter, M. V. O., Hansen, O., Nielsen, T. B., Suppli, M. H., Josipovic, M., Poulsen, L. O., Gaard-Petersen, F., Sand, H. M. B., Abramova, T. M., et al.. **Early toxicity after SABR of oligometastatic bony metastases in the BONY M phase II trial.** *Radiotherapy and oncology*. 2022. 170:S529-S530 10.1016/S0167-8140(22)02626-3	Publication type
Spohn, S. K. B., Adebahr, S., Huber, M., Jenkner, C., Wiehle, R., Nagavci, B., Schmucker, C., Carl, E. G., Chen, R. C., Weber, W. A., et al.. **Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients.** *BMC cancer*. 2022. 22:#pages# 10.1186/s12885-022-09434-2	Aim
Sprave, T., Verma, V., Förster, R., Schlampp, I., Bruckner, T., Bostel, T., El Shafie, R. A., Nicolay, N. H., Debus, J., Rief, H.. **Quality of Life Following Stereotactic Body Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Vertebral Metastases: secondary Analysis of an Exploratory Phase II Randomized Trial.** *Anticancer research*. 2018. 38:4961-4968 10.21873/anticanres.12814	Population
Sridharan, S., Steigler, A., Spry, N. A., Joseph, D., Lamb, D. S., Matthews, J. H., Atkinson, C., Tai, K. H., Duchesne, G., Christie, D., et al.. **Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial.** *Radiotherapy and oncology*. 2016. 121:98-102 10.1016/j.radonc.2016.07.021	Intervention

Staehler, Michael,Bader, Markus,Schlenker, Boris,Casuscelli, Jozefina,Karl, Alexander, Roosen, Alexander,Stief, Christian G,Bex, Axel,Wowra, Berndt,Muacevic, Alexander. **Single fraction radiosurgery for the treatment of renal tumors.** *The Journal of urology*. 2015. 193:771-775 #DOI#	Sample size
Stafford, S. L.,Pollock, B. E.,Leavitt, J. A.,Foote, R. L.,Brown, P. D.,Link, M. J.,Gorman, D. A.,Schomberg, P. J.. **A study on the radiation tolerance of the optic nerves and chiasm after stereotactic radiosurgery.** *International Journal of Radiation Oncology, Biology, Physics*. 2003. 55:1177-81 #DOI#	Population
Stahl JM, Ross R, Harder EM, et al. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. *Int J Radiat Oncol Biol Phys*. 2016;96(5):1011-1020. doi: 10.1016/j.ijrobp.2016.08.033.	Population
Stephans, K. L.,Djemil, T.,Reddy, C. A.,Gajdos, S. M.,Kolar, M.,Mason, D.,Murthy, S., Rice, T. W.,Mazzone, P.,Machuzak, M.,Mekhail, T.,Videtic, G. M.. **A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience.** *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*. 2009. 4:976-82 #DOI#	Population
Stephens, S. J., Oyekunle, T., Niedzwiecki, D., Eyler, C., Czito, B., Willett, C. G., Salama, J. K., Palta, M.. **The Role of Hypofractionated Radiation Therapy in the Management of Unresectable Hepatocellular Carcinoma (HCC).** *International journal of radiation oncology biology physics*. 2021. 111:e78-e79 10.1016/j.ijrobp.2021.07.444	Publication type
Steuber, T., Jilg, C., Tennstedt, P., De Bruycker, A., Tilki, D., Decaestecker, K., Zilli, T., Jereczek-Fossa, B. A., Wetterauer, U., Grosu, A. L., Schultze-Seemann, W., Heinzer, H., Graefen, M., Morlacco, A., Karnes, R. J., Ost, P.. **Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.** *European Urology Focus*. 2019. 5:1007-1013 https://dx.doi.org/10.1016/j.euf.2018.02.015	Intervention
Stokes WA, Bronsert MR, Meguid RA, et al. Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2018;36(7):642-651. doi: 10.1200/JCO.2017.75.6536.	Population
Stumpf, P. K., Yorke, E. D., El Naqa, I., Cuneo, K. C., Grimm, J., Goodman, K. A.. **Modeling of Tumor Control Probability in Stereotactic Body Radiation Therapy for Adrenal Tumors.** *International Journal of Radiation Oncology, Biology, Physics*. 2021. 110:217-226 https://dx.doi.org/10.1016/j.ijrobp.2020.05.062	Publication type
Su, K., Gu, T., Xu, K., Wang, J., Liao, H., Li, X., Wen, L., Song, Y., Zhong, J., He, B., Liu, X., He, J., Liu, Y., Li, Q., Feng, X., Chen, S., Yang, B., Huang, W., Jin, H., Luo, X., Hu, T., Chen, J., Wu, Z., Lu, S., Zhang, J., Rao, M., Xie, Y., Wang, J., Zhu, X., Chen, L., Li, B., Su, S., Yang, X., Wang, J., Zeng, H., Wang, P., Yan, M., Chen, X., He, K., Han, Y.. **Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study.** *Hepatology International*. 2022. 16:858-867 https://dx.doi.org/10.1007/s12072-022-10339-2	Setting
Su, T. S., Liang, P., Zhou, Y., Huang, Y., Cheng, T., Qu, S., Chen, L., Xiang, B. D., Zhao, C., Huang, D. J., Liang, S. X., Li, L. Q.. **Stereotactic Body Radiation Therapy vs. Transarterial Chemoembolization in Inoperable Barcelona Clinic Liver Cancer Stage a**	Setting

Hepatocellular Carcinoma: A Retrospective, Propensity-Matched Analysis. *Frontiers in Oncology.* 2020. 10:347 https://dx.doi.org/10.3389/fonc.2020.00347	
Su, T. S.,Liang, P.,Liang, J.,Lu, H. Z.,Jiang, H. Y.,Cheng, T.,Huang, Y.,Tang, Y.,Deng, X.. **Long-term survival analysis of stereotactic ablative radiotherapy versus liver resection for small hepatocellular carcinoma.** *Int J Radiat Oncol Biol Phys.* 2017. 98:639-646 #DOI#	Setting
Sughrue, M. E.,Yang, I.,Han, S. J.,Aranda, D.,Kane, A. J.,Amoils, M.,Smith, Z. A.,Parsa, A. T.. **Non-audiofacial morbidity after Gamma Knife surgery for vestibular schwannoma.** *Neurosurgical Focus.* 2009. 27:E4 #DOI#	Population
Sumodhee, S., Bondiau, P. Y., Poudenx, M., Cohen, C., Naghavi, A. O., Padovani, B., Maneval, D., Gal, J., Leysalle, A., Ghalloussi, H., Otto, J., Doyen, J.. **Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer.** *BMC Cancer.* 2019. 19:305 https://dx.doi.org/10.1186/s12885-019-5542-3	Sample size
Sun, J., Li, W. G., Wang, Q., He, W. P., Wang, H. B., Han, P., Zhang, T., Zhang, A. M., Fan, Y. Z., Sun, Y. Z., Duan, X. Z.. **Hepatic Resection Versus Stereotactic Body Radiation Therapy Plus Transhepatic Arterial Chemoembolization for Large Hepatocellular Carcinoma: A Propensity Score Analysis.** *Journal of Clinical & Translational Hepatology.* 2021. 9:672-681 https://dx.doi.org/10.14218/JCTH.2020.00188	Setting
Sun, J., Zhang, A., Li, W., Wang, Q., Li, D., Zhang, D., Duan, X.. **Biologically effective dose (BED) escalation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma patients (≤ 5 cm) with CyberKnife: protocol of study.** *Radiation oncology (London, England).* 2020. 15:#pages# 10.1186/s13014-020-1471-1	Publication type
Sun, Jing,Wang, Quan,Hong, Zhi-Xian,Li, Wen-Gang,He, Wei-Ping,Zhang, Tao,Zhang, Ai-Min,Fan, Yu-Ze,Sun, Ying-Zhe,Zheng, Li,Duan, Xue-Zhang. **Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (<= 5 cm): a propensity score analysis.** *Hepatology international.* 2020. 14:788-797 #DOI#	Setting
Suzuki, O., Mitsuyoshi, T., Miyazaki, M., Teshima, T., Nishiyama, K., Ubbels, J. F., Bolt, R. A., Langendijk, J. A., Widder, J.. **Dose-volume-response analysis in stereotactic radiotherapy for early lung cancer.** *Radiother Oncol.* 2014. 112:262-6 10.1016/j.radonc.2014.07.004	Outcomes
Svedman, C.,Karlsson, K.,Rutkowska, E.,Sandstrom, P.,Blomgren, H.,Lax, I.,Wersall, P.. **Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney.** *Acta Oncol.* 2008. 47:1578-83 #DOI#	Sample size
Szeifert, G. T.,Prasad, D.,Kamyrio, T.,Steiner, M.,Steiner, L. E.. **The role of the Gamma Knife in the management of cerebral astrocytomas.** *Progress in Neurological Surgery.* 2007. 20:150-163 #DOI#	Population
Takeda A, Kunieda E, Ohashi T, Aoki Y, Koike N, Takeda T. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. *Radiother Oncol.* 2011;101(2):255-259. doi: 10.1016/j.radonc.2011.05.033.	Population
Takeda, A., Sanuki, N., Eriguchi, T., Kobayashi, T., Iwabutchi, S., Matsunaga, K., Mizuno, T., Yashiro, K., Nisimura, S., Kunieda, E.. **Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma.** *J Gastroenterol Hepatol.* 2014. 29:372-9 10.1111/jgh.12350	Sample size

Takeda, A., Sanuki, N., Tsurugai, Y., Iwabuchi, S., Matsunaga, K., Ebinuma, H., Imajo, K., Aoki, Y., Saito, H., Kunieda, E.. **Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation.** *Cancer.* 2016. 122:2041-9 10.1002/cncr.30008	Sample size
Talacchi, A.,Muggiolu, F.,De Carlo, A.,Nicolato, A.,Locatelli, F.,Meglio, M.. **Recurrent atypical meningiomas: combining surgery and radiosurgery in one effective multimodal treatment.** *World Neurosurg.* 2016. 87:565-72 #DOI#	Population
Tan, S. S.,van Putten, E.,Nijdam, W. M.,Hanssens, P.,Beute, G. N.,Nowak, P. J.,Dirven, C. M.,Hakkaart-van Roijen, L.. **A microcosting study of microsurgery, LINAC radiosurgery, and gamma knife radiosurgery in meningioma patients.** *Journal of Neuro-Oncology.* 2011. 101:237-45 #DOI#	Population
Tanadini-Lang, S., Rieber, J., Filippi, A. R., Fode, M. M., Streblow, J., Adebahr, S., Andratschke, N., Blanck, O., Boda-Heggemann, J., Duma, M., Eble, M. J., Ernst, I., Flentje, M., Gerum, S., Hass, P., Henkenberens, C., Hildebrandt, G., Imhoff, D., Kahl, H., Klass, N. D., Krempien, R., Lohaus, F., Petersen, C., Schrade, E., Wendt, T. G., Wittig, A., Hoyer, M., Ricardi, U., Sterzing, F., Guckenberger, M.. **Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease.** *Radiotherapy & Oncology.* 2017. 123:182-188 https://dx.doi.org/10.1016/j.radonc.2017.01.003	Aim
Tang, Chad,Msaouel, Pavlos,Hara, Kieko,Choi, Haesun,Le, Venus,Shah, Amishi Y,Wang, Jennifer,Jonasch, Eric,Choi, Seungtaek,Nguyen, Quynh-nhu. **Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.** *The Lancet Oncology.* 2021. 22:1732-1739 #DOI#	Sample size
Taremi M, Hope A, Dahele M, et al. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. *Int J Radiat Oncol Biol Phys.* 2012;82(2):967-973. doi: 10.1016/j.ijrobp.2010.12.039.	Population
Teh, B. S.,Ishiyama, H.,Mathews, T.,Xu, B.,Butler, E. B.,Mayr, N. A.,Lo, S. S.,Lu, J. J., Blanco, A. I.,Paulino, A. C.,Timmerman, R. D.. **Stereotactic body radiation therapy (SBRT) for genitourinary malignancies.** *Discov Med.* 2010. 10:255-62 #DOI#	Publication type
Teke, M. E., Sarvestani, A. L., Hernandez, J. M., Fernando, H. C., Timmerman, R. D.. **A Randomized, Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High-Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC).** *Annals of surgical oncology.* 2022. 29:4686-4687 10.1245/s10434-022-11584-3	Publication type
Teo, M. Y., McBride, S., Gopalan, A., Benoliel, H., Eastham, J. A., Goh, A., Szmulewitz, R., Morgans, A. K., Bubley, G., Gupta, S., et al.. **Biochemical response (PSA0) and testosterone (T) recovery in Metacure, a multi-arm multi-modality (MM) therapy (tx) for very high risk localized (HRL) and low volume metastatic (LVM) prostatic adenocarcinoma.** *Annals of oncology.* 2021. 32:S667-S668 10.1016/j.annonc.2021.08.1150	Publication type
Teo, M. Y., Taplin, M. E., Eastham, J. A., Benoliel, H., Kibel, A. S., McBride, S. M., Nguyen, P. L., Gopalan, A., Lis, R., Scher, H. I.. **Metacure: multi-arm multimodality therapy for very high risk localized and low volume metastatic prostatic adenocarcinoma.** *Journal of clinical oncology.* 2019. 37:#pages# #DOI#	Publication type
Thariat, J., Sun, X. S., Tao, Y., Maingon, P., Racadot Deloge, S., Huguet, F., Wiazzane, N., Franck, D., Bollet, M. A., Chapet, S., et al.. **Quality assurance (QA) of randomized phase**	Aim

2 gortec trial 2014-04 of stereotactic irradiation in patients with oligometastatic squamous cell carcinomas of the head and neck. *International journal of radiation oncology*. 2016. 96:E607- 10.1016/j.ijrobp.2016.06.2150	
Tharmalingam H, Tsang Y, Ostler P, et al. Single dose high-dose rate (HDR) brachytherapy (BT) as monotherapy for localised prostate cancer: Early results of a UK national cohort study. *Radiotherapy and Oncology*. 2020;143:95-100. *EXC - not intervention of interest	Intervention
Theelen, W., Peulen, F. H., Lalezari, F., De Vries, J., De Langen, J., Aerts, J., Monkhorst, K., Baas, P.. **Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: the PEMBRO-RT study.** *Journal of clinical oncology*. 2018. 36:#pages# 10.1200/JCO.2018.36.15-suppl.9023	Publication type
Tian, L. X., Yu, W., Li, C. L.. **Clinical research of gamma knife radiotherapy combined with yiqijieduxiaoliu decoction in patients with advanced hepatocellular carcinoma.** *Hepatology international.* 2017. 11:S454- 10.1007/s12072-016-9783-9	Publication type
Tian, S., Switchenko, J. M., Buchwald, Z. S., Patel, P. R., Shelton, J. W., Kahn, S. E., Pillai, R. N., Steuer, C. E., Owonikoko, T. K., Behera, M., Curran, W. J., Higgins, K. A.. **Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis.** *International Journal of Radiation Oncology, Biology, Physics*. 2020. 108:304-313 https://dx.doi.org/10.1016/j.ijrobp.2019.12.030	Comparator
Tibdewal, A., Agarwal, J. P., Srinivasan, S., Mummudi, N., Noronha, V., Prabhash, K., Patil, V., Purandare, N., Janu, A., Kannan, S.. **Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1-5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial.** *BMJ open*. 2021. 11:#pages# 10.1136/bmjopen-2020-043628	Setting
Timmer, F. C.,Hanssens, P. E.,van Haren, A. E.,Mulder, J. J.,Cremers, C. W.,Beynon, A. J.,van Overbeeke, J. J.,Graamans, K.. **Gamma knife radiosurgery for vestibular schwannomas: results of hearing preservation in relation to the cochlear radiation dose.** *Laryngoscope*. 2009. 119:1076-81 #DOI#	Population
Timmerman, R. D.,Kavanagh, B. D.,Cho, L. C.,Papiez, L.,Xing, L.. **Stereotactic body radiation therapy in multiple organ sites.** *J Clin Oncol*. 2007. 25:947-52 #DOI#	Publication type
Timmerman, R.,McGarry, R.,Yiannoutsos, C.,Papiez, L.,Tudor, K.,DeLuca, J.,Ewing, M., Abdulrahman, R.,DesRosiers, C.,Williams, M.,Fletcher, J.. **Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.** *J Clin Oncol*. 2006. 24:4833-9 #DOI#	Sample size
Timmerman, R.,Paulus, R.,Galvin, J.,Michalski, J.,Straube, W.,Bradley, J.,Fakiris, A., Bezjak, A.,Videtic, G.,Johnstone, D.,Fowler, J.,Gore, E.,Choy, H.. **Stereotactic body radiation therapy for inoperable early stage lung cancer.** *JAMA*. 2010. 303:1070-6 #DOI#	Sample size
Torres, R. C.,Frighetto, L.,De Salles, A. A.,Goss, B.,Medin, P.,Solberg, T.,Ford, J. M., Selch, M.. **Radiosurgery and stereotactic radiotherapy for intracranial meningiomas.** *Neurosurgical Focus*. 2003. 14:e5 #DOI#	Population
Townsend, N. C.,Huth, B. J.,Ding, W.,Garber, B.,Mooreville, M.,Arrigo, S.,Lamond, J., Brady, L. W.. **Acute toxicity after cyberknife-delivered hypofractionated radiotherapy for treatment of prostate cancer.** *Am J Clin Oncol*. 2011. 34:6-10 #DOI#	Sample size

Tran PT, Phillips R, Shi W, et al. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). *Journal of Clinical Oncology*. 2020;38(6_suppl):116-116. doi: 10.1200/JCO.2020.38.6_suppl.116.	Publication type
Tran, P. T., Phillips, R., Shi, W., Lim, S. J., Antonarakis, E. S., Rowe, S. P., Ross, A., Gorin, M. A., Deville, C., Greco, S. C., et al.. **A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).** *Journal of clinical oncology*. 2020. 38:#pages# 10.1200/JCO.2020.38.6_suppl.116	Publication type
Tree AC, Hall E, Ostler P, et al. OC-0289 Comparison of side effects at 2 years in the randomised PACE-B trial (SBRT vs standard radiotherapy). *Radiotherapy and Oncology*. 2021;161:S196-S197. doi: 10.1016/s0167-8140(21)06839-0.	Publication type
Tree, A. C., Hall, E., Ostler, P., Van Der Voet, H., Loblaw, A., Chu, W., Ford, D., Tolan, S., Jain, S., Martin, A., et al.. **Comparison of side effects at 2 years in the randomised PACE-B trial (SBRT vs standard radiotherapy).** *Radiotherapy and oncology*. 2021. 161:S196-S197 10.1016/S0167-8140(21)06839-0	Publication type
Trovo, M., Furlan, C., Polesel, J., Fiorica, F., Arcangeli, S., Giaj-Levra, N., Alongi, F., Del Conte, A., Militello, L., Muraro, E., et al.. **Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial.** *Radiotherapy and oncology*. 2017. (no pagination):#pages# 10.1016/j.radonc.2017.08.032	Sample size
Trovo, M., Minatel, E., Durofil, E., Polesel, J., Avanzo, M., Baresic, T., Bearz, A., Del Conte, A., Franchin, G., Gobitti, C., Rumeileh, I. A., Trovo, M. G.. **Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer.** *Int J Radiat Oncol Biol Phys*. 2014. 88:1114-9 10.1016/j.ijrobp.2014.01.012	Sample size
Tsang, Y. M., Tharmalingam, H., Belessiotis-Richards, K., Armstrong, S., Ostler, P., Hughes, R., Alonzi, R., Hoskin, P.. **OC-0040 Ultrafractionated radiotherapy(RT) in localised prostate cancer: HDR brachytherapy vs stereotactic RT.** *Radiotherapy and oncology*. 2021. 158:S27-S28 10.1016/S0167-8140(21)06282-4	Publication type
Tse, R. V.,Hawkins, M.,Lockwood, G.,Kim, J. J.,Cummings, B.,Knox, J.,Sherman, M., Dawson, L. A.. **Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.** *J Clin Oncol*. 2008. 26:657-64 #DOI#	Sample size
Tu CY, Hsia TC, Fang HY, et al. A Population-based Study of the Effectiveness of Stereotactic Ablative Radiotherapy Versus Conventional Fractionated Radiotherapy for Clinical Stage I Non-small Cell Lung Cancer Patients. *Radiology & Oncology*. 2018;52(2):181-188. doi: https://dx.doi.org/10.1515/raon-2017-0058.	Setting
Ulm, A. J., 3rd,Friedman, W. A.,Bradshaw, P.,Foote, K. D.,Bova, F. J.. **Radiosurgery in the treatment of malignant gliomas: the University of Florida experience.** *Neurosurgery*. 2005. 57:512-7; discussion 512-7 #DOI#	Population
Unger, F.,Walch, C.,Schrottner, O.,Eustacchio, S.,Sutter, B.,Pendl, G.. **Cranial nerve preservation after radiosurgery of vestibular schwannomas.** *Acta Neurochirurgica - Supplement*. 2002. 84:77-83 #DOI#	Population
Unger, K. R.,Lominska, C. E.,Deeken, J. F.,Davidson, B. J.,Newkirk, K. A.,Gagnon, G. J., Hwang, J.,Slack, R. S.,Noone, A. M.,Harter, K. W.. **Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer.** *International Journal of Radiation Oncology, Biology, Physics*. 2010. 77:1411-9 #DOI#	Sample size

Vachhrajani, S.,Fawaz, C.,Mathieu, D.,Menard, C.,Cusimano, M. D.,Gentili, F.,Hodaie, M.,Kenny, B.,Kulkarni, A. V.,Laperriere, N.,Schwartz, M.,Tsao, M.,Bernstein, M.. **Complications of Gamma Knife surgery: an early report from 2 Canadian centers.** *Journal of Neurosurgery*. 2008. 109 Suppl:2-7 #DOI#	Population
Valle LF, Ruan D, Dang A, et al. Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy. *Frontiers in Oncology*. 2020;10:786. doi: https://dx.doi.org/10.3389/fonc.2020.00786.	Aim
Van As, N. J., Brand, D., Tree, A., Ostler, P. J., Chu, W., Loblaw, A., Ford, D., Tolan, S. P., Jain, S., Martin, A. S., et al.. **PACE: analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa).** *Journal of clinical oncology*. 2019. 37:#pages# #DOI#	Publication type
van Dams R, Jiang NY, Fuller DB, et al. Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients. *Int J Radiat Oncol Biol Phys*. 2021;110(3):731-737. doi: 10.1016/j.ijrobp.2021.01.016 Accessed 20210123//.	Aim
van Dams, R.,Jiang, N. Y.,Fuller, D. B.,Loblaw, A.,Jiang, T.,Katz, A. J.,Collins, S. P., Aghdam, N.,Suy, S.,Stephans, K. L.,Yuan, Y.,Nickols, N. G.,Murthy, V.,Telkhade, T. P., Kupelian, P. A.,Steinberg, M. L.,Romero, T.,Kishan, A. U.. **Stereotactic body radiotherapy for high-risk localized carcinoma of the prostate (SHARP) consortium: analysis of 344 prospectively treated patients.** *Int J Radiat Oncol Biol Phys*. 2021. 110:731-737 #DOI#	Study design
van de Langenberg, R.,Hanssens, P. E.,Verheul, J. B.,van Overbeeke, J. J.,Nelemans, P. J.,Dohmen, A. J.,de Bondt, B. J.,Stokroos, R. J.. **Management of large vestibular schwannoma. Part II. Primary Gamma Knife surgery: radiological and clinical aspects.** *Journal of Neurosurgery*. 2011. 115:885-93 #DOI#	Population
van de Ven S, van den Bongard D, Pielkenrood B, et al. Patient-Reported Outcomes of Oligometastatic Patients After Conventional or Stereotactic Radiation Therapy to Bone Metastases: An Analysis of the PRESENT Cohort. *International Journal of Radiation Oncology, Biology, Physics*. 2020;107(1):39-47. doi: https://dx.doi.org/10.1016/j.ijrobp.2019.12.041.	Population
van de Water, Steven,Valli, Lorella,Aluwini, Shafak,Lanconelli, Nico,Heijmen, Ben, Hoogeman, Mischa. **Intrafraction prostate translations and rotations during hypofractionated robotic radiation surgery: dosimetric impact of correction strategies and margins.** *International Journal of Radiation Oncology* Biology* Physics*. 2014. 88:1154-1160 #DOI#	Sample size
van den Berg LL, Klinkenberg TJ, Groen HJM, Widder J. Patterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLC. *J Thorac Oncol*. 2015;10(5):826-831. doi: 10.1097/JTO.0000000000000483.	Population
van der Velden, J. M., Verkooijen, H. M., Seravalli, E., Hes, J., Gerlich, A. S., Kasperts, N., Eppinga, W. S., Verlaan, J. J., van Vulpen, M.. **Comparing conVEntional RadioTherapy with stereotactIC body radiotherapy in patients with spinAL metastases: study protocol for an randomized controlled trial following the cohort multiple randomized controlled trial design.** *BMC Cancer*. 2016. 16:909 10.1186/s12885-016-2947-0	Population

Vargo, J. A.,Wegner, R. E.,Heron, D. E.,Ferris, R. L.,Rwigema, J. C.,Quinn, A.,Gigliotti, P., Ohr, J.,Kubicek, G. J.,Burton, S.. **Stereotactic body radiation therapy for locally recurrent, previously irradiated nonsquamous cell cancers of the head and neck.** *Head Neck.* 2012. 34:1153-61 #DOI#	Sample size
Varlotto J, Fakiris A, Flickinger J, et al. Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery. *Cancer.* 2013;119(15):2683-2691. doi: 10.1002/cncr.28100.	Population
Verma, V., Cushman, T. R., Selek, U., Tang, C., Welsh, J. W.. **Safety of Combined Immunotherapy and Thoracic Radiation Therapy: analysis of 3 Single-Institutional Phase I/II Trials.** *International journal of radiation oncology, biology, physics.* 2018. 101:1141-1148 10.1016/j.ijrobp.2018.04.054	Sample size
Verma, V., Lazenby, A. J., Zheng, D., Bhirud, A. R., Ly, Q. P., Are, C., Sasson, A. R., Lin, C.. **Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: secondary analysis of a prospective clinical trial.** *Radiotherapy and oncology. (no pagination), 2017.* 2017. Date of Publication: October 20:#pages# 10.1016/j.radonc.2016.12.030	Sample size
Verstegen NE, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. *Radiother Oncol.* 2011;101(2):250-254. doi: 10.1016/j.radonc.2011.09.017.	Population
Verstegen NE, Oosterhuis JW, Palma DA, et al. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. *Annals of Oncology.* 2013;24(6):1543-1548. doi: https://dx.doi.org/10.1093/annonc/mdt026.	Population
Viani, G. A., Gouveia, A. G., Jacinto, A. A., Moraes, F. Y.. **Stereotactic Body Radiotherapy for Prostate Cancer: Where, When, and Who? A Bibliometric Analysis.** *American Journal of Clinical Oncology.* 2021. 44:553-558 https://dx.doi.org/10.1097/COC.0000000000000869	Aim
Vladyka, V.,Liscak, R.,Novotny, J., Jr.,Marek, J.,Jezkova, J.. **Radiation tolerance of functioning pituitary tissue in gamma knife surgery for pituitary adenomas.** *Neurosurgery.* 2003. 52:309-16; discussion 316-7 #DOI#	Population
Voges, J.,Kocher, M.,Runge, M.,Poggenborg, J.,Lehrke, R.,Lenartz, D.,Maarouf, M., Gouni-Berthold, I.,Krone, W.,Muller, R. P.,Sturm, V.. **Linear accelerator radiosurgery for pituitary macroadenomas: a 7-year follow-up study.** *Cancer.* 2006. 107:1355-64 #DOI#	Population
Vu CC, Haas JA, Katz AE, Witten MR. Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer. *Frontiers in oncology.* 2014;4:8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904182/pdf/fonc-04-00008.pdf.	Outcomes
Vu, C. C., Matthews, R., Kim, B., Franceschi, D., Bilfinger, T. V., Moore, W. H.. **Prognostic value of metabolic tumor volume and total lesion glycolysis from (1)(8)F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.** *Nucl Med Commun.* 2013. 34:959-63 10.1097/MNM.0b013e32836491a9	Sample size

Vu, Charles C,Haas, Jonathan A,Katz, Aaron E,Witten, Matthew R. **Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer.** *Frontiers in oncology*. 2014. 4:8 #DOI#	Outcomes
Wackym, P. A.,Hannley, M. T.,Runge-Samuelson, C. L.,Jensen, J.,Zhu, Y. R.. **Gamma Knife surgery of vestibular schwannomas: longitudinal changes in vestibular function and measurement of the Dizziness Handicap Inventory.** *Journal of Neurosurgery*. 2008. 109 Suppl:137-43 #DOI#	Population
Wackym, P. A.,Runge-Samuelson, C. L.,Poetker, D. M.,Michel, M. A.,Alkaf, F. M.,Burg, L. S.,Firszt, J. B.. **Gamma knife radiosurgery for acoustic neuromas performed by a neurotologist: early experiences and outcomes.** *Otology & Neurotology*. 2004. 25:752-61 #DOI#	Population
Wang SC, Ting WC, Chang YC, et al. Whole Pelvic Radiotherapy With Stereotactic Body Radiotherapy Boost vs. Conventionally Fractionated Radiotherapy for Patients With High or Very High-Risk Prostate Cancer. *Frontiers in Oncology*. 2020;10:814. doi: https://dx.doi.org/10.3389/fonc.2020.00814.	Setting
Wang, F.,Numata, K.,Takeda, A.,Ogushi, K.,Fukuda, H.,Hara, K.,Chuma, M.,Eriguchi, T., Tsurugai, Y.,Maeda, S.. **Safety and efficacy study: short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0-B1 hepatocellular carcinoma.** *PLoS One*. 2021. 16:e0245076 #DOI#	
Wang, P.,Zhang, D.,Guo, X. G.,Li, X. M.,Du, L. H.,Sun, B. J.,Fang, X. Q.,Guo, Y. H.,Guo, J., An, L.,Qu, G. P.,Liu, C. T.. **A propensity-matched analysis of surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer in the elderly.** *Medicine (Baltimore)*. 2016. 95:e5723 #DOI#	Setting
Wang, Q., Li, S., Qiao, S., Zheng, Z., Duan, X., Zhu, X.. **Changes in T Lymphocyte Subsets in Different Tumors Before and After Radiotherapy: A Meta-analysis.** *Frontiers in Immunology*. 2021. 12:648652 https://dx.doi.org/10.3389/fimmu.2021.648652	Aim
Wang, S. C., Ting, W. C., Chang, Y. C., Yang, C. C., Lin, L. C., Ho, H. W., Chu, S. S., Lin, Y. W.. **Whole Pelvic Radiotherapy With Stereotactic Body Radiotherapy Boost vs. Conventionally Fractionated Radiotherapy for Patients With High or Very High-Risk Prostate Cancer.** *Frontiers in Oncology*. 2020. 10:814 https://dx.doi.org/10.3389/fonc.2020.00814	Setting
Wang, S. W., Ren, J., Yan, Y. L., Xue, C. F., Tan, L., Ma, X. W.. **Effect of image-guided hypofractionated stereotactic radiotherapy on peripheral non-small-cell lung cancer.** *OncoTargets and therapy*. 2016. 9:4993-5003 10.2147/OTT.S101125	Setting
Wang, Y., Wang, X., Guan, Y., Song, Y., Zhuang, H., Wang, E.. **Stereotactic radiosurgery combined with anlotinib for limited brain metastases with perilesional edema in non-small cell lung cancer: Rvision-001 study protocol.** *Thorac Cancer*. 2020. 11:1361-1364 10.1111/1759-7714.13386	Setting
Wegner, R. E., Abel, S., Hasan, S., Schumacher, L. Y., Colonias, A.. **Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series.** *Frontiers in Oncology*. 2019. 9:334 https://dx.doi.org/10.3389/fonc.2019.00334	Sample size
Wegner, R. E., Ahmed, N., Hasan, S., Schumacher, L. Y., Colonias, A.. **Lung stereotactic body radiotherapy after past ablative therapy: a single institution case series.** *Lung Cancer Manag*. 2018. 7:LMT05 10.2217/lmt-2018-0012	Sample size

Welsh J, Menon H, Chen D, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. *Journal for immunotherapy of cancer.* 2020;8(2). doi: 10.1136/jitc-2020-001001.	Aim
Welsh JW, Tang C, De Groot P, et al. Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation-related abscopal responses. *Cancer immunology research.* 2019;7(12):1903-1909. doi: 10.1158/2326-6066.CIR-18-0793.	Comparator
Welsh, J. W., Menon, H., Tang, C., Verma, V., Altan, M., Hess, K. R., De Groot, P., Nguyen, Q., Simon, G. R., Skoulidis, F., et al.. **Randomized phase I/II trial of pembrolizumab with and without radiotherapy for metastatic non-small cell lung cancer.** *Journal of clinical oncology.* 2019. 37:#pages# 10.1200/JCO.2019.37.15_suppl.9104	Publication type
Wolf, K., Kruse, V., Sundahl, N., Gele, M., Chevolet, I., Speeckaert, R., Brochez, L., Ost, P.. **A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response.** *Journal of translational medicine.* 2017. 15:#pages# 10.1186/s12967-017-1123-x	Publication type
Wolff HB, Alberts L, Kastelijn EA, et al. Differences in Longitudinal Health Utility between Stereotactic Body Radiation Therapy and Surgery in Stage I Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer.* 2018;13(5):689-698. doi: https://dx.doi.org/10.1016/j.jtho.2018.01.021.	Population
Wolff, H. B., Alberts, L., van der Linden, N., Bongers, M. L., Verstegen, N. E., Lagerwaard, F. J., Hofman, F. N., Uyl-de Groot, C. A., Senan, S., El Sharouni, S. Y., Kastelijn, E. A., Schramel, Fmnh, Coupe, V. M. H.. **Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study.** *Lung Cancer.* 2020. 141:89-96 https://dx.doi.org/10.1016/j.lungcan.2020.01.011	Setting
Wong JK, Shaikh T, DeMora L, et al. Predictors of Distant Recurrence Following Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. *Am J Clin Oncol.* 2020;43(4):243-248. doi: 10.1097/COC.0000000000000662.	Population
Wong, N. S. M., Chiang, C. L., Chiu, W. H. K., Ho, C. H., Zhang, S., Ha, J. S., Yeung, C. S. Y., Chan, M., Lee, V. W., Lee, A. S., et al.. **Individualized Hypo-fractionated Radiotherapy (IHRT) for Advanced Hepatocellular Carcinoma (HCC): 11-Year Experience of 172 patients.** *International journal of radiation oncology biology physics.* 2019. 105:S159- 10.1016/j.ijrobp.2019.06.175	Publication type
Wowra, B.,Muacevic, A.,Jess-Hempen, A.,Hempel, J. M.,Muller-Schunk, S.,Tonn, J. C.. **Outpatient gamma knife surgery for vestibular schwannoma: definition of the therapeutic profile based on a 10-year experience.** *Journal of Neurosurgery.* 2005. 102 Suppl:114-8 #DOI#	Population
Wu J, Bai HX, Chan L, et al. Sublobar resection compared with stereotactic body radiation therapy and ablation for early stage nonâ€“small cell lung cancer: a National Cancer Database study. *Journal of thoracic and cardiovascular surgery.* 2020. doi: 10.1016/j.jtcvs.2019.11.132.	Population
Wu, C., Chen, B., Wang, M., Tang, Y.. **Chemotherapy with a TP Regimen in Combination with Stereotactic Radiotherapy Could Significantly Optimize the Clinical Efficacy of NSCLC Treatment.** *Evidence-based complementary and alternative medicine.* 2022. 2022:#pages# 10.1155/2022/8495452	Setting

Wu, S. X.,Chua, D. T.,Deng, M. L.,Zhao, C.,Li, F. Y.,Sham, J. S.,Wang, H. Y.,Bao, Y.,Gao, Y. H.,Zeng, Z. F.. **Outcome of fractionated stereotactic radiotherapy for 90 patients with locally persistent and recurrent nasopharyngeal carcinoma.** *International Journal of Radiation Oncology, Biology, Physics.* 2007. 69:761-9 #DOI#	Sample size
Xie, Yaoqin,Djajaputra, David,King, Christopher R,Hossain, Sabbir,Ma, Lijun,Xing, Lei. **Intrafractional motion of the prostate during hypofractionated radiotherapy.** *International Journal of Radiation Oncology* Biology* Physics.* 2008. 72:236-246 #DOI#	Sample size
Xu, D.,Liu, D.,Zhang, Z.,Zhang, Y.,Li, Y.,Liu, X.,Jia, Q.,Zheng, L.,Song, G.. **Gamma Knife surgery in the management of orbital tumors.** *Journal of Neurosurgery.* 2010. 113 Suppl:34-8 #DOI#	Setting
Xu, Y., Chen, W., Lin, Q., Sun, X., Liu, J., Chen, Q., Mao, W.. **A propensity matched analysis of sbrt and sublobar resection for stage i non-small cell lung cancer in patients at high risk for lobectomy.** *Journal of thoracic oncology.* 2017. 12:S2336- #DOI#	Publication type
Yamaguchi, M., Furuya, A., Edagawa, M., Taguchi, K., Shimamatsu, S., Toyokawa, G., Toyozawa, R., Nosaki, K., Hirai, F., Seto, T., Takenoyama, M., Ichinose, Y.. **How should we manage small focal pure ground-glass opacity nodules on high-resolution computed tomography? A single institute experience.** *Surgical Oncology.* 2015. 24:258-63 https://dx.doi.org/10.1016/j.suronc.2015.08.004	Aim
Yamamoto, T., Niibe, Y., Matsumoto, Y., Aoki, M., Oh, R. J., Ozaki, M., Kobayashi, M., Manabe, Y., Shintani, T., Dekura, Y., Onishi, H., Yamashita, H., Jingu, K.. **Factors related to primary cancer death and non-primary cancer death in patients treated with stereotactic body radiotherapy for pulmonary oligometastases.** *Cancer Medicine.* 2020. 9:8902-8911 https://dx.doi.org/10.1002/cam4.3508	Outcomes
Yamashita H, Kobayashi-Shibata S, Terahara A, et al. Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. *Radiat Oncol.* 2010;5:32. doi: 10.1186/1748-717X-5-32.	Population
Yamashita, H., Onishi, H., Murakami, N., Matsumoto, Y., Matsuo, Y., Nomiya, T., Nakagawa, K., Japanese Radiological Society multi-institutional, Sbrt study group. **Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma.** *Journal of Radiation Research.* 2015. 56:561-7 https://dx.doi.org/10.1093/jrr/rru130	Sample size
Yamazaki, H.,Demizu, Y.,Okimoto, T.,Ogita, M.,Himei, K.,Nakamura, S.,Suzuki, G., Yoshida, K.,Kotsuma, T.,Yoshioka, Y.,Oh, R.. **Reirradiation for recurrent head and neck cancers using charged particle or photon radiotherapy.** *Strahlenther Onkol.* 2017. 193:525-533 #DOI#	
Yang JF, Lo CH, Lee MS, et al. Stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the treatment of hepatocellular carcinoma with portal vein invasion: a retrospective analysis. *Radiation Oncology.* 2019;14(1):180. doi: https://dx.doi.org/10.1186/s13014-019-1382-1.	Setting
Yang, H. C.,Kano, H.,Awan, N. R.,Lunsford, L. D.,Niranjan, A.,Flickinger, J. C.,Novotny, J., Jr.,Bhatnagar, J. P.,Kondziolka, D.. **Gamma Knife radiosurgery for larger-volume vestibular schwannomas. Clinical article.** *Journal of Neurosurgery.* 2011. 114:801-7 #DOI#	Population

Yang, J. F., Lo, C. H., Lee, M. S., Lin, C. S., Dai, Y. H., Shen, P. C., Chao, H. L., Huang, W. Y.. **Stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the treatment of hepatocellular carcinoma with portal vein invasion: a retrospective analysis.** *Radiation Oncology*. 2019. 14:180 https://dx.doi.org/10.1186/s13014-019-1382-1	Setting
Ye, Y., Zhu, X., Zhao, X., Jiang, L., Cao, Y., Zhang, H.. **Biologically effective doses of 60-70Gy versus >70Gy of stereotactic body radiotherapy (SBRT) combined with chemotherapy in locally advanced pancreatic cancer: protocol of a single-centre, phase II clinical trial.** *BMJ open.* 2022. 12:e049382- 10.1136/bmjopen-2021-049382	Setting
Yoon, S. M., Lim, Y. S., Park, M. J., Kim, S. Y., Cho, B., Shim, J. H., Kim, K. M., Lee, H. C., Chung, Y. H., Lee, Y. S., Lee, S. G., Lee, Y. S., Park, J. H., Kim, J. H.. **Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma.** *PLoS ONE [Electronic Resource].* 2013. 8:e79854 https://dx.doi.org/10.1371/journal.pone.0079854	Sample size
Yu JB, Soulos PR, Cramer LD, Decker RH, Kim AW, Gross CP. Comparative effectiveness of surgery and radiosurgery for stage I non-small cell lung cancer. *Cancer*. 2015;121(14):2341-2349. doi: https://dx.doi.org/10.1002/cncr.29359.	Population
Yu, W.,Tang, L.,Lin, F.,Li, D.,Wang, J.,Yang, Y.,Shen, Z.. **Stereotactic radiosurgery, a potential alternative treatment for pulmonary metastases from osteosarcoma.** *Int J Oncol.* 2014. 44:1091-8 #DOI#	Setting
Yuan Y, Aghdam N, King CR, et al. Testosterone Levels and Sexual Quality of Life After Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials. *International Journal of Radiation Oncology, Biology, Physics*. 2019;105(1):149-154. doi: https://dx.doi.org/10.1016/j.ijrobp.2019.05.014.	Outcomes
Yuan, B. Y.,Hu, Y.,Zhang, L.,Chen, Y. H.,Dong, Y. Y.,Zeng, Z. C.. **Radiotherapy for adrenal gland metastases from hepatocellular carcinoma.** *Clin Transl Oncol.* 2017. 19:1154-1160 #DOI#	Setting
Yuan, X. S., Chen, W. C., Lin, Q. R., Liu, Y. J., Zhu, Y. Y., Sun, X. J., Wu, Q. Y., Liu, J. S., Xu, Y. P.. **A propensity-matched analysis of stereotactic body radiotherapy and sublobar resection for stage I non-small cell lung cancer in patients at high risk for lobectomy: the results in a Chinese population.** *Journal of Thoracic Disease.* 2021. 13:1822-1832 https://dx.doi.org/10.21037/jtd-21-339	Setting
Yuan, Y., Aghdam, N., King, C. R., Fuller, D. B., Weng, J., Chu, F. I., Mardirossian, G., Patel, A., Nickols, N. G., Kupelian, P. A., Steinberg, M. L., Collins, S. P., Kishan, A. U.. **Testosterone Levels and Sexual Quality of Life After Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials.** *International Journal of Radiation Oncology, Biology, Physics.* 2019. 105:149-154 https://dx.doi.org/10.1016/j.ijrobp.2019.05.014	Outcomes
Yuan, Zhi-Yong,Meng, Mao-Bin,Liu, Chun-Lei,Wang, Huan-Huan,Jiang, Chao,Song, Yong-Chun,Zhuang, Hong-Qing,Yang, Dong,Wang, Jing-Sheng,Wei, Wang. **Stereotactic body radiation therapy using the CyberKnife® system for patients with liver metastases.** *OncoTargets and therapy*. 2014. 7:915 #DOI#	Sample size
Yuan, Zhiyong,Tian, Lijun,Wang, Ping,Song, Yongchun,Dong, Yang,Zhuang, Hongqing. **Comparative research on the efficacy of CyberKnife® and surgical excision for Stage I hepatocellular carcinoma.** *OncoTargets and therapy.* 2013. 6:1527 #DOI#	Sample size

Zaorsky NG, Shaikh T, Murphy CT, et al. Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer. *Cancer Treatment Reviews*. 2016;48:50-60. doi: https://dx.doi.org/10.1016/j.ctrv.2016.06.006.	Study design
Zaorsky, N. G., Hurwitz, M. D., Dicker, A. P., Showalter, T. N., Den, R. B.. **Is robotic arm stereotactic body radiation therapy "virtual high dose ratebrachytherapy" for prostate cancer? An analysis of comparative effectiveness using published data [corrected].** *Expert Review of Medical Devices*. 2015. 12:317-27 https://dx.doi.org/10.1586/17434440.2015.994606	Publication type
Zaorsky, N. G., Lehrer, E. J., Handorf, E., Meyer, J. E.. **Dose Escalation in Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Meta-Analysis.** *American Journal of Clinical Oncology*. 2019. 42:46-55 https://dx.doi.org/10.1097/COC.0000000000000472	Comparator
Zaorsky, N. G., Shaikh, T., Murphy, C. T., Hallman, M. A., Hayes, S. B., Sobczak, M. L., Horwitz, E. M.. **Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer.** *Cancer Treatment Reviews*. 2016. 48:50-60 https://dx.doi.org/10.1016/j.ctrv.2016.06.006	Study design
Zelefsky MJ, Yamada Y, Greco C, et al. Phase 3 Multi-Center, Prospective, Randomized Trial Comparing Single-Dose 24 Gy Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Cancer. *International journal of radiation oncology, biology, physics*. 2021;110(3):672-679. doi: 10.1016/j.ijrobp.2021.01.004.	Comparator
Zeng, Xian-Liang,Wang, Huan-Huan,Meng, Mao-Bin,Wu, Zhi-Qiang,Song, Yong-Chun, Zhuang, Hong-Qing,Qian, Dong,Li, Feng-Tong,Zhao, Lu-Jun,Yuan, Zhi-Yong. **Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump.** *OncoTargets and therapy*. 2016. 9:3985 #DOI#	Sample size
Zhang, Huailing,Zhao, Guoru,Djajaputra, David,Xie, Yaoqin. **Determination of acquisition frequency for intrafractional motion of pancreas in CyberKnife radiotherapy.** *The Scientific World Journal*. 2014. 2014:#pages# #DOI#	Sample size
Zhang, Li,Johnson, Julian,Gottschalk, Alexander R,Chang, Albert J,Hsu, I-Chow,Roach III, Mack,Seymour, Zachary A. **Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer.** *Practical Radiation Oncology*. 2017. 7:e109-e116 #DOI#	Sample size
Zhang, Z. L., Yang, X. D., Wen, A. M., Wan, J. P.. **Evaluation of TACE combined with gamma-knife radiotherapy for primary hepatocellular carcinoma.** *Journal of interventional radiology (china)*. 2012. 21:596-599 10.3969/j.issn.1008-794X.2012.07.17	Non-English
Zhang, Z., Li, C., Liao, W., Huang, Y., Wang, Z.. **A Combination of Sorafenib, an Immune Checkpoint Inhibitor, TACE and Stereotactic Body Radiation Therapy versus Sorafenib and TACE in Advanced Hepatocellular Carcinoma Accompanied by Portal Vein Tumor Thrombus.** *Cancers*. 2022. 14:25 https://dx.doi.org/10.3390/cancers14153619	Setting
Zhao, J., Zeng, L., Wu, Q., Wang, L., Lei, J., Luo, H., Yi, F., Wei, Y., Yu, J., Zhang, W.. **Stereotactic Body Radiotherapy Combined with Transcatheter Arterial Chemoembolization versus Stereotactic Body Radiotherapy Alone as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review.** *Chemotherapy*. 2019. 64:248-258 https://dx.doi.org/10.1159/000505739	Setting

Zhao, X., Wang, T., Ye, Y., Li, J., Gao, X., Zhang, H.. **Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial.** *BMJ open.* 2022. 12:e051371- 10.1136/bmjopen-2021-051371	Publication type
Zhong, J.,Switchenko, J.,Behera, M.,Kooby, D.,Maithel, S. K.,McDonald, M. W.,Lin, J. Y., Cassidy, R. J.,El-Rayes, B.,Landry, J.,Patel, P. R.. **Chemotherapy with or without definitive radiation therapy in inoperable pancreatic cancer.** *Ann Surg Oncol.* 2018. 25:1026-1033 #DOI#	
Zhu, X., Ju, X., Cao, F., Fang, F., Qing, S., Shen, Y., Jia, Z., Cao, Y., Zhang, H.. **Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trial.** *BMJ open.* 2016. 6:#pages# 10.1136/bmjopen-2016-013220	Publication type
Zhu, X., Li, F., Liu, W., Shi, D., Ju, X., Cao, Y., Shen, Y., Cao, F., Qing, S., Fang, F., Jia, Z., Zhang, H.. **Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: A propensity score-matched analysis of a prospectively collected database.** *Cancer management and research.* 2018. 10:1295-1304 https://dx.doi.org/10.2147/CMAR.S163655	Setting
Zhu, Xiaofei,Li, Fuqi,Ju, Xiaoping,Cao, Fei,Cao, Yangsen,Fang, Fang,Qing, Shuiwang, Shen, Yuxin,Jia, Zhen,Zhang, Huojun. **Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer.** *Cancer medicine.* 2017. 6:2263-2270 #DOI#	Setting
Zilli T, Jorcano S, Bral S, et al. Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results. *Cancer medicine*. 2020;9(9):3097-3106. doi: 10.1002/cam4.2966	Comparator
Zilli, T., Bruynzeel, A., Minn, H., Sanchez-Saugar, E., Oliveira, A., Bral, S., Jorcano, S., Abacioglu, U., Symon, Z., Miralbell, R.. **Short vs protracted urethra-sparing prostate SBRT: feasibility and early toxicity from a randomized phase II trial.** *Radiotherapy and oncology*. 2015. 115:S356 #DOI#	Publication type
Zilli, T., Jorcano, S., Bral, S., Rubio, C., Bruynzeel, A. M. E., Oliveira, A., Abacioglu, U., Minn, H., Symon, Z., Miralbell, R.. **Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results.** *Cancer medicine*. 2020. 9:3097-3106 10.1002/cam4.2966	Comparator
Zilli, T., Jorcano, S., Bral, S., Rubio, C., Bruynzeel, A., Oliveira, A., Abacioglu, U., Minn, H., Symon, Z., Miralbell, R.. **Urethra-sparing SBRT for prostate cancer: acute toxicity results from a randomized phase II trial.** *Radiotherapy and oncology*. 2017. 123:S295- #DOI#	Publication type
Zilli, T., Jorcano, S., Bral, S., Rubio, C., Bruynzeel, A., Oliveira, A., Abacioglu, U., Minn, H., Symon, Z., Miralbell, R.. **Weekly vs. Every-other-day prostate cancer SBRT: 18-months results from a randomized phase II trial.** *Radiotherapy and oncology*. 2018. 127:S260- #DOI#	Publication type